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ABSTRACT 
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that binds 
pollutants, therapeutic drugs and endogenous ligands. AHR is of particular interest in cancer and 
has been shown to play roles in both tumor progression and tumor suppression. As a result, it has 
received growing attention as a possible chemotherapeutic target. AHR is expressed in all breast 
cancer subtypes and can promote or inhibit breast cancer depending on the ligand it binds. The 
Notch signaling pathway is a highly conserved evolutionary pathway that plays extremely vital 
roles during development by regulating cell fate and differentiation. Notch signaling has 
increasingly attracted attention as a therapeutic target for cancer treatments and ligand-induced 
Notch activation has been reported to promote the progression of several cancers including 
breast cancer. Jagged 1 (JAG1) is a Notch receptor ligand that is overexpressed in all breast 
cancer subtypes, including triple negative breast cancer (TNBC). JAG1 promotes various vital 
functions of cancer biology including cancer stem cell maintenance, drug-resistance, epithelial-
mesenchymal transition (EMT), and metastasis. The regulation of JAG1 by AHR in breast 
cancer cells via two AHR ligands, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 2-(1’H-
indole-3’-carbonyl)-thiazole-4-carboxylic acid methylester (ITE), were investigated for this 
dissertation. TCDD is the prototype AHR ligand, and ITE is a non-toxic endogenous AHR ligand 
with anti-cancer activity. Our laboratory has discovered that ligand-activated AHR inhibits the 
expression and activity of the JAG1-Notch pathway in human breast cancer cells, which in turn 
decreases breast cancer cell invasion. By conducting ribonucleic acid (RNA)-sequencing and 
analyzing the data via Ingenuity Pathway Analysis (IPA), we identified a significant association 
between TCDD-regulated genes (TRGs) and cell movement. We found that silencing AHR 
expression by short-interfering RNA (siRNA) or antagonizing its activity with the AHR 
xviii 
antagonist CH-223191 in breast cancer cells restored JAG1 expression, which established that 
ligand-activated AHR is an inhibitor of the JAG1-Notch pathway in breast cancer cells. AHR 
was also found to be necessary for suppressing the expression of the EMT regulator Snail, a 
crucial protein required for promoting cancer metastasis. Finally, we have shown that other non-
toxic AHR agonists such as tranilast also decreases JAG1 expression in TNBC cells. 
Collectively, my work is the first to show that ITE is a tumor-suppressing AHR ligand in breast 
cancer cells in part because it reduces JAG1 expression. The findings presented in this 
dissertation suggest targeting the JAG1-Notch pathway with non-toxic AHR ligands could be a 
new mechanism to suppress the invasive activity of TNBC, which is a breast cancer subtype for 
which there are no targeting therapies.
1 
CHAPTER 1 
OVERVIEW OF CURRENT KNOWLEDGE IN BREAST CANCER 
1.1. Survival Rates and Subtypes 
There are more than 3.5 million women with breast cancer in the United States 
(American Cancer Society, 2016). Breast cancer is a heterogeneous disease that has been 
clinically organized into four subtypes (Figure 1) based on certain molecular markers: 1) 
Luminal A (Estrogen Receptor (ER)+/Progesterone Receptor (PR)+/Human Epidermal Growth 
Factor Receptor 2 (HER2)-) makes up ~40-50% of breast cancers, 2) Luminal B 
(ER+/PR+/HER2+) makes up ~15-20% of breast cancers, 3) HER2-enriched (ER-/PR-/HER2+) 
makes up ~8-10% of breast cancers and 4) triple negative breast cancer (TNBC) (ER-/PR-
/HER2-) makes up ~15-20% of breast cancers (Keegan, DeRouen, Press, Kurian, & Clarke, 
2012). Women with Luminal A tumors have the best 10-year survival rates (70%), compared 
with women with Luminal B (54%), HER2-enriched (48%), and TNBC (53%) tumors 
(Kennecke, et al., 2010). Women with Luminal A and B, and HER2-enriched subtypes can be 
treated with anti-estrogen or HER2 targeting therapy, respectively. However, TNBC lacks 
molecular targets for specific cancer targeting. Currently, women with TNBC are treated with 
chemotherapy and endure the associated toxicities of these non-specific drugs.   
Recent studies have identified a small subpopulation of cells within breast tumors that 
exhibit stem-cell like characteristics that confer these cells with heightened tumorigenic activity, 
drug resistance (Gottesman, Fojo, & Bates, 2002; Ma & Allan, 2011), tumor recurrence (Yi, 
Kabha, Papadopoulos, & Wagner, 2014; Bosukonda & Carlson, 2017) and metastatic activity 
(Xie, et al., 2012; Uchino, et al., 2010). This small subpopulation of cells has been termed cancer 
stem cells (CSCs) and they are driven by signaling pathways that are triggered by  
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Figure 1. Subtypes of Breast Cancer Tumors 
Each subtype has a different prognosis and treatment response. For ER+/PR+ group, because ER 
is a therapeutic target, the Luminal A and Luminal B subtypes are amenable to hormone therapy. 
Similarly, the HER2 groups are potential candidates for trastuzumab therapy. For the ER-/PR- 
group, in the current absence of expression of a recognized therapeutic target, basal tumors are 
difficult to treat, more biologically aggressive and often have a poor prognosis. This is because 
the basal phenotype is characterized by the lack of expression of ER, PR and HER2 and is 
sometimes referred to as triple negative breast cancer. TNBC = Triple Negative Breast Cancer, 
ER = Estrogen Receptor, PR = Progesterone Receptor, HER2 = Human Epidermal Growth 
Factor Receptor 2. 
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extracellular signals, mutations, and epigenetic control (Hartwig, et al., 2014). In this section, the 
subtypes of breast cancer, breast cancer therapies and breast cancer stem cells (BCSCs) will be 
discussed. 
1.2. Breast Cancer Subtype Characteristics and Current Treatment Strategies 
1.2.1. Luminal A and B Subtype 
The Luminal A and B subtypes are highly associated with proliferation/cell cycle-related 
pathways and luminal/hormone-regulated cell processes (Prat, et al., 2015). The ER is expressed 
in the Luminal A and Luminal B breast cancer subtypes. The five and ten-year survival rates for 
Luminal B breast cancer are worse than for Luminal A breast cancer, irrespective of therapy. 
Compared with Luminal A breast cancer, Luminal B breast cancer exhibits higher expression of 
proliferation/cell cycle-related genes and proteins as well as lower expression of several genes 
that link with luminal breast cells, including the PR (Prat, et al., 2013). The analysis of mutation 
rates has demonstrated that Luminal A breast cancer exhibits fewer mutations than Luminal B 
breast cancer. The Luminal A subtype has a lower percentage of gene amplification events such 
as lower rates of cyclin D1 (CCND1) gene amplification, fewer tumor protein 53 (TP53) 
mutations (12% vs. 29%), and a higher rate of phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA) (45% vs. 29%) and mitogen-activated protein kinase kinase 
kinase 1 (MAP3K1) mutations (13% versus 5%) compared to Luminal B tumors (Cancer 
Genome Atlas Network, 2012). The differences in these particular molecular markers (i.e., PR, 
CCND1, TP53, PIK3CA and MAP3K1) are used to distinguish Luminal A breast cancer from 
Luminal B breast cancer.   
Luminal A and Luminal B breast cancers are responsive to chemotherapy in a 
neoadjuvant setting in which treatment is given as a first step to shrink a tumor before surgery. 
4 
Although surgery is the frontline therapy, Luminal A and Luminal B breast cancers are also 
treated with chemotherapy, radiation therapy, and hormone therapy. A clinical study was 
conducted on 208 women with Luminal A or Luminal B breast cancer that were treated with 
anthracycline/taxane-based chemotherapy. According to the pathologic complete response (pCR) 
data, which is the absence of residual invasive disease in the breast and in the auxiliary lymph 
nodes at the completion of the neoadjuvant treatment, the pCR rates in patients with Luminal A 
and Luminal B subtypes were 3% and 16%, respectively (Prat, Parker, & Fan, 2012). The results 
from a study comparing Luminal A to Luminal B breast cancer identified that women with low-
proliferating Luminal A breast tumors were more responsive to paclitaxel compared with women 
that had high-proliferating Luminal B tumors (Martín, et al., 2013).  
The use of drugs that specifically target estrogen signaling in Luminal A or Luminal B 
breast cancer has been in clinical practice for nearly fifty years (Lumachi, Santeufemia, & Basso, 
2015). The estrogen targeting drugs target several different aspects of estrogen signaling in 
breast cancer (Figure 2). For instance, aromatase converts androgen into estrogen 
(Brueggemeier, Hackett, & Diaz-Cruz, 2005). The aromatase inhibitors (AIs), anastrozel and 
letrozol, bind to aromatase and block its activity, which reduces estrogen production. AIs are 
approved for the treatment of ER positive breast cancer in postmenopausal, but not 
premenopausal, women. Aromatase inhibition is ineffective in premenopausal women with 
functionally active ovaries, because reducing estrogen levels in these women with AIs induces a 
compensatory increase in the secretion of luteinizing hormone (LH) and follicle stimulating 
hormone (FSH), which in turn increases aromatase activity leading to increases in estrogen levels 
(Ma, Reinert, Chmielewska, & Ellis, 2015). The selective estrogen receptor modulators (SERMs) 
include tamoxifen, raloxifen and toremifine. The SERMs bind to the ER and have tissue-specific  
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Figure 2. Current Strategies for Endocrine Therapies in Breast Cancer  
Estrogen activates nuclear ER (genomic pathway) and ER in or near the membrane (non-
genomic pathway). Membrane associated ER binds to growth factor signaling components such 
as PI3K. Estrogen then activates growth factor signaling, activating key molecules such as Akt or 
RAS, and downstream molecules such as mTOR and MAPK, which promote cell proliferation 
and survival. (A) AIs assist in decreasing the synthesis of estrogen as an approach for reducing 
growth-stimulatory effects. (B) SERDs function as high affinity competitive antagonists and 
induce a conformational change that is incompatible with co-regulator interactions and target the 
receptor for proteasomal degradation. (C) Humanized monoclonal antibodies target different 
growth factor receptors that promote cancer growth by blocking their activation. (D) Small-
molecule TKIs bind the intracellular domains of growth factor receptors to block activation of 
their downstream signaling pathways. (E) SERMs act as a competitive receptor inhibitor in the 
breast tissue by selectively blocking ER signaling and inhibiting the proliferation of tumor cells. 
ER = Estrogen Receptor, EGFR = Epidermal Growth Factor Receptor, HER2 = Human 
Epidermal Growth Factor Receptor 2, MAPK = Mitogen-activated Protein Kinase, mTOR = 
Mechanistic Target of Rapamycin, PI3K = Phosphoinositide 3-kinase, SERDs = Selective 
Estrogen Receptor Down Regulators, TKIs = Tyrosine Kinase Inhibitors, SERMs = Selective 
Estrogen Receptor Modulators, RAS = Rat Sarcoma Viral Proto-Oncogene, Akt = Serine-
threonine Protein Kinase. 
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effects. For instance, tamoxifen acts as a partial nonsteroidal agonist in some tissues such as the 
liver, uterus, and bone. However, tamoxifen is a competitive ER inhibitor in breast and brain. 
Hence, the SERMs are categorized as being “modulators” rather than “down-regulators” of ER 
or estrogen signaling (Powles, Ashley, Tidy, Smith, & Dowsett, 2007).  
Tamoxifen is metabolized by cytochrome P450 (CYP450) enzymes into active 
metabolites endoxifen and 4-hydroxytamoxifen (4-HT), which then bind to ER and suppress the 
proliferation of ER-positive breast cancer cells (Lumachi, Brunello, Maruzzo, Basso, & Basso, 
2013; Wu, X. et al., 2009). The SERMs, such as tamoxifen, are extensively used to treat ER 
expressing breast cancer in both pre- and post-menopausal women (Lumachi, et al., 2013). The 
selective estrogen receptor down-regulators (SERDs) are different from SERMs, because they 
function as ER antagonists in all tissues (Yeh, et al., 2013; Lumachi, et al., 2011). Fulvestrant is 
the only Food and Drug Administration (FDA) approved SERD to treat breast cancer and 
competes with estrogen for the ligand-binding pocket in the ER, which induces proteolytic 
downregulation of the ER in breast cancer cells. The affinity of fulvestrant for the ER is 100 
times stronger than the affinity of tamoxifen (Wardell, Marks, & McDonnell, 2011). Fulvestrant 
is efficacious in treating tamoxifen resistant breast cancer, and it is combined with an AI when 
treating metastatic ER-positive breast cancer (Ikeda, et al., 2011; Jiang, et al., 2014).  
1.2.2. HER2-enriched Subtype 
The breast cancer subtype with HER2 gene amplification is termed HER2-enriched 
breast cancer (Prat, et al., 2015). Because HER2-enriched breast cancer has aggressive biological 
behavior and a poor clinical outcome, its overall survival rate is worse than Luminal A and 
Luminal B breast cancer subtypes (Burstein, 2005). The HER2 gene encodes a transmembrane 
protein that plays a vital role in the regulation of cell growth, survival, and differentiation 
7 
(Wahler & Suh, 2015; Ménard, Pupa, Campiglio, & Tagliabue, 2003). HER2-enriched tumors 
have a higher frequency of mutations across the genome compared with Luminal A and Luminal 
B breast cancer (Neve, Lane, & Hynes, 2001); 72% and 39% of HER2 breast cancers exhibit 
mutations in TP53 and PIK3CA, respectively (Prat, et al., 2015). The overexpression of HER2 in 
breast cancer promotes metastatic properties of tumor cells and increases the chances for drug 
resistance in response to chemotherapy and endocrine therapy (Prat & Baselga, 2008). There are 
four anti-HER2 drug categories that are used to treat HER2 positive breast cancer; they include 
1) monoclonal antibodies (mAbs), 2) small molecule tyrosine kinase inhibitors (TKIs), 3) 
antibody-drug conjugates (ADCs), and 4) new emerging therapies such as heat shock protein 90 
(HSP90) inhibitors. 
The epidermal growth factor receptor (EGFR) family of proteins is a group of 
transmembrane receptor tyrosine kinases that includes HER2, human epidermal growth factor 
receptor 3 (HER3), and human epidermal growth factor receptor 4 (HER4) (Lv, et al., 2016). The 
ligands that bind these receptors include epidermal growth factor (EGF), heregulin, and tumor 
growth factor a (TGFa). Upon activation, HER2 will form a heterodimer with another member 
of the EGFR family of receptors and induce phosphorylation-mediated signaling pathways that 
promote breast cancer progression (Tzahar, et al., 1996) (Figure 2). The HER2 monoclonal 
antibodies trastuzumab and pertuzumab inhibit HER2 signaling by preventing the 
homodimerization or heterodimerization of HER2 receptor complexes, which inhibits HER2-
mediated signaling in breast cancer cells (Hudis, 2007). Trastuzumab has also been shown to 
induce endocytosis of HER2, leading to its degradation and increases in cellular apoptosis 
(Hudis, 2007). Even though trastuzumab has extended survival in patients with breast tumors 
that overexpress HER2, resistance occurs through alterations of HER2-regulated downstream 
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signaling pathways that are induced by other tyrosine kinase receptors and or shedding of HER2 
receptors (Wong & Lee, 2012; Rexer & Arteaga, 2012) (Figure 2). 
Small molecule TKIs were developed to overcome HER2 resistance (Figure 2). TKIs 
bind to the intracellular tyrosine kinase domain of HER2 to prevent the phosphorylation of 
tyrosine kinase, which inhibits the activation of signaling pathways that are downstream of 
HER2 signaling (Lv, et al., 2016). One example is lapatinib, the second FDA approved anti-
HER2 targeting agent. Lapatinib is an orally active, dual small molecular inhibitor of HER2 and 
human epidermal growth factor receptor 1 (HER1) that induces prolonged inhibition of tyrosine 
phosphorylation in tumor cells (Johnston & Leary, 2006; Nahta, Yu, Hung, Hortobagyi, & 
Esteva, 2006). A previous study found that lapatinib had a high efficacy in halting the 
progression of HER2 expressing breast cancer when used as a first line therapy, where 24% of 
patients demonstrated an increase in overall response and progression-free survival rate (Gomez, 
et al., 2008). The mechanism of action for lapatinib has not been determined; however, there are 
several hypotheses to explain how the drug suppresses HER1 and HER2 (Tai, Mahato, & Cheng, 
2010). The first hypothesis is that lapatinib specifically targets the tyrosine kinase domain of 
HER2 and HER1 to inhibit downstream signaling (Xia, et al., 2002). The second hypothesis 
proposes that lapatinib perturbs the activity of signaling proteins that sit downstream of HER2 
(Xia, et al., 2002). The third hypothesis is that lapatinib induces breast cancer cell apoptosis by 
inhibiting insulin-like growth factor-1 receptor (IGF-1R). Lapatinib, in combination with HER2 
monoclonal antibodies has been shown to induce a synergistic effect in the treatment of HER2-
enriched breast cancer (Konecny, et al., 2006; Xia, et al., 2005). The observed synergistic effect 
of combining lapatinib with a HER2 blocking antibody has been attributed to differences in the 
mechanism by which lapatinib and HER2 blocking antibodies target HER2 (Xia, et al., 2005).   
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ADCs are a newer class of HER2-targeting agents, where the monoclonal antibody is 
conjugated with a cytotoxic agent through a thioester linker. Ado-trastuzumab emtansine (T-
DM1) is an ADC that was FDA approved in 2013 (Amiri-Kordestani, et al., 2014). The 
mechanism of action has been postulated to initially start with trastuzumab binding specifically 
to the extracellular portion of HER2. Binding between trastuzumab and HER2 is postulated to 
induce a form of passive endocytosis of HER2-trastuzumab complexes. These HER2-drug 
complexes enter the cytoplasm, followed by their degradation by the lysosome, which then 
releases the emtansine (DM1) component from the complex via cleavage of the thioester linker 
and allows DM1 to exert its cytotoxicity by inhibiting microtubule formation, inducing cell cycle 
arrest and promoting apoptosis (Martínez, et al., 2016; Lewis Phillips, et al., 2008).  
Other emerging HER2 targeting agents include HSP90 inhibitors. The stability and 
function of several cellular proteins is dependent on the molecular chaperon function of HSP90 
(Chen, Singh, & Perdew, 1997). Consequently, HSP90 inhibitors will induce the degradation of 
various cytosolic transcription factors but is postulated to be very effective at inhibiting breast 
cancer progression because breast cancer cells exhibit high levels of HSP90 (Solit, et al., 2002; 
Pick, et al., 2007). HER2 stability is dependent on HSP90. Therefore, the inhibition of HSP90 
reduces the stability of HER2, which in turn reduces the survival of HER2 positive breast cancer 
cells (Huszno & Nowara, 2016; Munagala, Agil, & Gupta, 2011). The first generation HSP90 
inhibitor tanespinmycin, has reported anti-tumor activity in HER2-enriched breast cancer and is 
currently undergoing clinical trials in combination with trastuzumab (Tsang & Finn, 2012). 
1.2.3. Triple Negative Subtype 
TNBC is an aggressive breast cancer subtype that lacks the expression of the ER, PR, and 
HER2 receptors. Because there are no specific molecular targets for the treatment of TNBC, 
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women with this disease have high rates of metastatic breast cancer and breast cancer recurrence 
(Zhang, Liu, Wang, & Zhang, 2016; Ismail-Khan & Bui, 2010). The only option for women with 
TNBC is systemic chemotherapy that comes with inherent toxicities (Figure 3). TNBC is 
correlated with a high risk for relapse and poor overall survival compared to the other breast 
cancer subtypes. The high rate of TNBC relapse is postulated to be attributed to the lack of drugs 
that are specific for TNBC (Zhang, Liu, Wang, & Zhang, 2016). Clinical studies, however, have 
demonstrated that TNBC is initially responsive to chemotherapy. Indeed, a meta-analysis of five 
adjuvant trials was conducted to compare anthracycline-containing regimens which include: 
cyclophosphamide, methotrexate, and fluorouracil (CMF). The results of the study showed that 
anthracycline-containing regimens were superior to CMF for the treatment of TNBC (Di Leo, et 
al., 2010). Therefore, anthracycline/taxane-based adjuvant regimens are currently the most 
rational therapy for women with TNBC. Although TNBC is initially responsive to 
chemotherapy, prolonged therapy with these drugs usually leads to drug-resistance. Despite 
initial responses to anthracycline/taxane-based regimens, women with TNBC often relapse and 
tumors return more drug resistant and aggressive. Therefore, the identification of TNBC 
molecular targets will be important for improving the survival of women with this disease. 
To find a solution for TNBC relapse and drug-resistance, Burstein et al. identified 4 
stable characterized subgroups of TNBC to help identify any potential molecular targets and 
novel treatment strategies (Table 1): 1) Luminal/Androgen Receptor (LAR), 2) Mesenchymal 
(MES), 3) Basal-like Immune Suppressed (BLIS) and 4) Basal-like Immune Activated (BLIA) 
(Burstein, et al., 2015). The identification of novel molecular targets is critical for improving 
patient survival with TNBC and must be fundamentally different than what is currently being 
used (Zhang, Liu, Wang, & Zhang, 2016). Novel agents for TNBC that are currently being  
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Figure 3. Current Systemic Chemotherapy Agents that are Used in the Treatment of Triple 
Negative Breast Cancer 
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Table 1. The Novel Subtypes of Triple Negative Breast Cancer 
The novel subtypes of TNBC along with prognostic factors and some selected genes with 
significant overexpression unique to each subtype that can serve as potential drug targets. 1) 
LAR, 2) MES, 3) BLIS, and 4) BLIA. Using independent TNBC datasets, Burstein et al. 
determined that BLIS and BLIA tumors have the worst and best prognoses, respectively 
(independently of other known prognostic factors), compared to the other subtypes. Collectively, 
RNA and DNA genomic studies identified stable, reproducible TNBC subtypes characterized by 
specific RNA and DNA markers, which can help identify potential targets for more effective 
treatments of TNBC cells. TNBC subtype classification is also based on molecules they do 
express as opposed to molecules they do not express. All molecules shown in this table have the 
potential to be targeted for treatment or are already undergoing clinical trials. 
 
 
 
 
 
TNBC Subtype Prognostic Status Gene Expression Unique to TNBC Subtype 
Luminal/Androgen
Subtype
(LAR)
• Gene expression exhibits ER, AR, 
and HER4 signaling
• Demonstrates expression of ER and 
other ER-regulated genes 
• May respond to anti-estrogen and -
androgen therapies in conjunction 
with chemotherapies
• ER: Estrogen Receptor 
• CAXII: Carbonic Anhydrase 12
• AR: Androgen Receptor
• RET: Ret Proto-oncogene
Mesenchymal Subtype
(MES)
• Previously described as “stem-like” 
or “claudin-low”
• Expresses genes normally exclusive 
to osteocytes and adipocytes
• May respond to PPAR!-inhibitors 
in conjunction with chemotherapies
• ADH1β: Alcohol Dehydrogenase 1β
• GHR: Growth Hormone Receptor
• PPAR!: Peroxisome Proliferator-activated Receptor !
• IL1R1: Interleukin 1 Receptor, Type I
Basal-like Immune 
Suppressed
(BLIS)
• Exhibits downregulation of 
immune- and cytokine-regulation 
pathways
• Exhibits the worst clinical outcome 
of TNBC subtypes
• May respond to immune-
checkpoint inhibitors in 
conjunction with chemotherapies
• VTCN1: V-set Domain Containing T-cell Activation 
Inhibitor I
• TUBB2B: Tubulin β, Class IIB
• KIT: KIT Proto-oncogene Receptor Tyrosine Kinase
• FGFR2: Fibroblast Growth Factor Receptor 2
Basal-like Immune 
Activated
(BLIA)
• Displays up-regulation of genes 
controlling immune function
• Exhibits the best clinical outcome 
of TNBC subtypes
• May respond to cytokine- or 
immune-checkpoint inhibitors in 
conjunction with chemotherapy
• CXCL10: C-X-C Motif Chemokine Ligand 10
• CTLA4: Cytotoxic T-lymphocyte-associated Protein 4
• TOP2α: Topoisomerase 2α
• LCK: Lymphocyte-specific Protein Tyrosine Kinase
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studied include poly-(adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitors, 
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitors and androgen receptor (AR) 
inhibitors (Burstein, et al., 2015). 
PARPs are a large family of enzymes that are important for the repair of single-stranded 
breaks in deoxyribonucleic acid (DNA) through the base excision repair pathway and were 
identified to be a potential target for the treatment of the MES subtype in TNBC (Burstein, et al., 
2015; Hoeijmakers, 2001). When certain chemotherapies cause DNA damage, PARP repairs the 
damage and this in turn promotes drug resistance (Figure 4). Because DNA contains various 
lesions such as single-strand breaks, double-stranded breaks, and homologous recombination, 
inhibiting PARP leads to the accumulation of double stranded breaks; resulting in genomic 
instability and eventually cell death (Amé, Spenlehauer, & de Murcia, 2004). Therefore, PARP 
inhibitors are postulated to increase the sensitivity and responsiveness of TNBC to 
chemotherapy. Currently, there are several PARP inhibitors in clinical development. The 
combination treatment of PARP inhibitors with chemotherapy in TNBC has been investigated in 
phase I-III clinical trials, and this combination showed a favorable clinical response. One 
example is a trial that showed the combination of carboplatin and PARP inhibitor, veliparib, 
added to weekly paclitaxel and followed by doxorubicin and cyclophosphamide led to a doubling 
of the complete response rate in patients with TNBC from 26% to 52% (Rugo, Olopade, 
DeMichele, & Yau, 2016). However, long-term treatment with PARP inhibitors resulted in drug 
resistance by increasing expression of P-glycoprotein (P-gp) efflux pumps (Rottenberg, et al., 
2008).  
Prior reports have established that breast cancer cells are able to initiate an immune 
response that increases the population of tumor infiltrating lymphocytes (TILs) into breast  
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Figure 4. PARP Mechanism and Inhibition 
The PARPs have a particularly critical role in the base-excision repair pathway, binding to 
single-strand breaks in DNA, modifying proteins in the vicinity, and ultimately leading to the 
recruitment of DNA repair proteins to the sites of damage. PARP inhibitors block the activity of 
the PARP enzymes by mimicking the nicotinamide moiety of NAD+ and binding to the PARP 
catalytic site, which either directly blocks PARP enzymatic activity or causes PARP to 
accumulate on DNA and promotes apoptosis. NAD+ = Nicotinamide Adenine Dinucleotide, 
PARP = Poly-(ADP-ribose) Polymerase. 
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tumors (Disis & Stanton, 2015). Increasing the number of TILs in breast tumors was correlated 
with a favorable treatment outcome depending on the intensity of the tumor immune response 
(Demaria, et al., 2001). CTLA4 is an immune checkpoint ligand found on the surface of T-cells 
that modulates the generation and maintenance of immune responses (Gross & Jure-Kunkel, 
2013). CTLA4 is critical for inhibiting T-cell immune response by regulating cell cycle 
progression and maintains a favorable tumor microenvironment (Greenwald, et al., 2002). The 
monoclonal antibody tremelimumab, which inhibits the CTLA4 pathway, was evaluated in 
hormone-positive breast cancer and has shown to abrogate immunosuppressive activity (Cimino-
Mathews, Foote, & Emens, 2015). Targeting CTLA4 effectively promotes T-cell activity, 
thereby potentiating the antitumor immune response (Chawla, Philips, Alatrash, & Mittendorf, 
2014). Therefore, immunomodulatory drugs can lay the foundation for immune-based therapies 
in TNBC, especially for the BLIA subtype, which was identified to express higher levels of 
CTLA4 compared to the other TNBC subtypes (Burstein, 2005).  
It has also been shown that the LAR subtype of TNBC represented a unique type of 
breast cancer with adverse clinical outcome. As a result, AR inhibition was regarded as a 
potential endocrine therapy for patients with this particular subtype of TNBC (Choi, Kang, Lee, 
& Bae, 2015). The LAR subtype characterized by AR expression was shown to be sensitive to 
the AR antagonist bicalutamide alone or in combination with PI3K inhibitors (Lehmann, et al., 
2011; Burstein, 2005; Crumbaker, Khoja, & Joshua, 2017). These new findings suggest that 
targeting the AR in TNBC could be beneficial.   
1.2.4. Breast Cancer Stem Cells 
The discovery of BCSCs came from a flow cytometry experiment that identified a small 
subpopulation (<1% of the tumor population) of cancer cells which expressed higher cluster of 
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differentiation 44 (CD44), lower cluster of differentiation 24 (CD24) and increased aldehyde 
dehydrogenase 1 (ALDH1) phenotype (i.e. CD44+CD24low/-ALDH1+) (Pires, Amorim, Souza, 
Rodrigues, & Mencalha, 2016). This CD44+CD24low/-ALDH1+ population of cells was highly 
tumorigenic, because transplanting a few hundred of them into mice was sufficient to regenerate 
a breast tumor (Al-Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke, 2003). Extensive 
evidence shows that BCSCs are associated with tumor initiation, cancer progression, metastasis, 
and resistance to chemotherapy. Furthermore, they are also associated with tumor relapse and 
treatment failure (Al-Ejeh, et al., 2011). Therefore, a better understanding of how BCSCs 
contribute to breast cancer progression may lead to better cancer therapies (Figure 5). Analogous 
to normal stem cells, BCSCs are reliant on embryonic pathways to maintain their capacity for 
pluripotency and self-renewal. The pathways that control these stem cell features include the 
wingless-type MMTV integration site family (Wnt)/b-catenin, Hedgehog (Hh), and Notch (Pires, 
Amorim, Souza, Rodrigues, & Mencalha, 2016). These signaling pathways not only maintain 
cancer stem cell features, they also allow tumor cells to thrive in hypoxic environments (Figure 
6). The roles of Wnt, Hedgehog and Notch pathways in breast cancer will be reviewed in the 
following sections. 
The Wnt/b-catenin signaling pathway plays a vital role in developmental processes that 
determine cell patterning and cell fate determination (Howe & Brown, 2004). Wnt-protein 
ligands are palmitoylated by porcupine, released from cells, and exert their cellular effects by 
binding to cell surface Frizzled receptors that are complexed with low-density lipoprotein 5 
(LRP5) and low-density lipoprotein 6 (LRP6) (Figure 6). The Wnt-Frizzled-LRP5-LRP6 
receptor complex attracts axin and dishevelled (DVL) to the cell membrane, which triggers the 
inhibition of glycogen synthase kinase-3b (GSK-3b). Inhibition of GSK-3b activity in response  
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Figure 5. The Strategy Behind Targeting the Breast Cancer Stem Cell Population in Breast 
Tumors  
Targeting the stem cell niche to eradicate BCSCs represents a new area of therapeutic 
development. Understanding the biology of BCSCs and the mechanisms that support them in 
breast cancer could help improve tumor treatment and prevent recurrence and metastasis. The 
theory behind targeting CSCs in breast tumors is to prevent tumor recurrence and drug 
resistance. BCSCs = Breast Cancer Stem Cells, CSCs = Cancer Stem Cells. 
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Figure 6. The Activation of Developmental Signaling Pathways in Cancer Stem Cells 
Notch, Wnt, and Hedgehog signaling pathways regulate normal and stem cell fate. (A) Notch 
signaling. Upon binding of Notch ligands to the Notch receptor, the NICD translocates to the 
nucleus where it binds with the CSL co-activator complex and MAML to induce transcription of 
its target genes for stem cell dedifferentiation. (B) Wnt signaling. Canonical Wnt signaling 
occurs through the stabilization and nuclear accumulation of β-catenin. Wnt ligands bind to the 
Frizzled receptor and the LRP co-receptor, activates DVL and recruits the axin degradation 
complex to the LRP receptor away from β-catenin, preventing its degradation. β-catenin is then 
free to translocate to the nucleus and associate with the transcription factors TCF/LEF and CBP 
to initiate transcription of target genes for mammary gland development and stem cell renewal. 
(C) Hedgehog signaling. Hh is a secreted ligand that binds to its receptor, Patched. When 
Patched is activated by Hh binding, inhibition of the SMO receptor is relieved, which allows 
SMO to localize to the plasma membrane. SMO is then able to inhibit the phosphorylation and 
cleavage of Gli which prevents the formation of Gli-R and instead promotes the formation of 
Gli-A, which translocates into the nucleus and initiates transcription of target genes for stem cell 
regulation. (D) In hypoxia, HIF-1α is not phosphorylated by PHD proteins and is stabilized in the 
cytoplasm by NICD, where it is then translocated into the nucleus and induces gene expression 
for maintaining undifferentiated cancer stem cells. JAG1 = Jagged1, DLL1 = Delta-like ligand 1, 
ADAM = A-disintegrin and metalloproteinase, NICD = Notch Intracellular Domain, HIF-1α = 
Hypoxia Inducible Factor 1α, RBP-Jk = Recombination Signal Binding Protein for 
Immunoglobulin Kappa J Region, CSL = RBP-Jk/Suppressor of Hairless/ Lag-1, MAML = 
Mastermind-like, LRP = Low-Density Lipoprotein Receptor, DVL = Dishevelled, GSK-3b = 
Glycogen Synthase Kinase-3b, APC = Adenomatous polyposis coli, CK1α = Casein Kinase 1α, 
TCF/LEF = T-cell Factor/Lymphoid Enhancing Factor, CBP = cAMP Binding Protein, PKA = 
Protein Kinase A, Hh = Hedgehog, SMO = Smoothened, Gli = glioma associated oncogene, Gli-
R = Restricted Gli, Gli-A = Activated Gli, PHD = Prolyl Hydroxylase Domain, CCNDI = Cyclin 
D1, VEGF = Vascular Endothelial Growth Factor, CCNE = Cyclin E, HES1 = Hairy Enhancer 
of Split 1. Dashed Arrows = Post-activation.  
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to a Wnt ligand promotes the accumulation of β-catenin. The increase in β-catenin promotes its 
translocation into the nucleus at which point it functions as a transcriptional activator by binding 
with cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) (also 
known as CREB binding protein (CBP)) and T-cell factor/lymphoid enhancing factor (TCF/LEF) 
transcription factors. The b-catenin-CBP-TCF/LEF complex then increases the transcription of 
oncogenes such as v-myc avain myelocytomatosis viral oncogene homolog (c-myc), CCND1, 
and Wnt (Howe & Brown, 2004; Macdonald, Semenov, & He, 2007). The Wnt signaling 
pathway is constitutively activated in BCSCs by an autocrine mechanism and is associated with 
the maintenance of stem cell properties (Giles, van Es, & Clevers, 2003; Jang, et al., 2015). The 
importance of Wnt signaling in CSCs was determined in a study where inhibition of Wnt 
signaling altered the stem cell phenotype (i.e. CD44+/CD24-/ALDH1-), which resulted in the 
reduction of in vitro and in vivo tumor formation and cell migration (Jang, et al., 2015; Zhao, et 
al., 2016; Kim do, et al., 2016).  
The Hedgehog (Hh) family is comprised of three members: Sonic hedgehog (Shh), Indian 
hedgehog (Ihh) and Desert hedgehog (Dhh). The Hedgehog signaling pathway controls 
embryonic development by regulating cell proliferation, cell fate determination and cell 
patterning (Chen, Wilson, & Chuang, 2007). The Hedgehog signaling pathway has also been 
identified to play an important role in maintaining the stem cell population in adult animals 
(Justilien & Fields, 2015). There are three Hh zinc finger protein transcription factors that are 
sequestered in the inactive state in the cytoplasm with kinesin family member 7 (KIF7) and 
suppressor of fused (SUFU): glioma associated oncogene-1 (Gli-1), glioma associated oncogene-
2 (Gli-2), and glioma associated oncogene-3 (Gli-3). Smoothened (SMO) is located in the 
cytosol and is responsible for transduction of Hh signaling inside the cell by regulating the 
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activation of the Gli transcription factors (Chen, Wilson, & Chuang, 2007). In the inactive Hh 
pathway, patched1 (PTCH1) blocks the activation and migration of SMO. In cancer cells, Hh is 
released into the tumor microenvironment and enhances stromal cell activity. Once Hh is 
secreted, it binds to PTCH1 on adjacent cells and allows for SMO to activate signal transduction 
at the cell membrane (Figure 6). Activated SMO undergoes phosphorylation by casein kinase 1a 
(CK1a) and protein kinase A (PKA), then removes the Gli transcription factors away from the 
KIF7-SUFU repressor complex (Chen, Wilson, & Chuang, 2007) (Figure 6). The Gli 
transcription factors are released and travel to the nucleus to activate transcription of Hh target 
genes (Lum & Beachy, 2004). There are several pieces of evidence showing that Hh signaling is 
important for breast cancer biology. One example being that overexpression of Hh or PTCH1 
mutations results in constitutively active SMO, which causes increased Gli activation (Tao, Mao, 
Zhang, & Li, 2011). Furthermore, these alterations have been demonstrated in the more 
aggressive breast cancer subtypes, such as TNBC (Tao, Mao, Zhang, & Li, 2011) and is essential 
for promoting growth and self-renewal, not just in BCSCs but also in stem cells from other 
tumors (Tanaka, et al., 2009; Liu & Micha, 2010; Wicha, Clarke, & Simeone, 2007; Su, et al., 
2012). 
The Notch signaling pathway controls self-renewal and asymmetric division of normal 
stem cells; however, its reactivation in epithelial cells contributes to tumorigenesis in the early 
stages of cancer (D’Angelo, et al., 2015). Notch signaling is predominately activated via cell-to-
cell interactions through the binding of one of the four Notch receptors (Notch1, Notch2, 
Notch3, and Notch4) expressed on the cell surface with one of five Notch ligands (Jagged1 
(JAG1), Jagged2 (JAG2), Delta-like ligand 1(DLL1), Delta-like ligand 3 (DLL3), and Delta-like 
ligand 4 (DLL4)) that are expressed on the cell surface of the signal receiving cell (Bray, 2006) 
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(Figure 7). The Notch ligand and Notch receptor interaction complex promotes the release of the 
Notch intracellular domain (NICD) via cleavage by A-disintegrin and metalloproteinase 
(ADAM) proteases and by the enzymatic complex g-secretase (Figure 7). Once cleaved, NICD is 
released into the cytoplasm and translocates into the nucleus where it binds with co-activators 
Mastermind-like (MAML) and p300 to induce transcription of Notch target genes (Bray, 2006; 
Ilagan & Kopan, 2007). It was reported that Notch1 expression in breast epithelial cells is 
enriched in BCSCs that express the CD44+CD24low/-ALDH1+ phenotype (Clarke, Anderson, 
Howell, & Potten, 2003) and was confirmed by D’Angelo et al. The work by D’Angelo et al. 
demonstrated that breast cancer cells that exhibit high levels of Notch signaling are capable of 
initiating the formation of mammospheres in cell culture, which is a hallmark feature of BCSCs 
(Sansone, et al., 2007a; D’Angelo, et al., 2015). Collectively, these results indicate that BCSCs 
exhibit high levels of Notch signaling that promote their stem cell like activity.   
Hypoxia is a hallmark of solid tumors, where the blood supply is not sufficient to meet 
the needs of the growing tumor (Déry, Michaud, & Richard, 2005). It is known that hypoxic 
tumors are indictors of poor prognosis and promotes treatment resistance to both radiation and 
chemotherapy (Qiang, et al., 2012). Hypoxia Inducible Factor 1a (HIF-1a) is translocated to the 
nucleus where it dimerizes with the aryl hydrocarbon receptor nuclear translocator (ARNT) and 
forms an active heterodimeric complex that regulates the expression of several genes responsible 
for promoting cell survival in a hostile environment, such as low oxygen levels, high acidity, and 
scarce nutrition (Hu, et al., 2014) (Figure 6). Interestingly, hypoxic conditions have been 
postulated to drive the formation of BCSCs (Helczynska, et al., 2003). The phenomenon occurs 
through a HIF-1a-NICD interaction, which is promoted by NICD stabilizing HIF-1a when in the 
absence of ARNT, resulting in the induction of tumor dedifferentiation to breast cancer with 
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stem cell characteristics (Cejudo-Martin & Johnson, 2005) (Figure 6). This same interaction 
occurs in embryonic stem cells, which is necessary for the stem cell to maintain an 
undifferentiated state. Schwab et al. showed that HIF-1a promotes BCSC viability by supporting 
the formation of mammospheres and maintaining their CD44+CD24low/-ALDH1+ phenotype in 
vivo through the increased expression of cluster of differentiation 133 (CD133), a direct target 
gene of the Notch pathway (Schwab, et al., 2012). Moreover, it has been shown in vitro that 
there is a high CD44 expression level in TNBC, which has been shown to be mediated by HIF-
1a (Krishnamachary, et al., 2012). The interaction between HIF-1a and the Notch pathway was 
confirmed by Qiang et al. in glioma stem cells (GSCs) by demonstrating that HIF-1a induced 
activation of the Notch pathway by binding and stabilizing NICD, driving the maintenance of 
GSCs (Qiang, et al., 2012). Collectively, the findings of these papers indicate that crosstalk 
between the Notch signaling pathway and HIF-1α is important for promoting stem cell activity in 
CSCs under hypoxic conditions.  
Inhibitors have been developed that target the embryonic pathways Wnt, Hh, and Notch, 
based on the rationale that these pathways are not only important for embryogenesis but also 
important for cancer progression (Figure 7). Regarding the Wnt pathway, LGK974 is a 
porcupine inhibitor and blocks Wnt palmitoylation and PRI-724 is a CBP/b-catenin antagonist; 
both have shown promising results and are currently undergoing phase I trials for breast cancer 
(Liu, et al., 2012; Lenz & Kahn, 2014). The inhibition of Hh signaling has also shown promising 
results in targeting BCSCs. Salinomycin, a carboxylic polyether ionophore, was shown to be 
selectively cytotoxic to BCSCs because it reduced Hh signaling by inhibiting the expression of 
the components necessary for the Hh pathway such as PTCH1, SMO, Gli-1, and Gli-2 (Fu, et al., 
2016). This finding has prompted the development of additional Hh inhibitors such as LDE225, a  
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Figure 7. Current Therapeutic Strategies for Targeting Wnt, Hedgehog and Notch 
Signaling in Breast Cancer Stem Cells 
Hedgehog, Notch, and Wnt/β-catenin pathways can be antagonized by molecular targeted agents 
including ligand-binding molecules, receptor antagonists, ligand receptor antagonists or agents 
inhibiting intracellular effectors. Red font indicates therapy strategies that target the Wnt 
signaling pathway, blue font indicates therapy strategies that target the Hedgehog signaling 
pathway, while purple font indicates strategies for targeting the Notch signaling pathway. Wnt = 
Wingless-type MMTV Integration Site Family, DVL = Dishevelled, LPS = Lipopolysaccharide, 
GSK2 = Glycogen Synthase Kinase 2, APC = Adenomatous Polyposis Coli, CK1a = Casein 
Kinase 1a, CBP = CREB Binding Protein, TCF/LEF = T-cell Factor/Lymphoid Enhancing 
Factor, COX2 = Cyclooxygenase 2, CD44 = Cluster of Differentiation 44, MMP7 = Matrix 
Metallopeptidase 7, PPARg = Peroxisome Proliferator-activated Receptor g, Hh = Hedgehog, 
COS2 = Kinesin Motor Protein Costal-2, SUFU = Suppressor of Fused, Gli = Glioma Associated 
Oncogene, Gli-A = Activated Gli, Gli-R = Restricted Gli, Gli1 = Glioma Associated Oncogene 
1, ADAM = A-Disintegrin and Metalloproteinase, NICD = Notch Intracellular Domain, MAML 
= Mastermind-like, RBP-Jk = Recombination Signal Binding Protein for Immunoglobulin kJ 
Region, CSL = RBP-Jk/Suppressor of Hairless/Lag1, myc = MYC Proto-oncogene, HES1 = 
Hairy Enhancer of Split 1, HER2 =  Human Epidermal Growth Factor Receptor 2, CDKN1A = 
Cyclin-dependent Kinase Inhibitor 1A, CCND1 = Cyclin D1, CCND3 = Cyclin D3, CCNE = 
Cyclin E. 
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SMO inhibitor, which is currently undergoing phase II trials for breast cancer (Irvine, et al., 
2016). 
More work has focused on the development of Notch inhibitors compared with the 
development of Wnt and Hh inhibitors. The g-secretase inhibitors (GSIs) are the most widely 
recognized Notch inhibitors that are effective against cancer that is resistant to endocrine therapy 
(Olsauskas-Kuprys, Zlobin, & Osipo, 2013). Anti-estrogen therapy with tamoxifen and 
fulvestrant increased the activity of BCSCs through activation of the JAG1-Notch4 signaling 
axis, but when combined with GSI RO4929097 the activity of BCSCs was suppressed (Simões, 
et al., 2015). The major side-effect to GSIs is gastrointestinal (GI) toxicity due to Notch 
signaling being vital to maintain the gut epithelium (Wong, et al., 2004). To avoid GI toxicity, 
new specific antibodies against the Notch receptors and Notch ligands are being developed for 
better selectivity and thus less toxicity. One example of a Notch receptor antibody targeted the 
Notch2 and Notch3 receptors (OMP-59R5, tarextumab), which was shown to reduce the breast 
cancer stem cell population in vivo. Therefore, targeting the stem cell niche to eradicate BCSCs 
represents a new area of therapeutic development to prevent tumor recurrence and metastasis 
(Yen, et al., 2015). 
1.3. Drug Resistance in Breast Cancer 
Despite the complex biological nature of cancer, there have been many recent successes 
in the treatment of various cancers due to the increased understanding of the diverse molecular 
mechanisms that modulate tumor development. However, the primary limitation of many cancer 
drugs is the development of tumors that are drug resistant (Zahreddine & Borden, 2013). Based 
on the tumor response to the initial therapy, drug resistance in cancer is categorized as either 
primary or acquired (Meads, Gatenby, & Dalton, 2009; Lippert, Ruoff, & Volm, 2011). While 
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primary drug resistance exists prior to treatment, acquired resistance occurs after the initial 
therapy, and unfortunately many patients will at some point develop resistance to treatment 
(Castells, Thibault, Delord, & Couderc, 2012). Therefore, it is vital to understand the various 
mechanisms that contribute to drug resistance in breast cancer.  
Both primary and acquired resistance can be caused by alterations in drug metabolism, 
uptake, efflux, and detoxification (Gottesman, 2002). The method of entry into cells depends on 
the chemical nature of the drug. Some drugs that do not enter the cell use receptors to bind to and 
activate cell signaling pathways. Other drugs utilize transporters, which allow them to enter the 
cell and induce cytotoxicity. From this perspective, resistance can result from mutations that alter 
the activity or reduce the expression of cell surface receptors (Atwood, Chang, & Oro, 2012; 
Kasper & Toftgård, 2013) or transporters (Galmarini, Mackey, & Dumontet, 2001; Damaraju, et 
al., 2003) and has been observed with the Hh signaling component SMO, where mutations 
caused a defective uptake in cyclopamine, a common chemotherapy agent (Yauch, et al., 2009).  
Increased drug efflux is promoted by the increased expression of adenosine triphosphate 
(ATP) binding cassette (ABC) membrane transporters (Gottesman, Fojo, & Bates, 2002). There 
are three members of the ABC transporter family that have their expression levels correlated 
with cancer chemo-resistance to various drugs: P-glycoprotein (P-gp), multidrug resistance-
associated protein 1 (MRP1), and breast cancer resistance protein (BCRP). P-gp has been 
identified to transport a wide variety of hydrophobic anti-cancer agents such as vinblastine, 
doxorubicin, vincristine, and taxol (Gottesman, 2002). MRP1 has been shown to transport 
natural-products and drugs with a negative charge or that have been modified by glutathione 
(GSH), glucuronic acid or sulfate (Hipfner, Deeley, & Cole, 1999; Borst, Evers, Kool, & 
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Wijnholds, 2000), while BCRP has been shown to promote resistance to topoisomerase I 
inhibitors, anthracyclines, and mitoxantrone (Gottesman, 2002). 
To exert cytotoxic effects, many anti-cancer drugs need to undergo metabolic activation 
(Sampath, et al., 2006). Therefore, drug inactivation also plays a major role in the development 
of drug resistance. One mechanism involves the conjugation of the drug to reduced GSH, a 
powerful anti-oxidant that protects the cells against the damaging effects of reactive oxygen 
species (ROS) (Wilson, Johnston, & Longley, 2009). GSH has been seen to conjugate with 
platinum-based drugs, which makes them susceptible substrates for ABC transporters and 
enhances their efflux (Meijer, et al., 1992). Other anti-cancer agents undergo inactivation via 
phase I drug metabolism, such as the topoisomerase I inhibitor irinotecan, which becomes 
inactivated by CYP450s. Metallothionein (MT) is a cysteine rich protein that acts like a chelator 
for various metals and has also been identified to bind platinum-based drugs as another means of 
drug inactivation (Kasahara, et al., 1991).   
Many cancers develop dependency on a particular oncogene, providing a basis for the 
development of targeted therapies. A primary example of this is endocrine therapy, which 
utilizes SERMs like tamoxifen, SERDs like fulvestrant, and AIs. Resistance to endocrine 
therapies are seen in 50%-60% of early breast cancer cases and eventually develops in almost all 
patients with advanced disease (Davies, et al., 2011). There are several mechanisms of resistance 
to endocrine therapy including loss or modification of ER expression, epigenetic regulation of 
ER expression and crosstalk between ER and different signaling pathways (Ali & Coombes, 
2002; Massarweh & Schiff, 2007). Other causes of drug resistance are due to hypoxia, increased 
EGFR (Schlessinger, 2004) and HER2 expression (Pietras, et al., 1995), as well as mitogen-
activated protein kinase (MAPK) hyperactivation (Ali, Metzger, & Chambon, 1993). However, 
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crosstalk between ER and different signaling pathways is the main mechanism of endocrine 
resistance, as targeting one protein alone can become ineffective as other parallel pathways can 
take over tumor survival. This endocrine crosstalk mechanism was demonstrated in breast cancer 
cells by Simões et al. who showed that short-term treatment with tamoxifen or fulvestrant 
decreased breast cancer cell proliferation, but increased BCSC activity through activation of 
Notch signaling and resulted in tumor recurrence and drug resistance (Simões, et al., 2015). By 
targeting the Notch pathway via GSIs, Notch signaling was reversed and suppressed BCSC 
activity that was originally induced by tamoxifen alone (Simões, et al., 2015). Current research 
shows that inhibiting the Notch signaling pathway via GSIs can decrease drug resistance 
(Nefedova, Cheng, Alsina, Dalton, & Gabrilovich, 2004) and promote apoptosis (Séveno, et al., 
2012) by restoring the effects of tamoxifen and other endocrine targeting agents. 
Drug resistance could also result by avoiding apoptotic pathways. Apoptotic resistance 
can be triggered by inactivating mutations in genes coding for apoptotic proteins (i.e. p53) or by 
activating mutations in genes coding for anti-apoptotic proteins, such as B-cell lymphoma-2 
(Bcl-2) (Evan & Vousden, 2001). Mutations in p53 have been correlated with resistance to 
doxorubicin treatment in patients with advanced breast cancer (Geisler, et al., 2001). In the case 
for endocrine therapy, the treatment fails if the balance between proliferation and apoptosis 
cannot be maintained because the pro-apoptotic genes are increased, and the anti-apoptotic genes 
are decreased (Ali, et al., 2016). Tamoxifen can act as an ER antagonist in breast cancer cells but 
in other cell types acts as an ER agonist. As a result, the anti-apoptotic proteins are promoted by 
estrogen to protect normal cells from cell death, but in the presence of tamoxifen, the pro-
apoptotic genes are decreased, and anti-apoptotic proteins are increased (Lewis-Wambi & 
Jordan, 2009). The tamoxifen resistance is promoted by ER-positive breast cancer via expression 
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of Bcl-2 (Kumar, Mandal, Lipton, & Harvey, 1996) and tumor growth factor b (TGFb) (Osborne 
& Fuqua, 1994). The HER2-enriched breast cancers already have high levels of Bcl-2 which 
leads to reduced tamoxifen-induced apoptosis. Current research shows that inhibiting the Notch 
signaling pathway via GSIs can decrease drug resistance and promote apoptosis by restoring the 
effects of tamoxifen and other endocrine targeting agents (Wang, et al., 2012). Given the 
importance of Notch signaling in cancer progression, the following chapter will cover the Notch 
pathway in both cancer and normal physiological functions.   
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CHAPTER 2 
THE NOTCH SIGNALING PATHWAY 
The Notch signaling pathway is a highly conserved evolutionary pathway that plays vital 
roles that have been established as fundamental in both multi-cellular and developmental 
processes (Borggrefe & Liefke, 2012). The Notch receptor was originally discovered in 
Drosophila as a neurogenic gene, and its signaling pathways were revealed to be pleiotropic, as it 
affected many other tissues (Artavanis-Tsakonas, Muskavitch, & Yedvobnick, 1983). These 
pleiotropic effects and physiological functionalities were identified to hold true in mammalian 
species, where the Notch signaling pathway was shown to play a pivotal role in embryonic and 
post-natal development (Andersson, Sandberg, & Lendahl, 2011; Ables, Breunig, Eisch, & 
Rakic, 2011). More specifically, Notch has been identified to regulate a variety of functional 
effects, ranging from cell differentiation, cell proliferation, cell survival and apoptosis. It is 
therefore not surprising that the Notch pathway and its functional effects are exploited in cancer 
progression (Koch & Radtke, 2010; Ranganathan, Weaver, & Capobianco, 2011). 
2.1. Canonical Notch Signaling 
When first studied, the Notch signaling pathway appeared to be remarkably simple, as it 
was activated through direct interactions between the Notch receptors and its ligands on 
neighboring cells (Figure 8). The mammalian Notch receptor family consists of four Notch 
receptors (Notch1, Notch2, Notch3, Notch4) and five Notch ligand receptors (JAG1, JAG2, 
DLL1, DLL3, and DLL4) (D’Souza, Miyamoto, & Weinmaster, 2008). Notch ligands are Delta-
Serrate-Lag1 (DSL)-containing type I transmembrane proteins that bind to the Notch receptor 
and induce a conformational change, exposing the cleavage site on the extracellular domain 
(ECD) to the ADAM/tumor necrosis factor a (TNFa) converting enzyme (TACE) complex  
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Figure 8. Canonical Notch Signaling  
Notch signaling is activated by interaction between the ligand-expressing cell and the Notch-
expressing cell, followed by proteolytic cleavage that releases the NICD. Before activation of 
Notch signaling, CSL is bound to DNA along with CoRs such as SPEN. Upon activation of 
Notch, the NICD recruits the co-activator MAML and others, and thus converts the CSL-
repressor complex into a transcriptional activator complex and drives the transcription of target 
genes. The signal is terminated by phosphorylation of the NICD, followed by ubiquitylation by 
FBXW7 and proteasomal degradation. Numb promotes ubiquitylation of the membrane-bound 
Notch1 and targets the NICD for proteasomal degradation. Signal transduction from Notch 
ligands also occurs. Proteolytic cleavage releases the ICD of the Notch ligands. The PDZ domain 
interacts with PDZ-containing proteins, resulting in a signaling cascade. The ICDs of Notch 
ligands JAG and DLL can also enter the nucleus and regulate transcription, possibly through 
interactions with AP-1 or the Smad proteins. This transcriptional regulation may be antagonized 
by the NICD. CoRs = Co-repressors, ICD = Intracellular Domain, PDZ = PSD-95/Dlg/ZO-1, 
CDK8 = Cyclin-dependent Kinase 8, ADAM = A-disintegrin and Metalloproteinase, FBXW7 = 
F-Box and WD Repeat Domain Containing 7, NICD = Notch Intracellular Domain, CSL = RBP-
Jk/Su(H)/LAG1, SPEN = MINT and SHARP, MAML = Mastermind-like, Ub = Ubiquitin, AP-1 
= Activator Protein-1, p = Phosphate Group. 
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(Fleming, 1998). The Notch receptor then undergoes another cleavage in the intercellular domain 
by the presenilin-g-secretase complex (Jorissen & De Strooper, 2010). This cleavage cascade 
results in the release of the NICD from the plasma membrane and its translocation to the nucleus 
(Bray, 2006). Once in the nucleus, the NICD then mediates the conversion of the RBP-
Jk/Suppressor of Hairless (Su(H))/Lag-1 (CSL) repressor complex into a transcriptional 
activation complex (Wilson & Kovall, 2006), leading to the recruitment of the co-activator 
mastermind-like (MAML) and the induction of gene expression (Nam, Sliz, Song, Aster, & 
Blacklow, 2006; Vasquez-Del Carpio, et al., 2011) (Figure 8). Several well-characterized target 
genes of the Notch pathway have been identified, such as the transcriptional repressors hairy 
enhancer of split (HES) family and the HES related family basic helix-loop-helix (bHLH) 
transcription factor with YRPW motif (HEY) family (Borggrefe & Oswald, 2009). Notch 
signaling is terminated by phosphorylating the NICD, which is targeted for ubiquinylation by F-
box and WD repeat domain containing 7 (FBXW7) E3 ligase and degraded via the proteasome 
(Le Bras, Loyer, & Le Borgne, 2011; Gupta-Rossi, et al., 2001; Le Friec, et al., 2012). 
Although the primary role of Notch ligands is to activate Notch signaling, Notch ligands 
can also have unique Notch-independent functions (Pintar, De Biasio, Popovic, Vanova, & 
Pongor, 2007). Recent evidence has shown that after binding to the Notch receptor, the DSL-
containing ligands also undergo proteolytic cleavage and initiate signaling events that are 
independent of the NICD (Ikeuchi & Sisodia, 2003). Signaling induction from DSL-containing 
ligands was determined when ectopic expression of JAG1 transformed rat kidney epithelial cells 
independently of Notch signaling and required an intact and functional postsynaptic density 
protein-95 (PSD-95)/discus large homolog (Dlg)/zona occludens 1 (ZO-1) (PDZ)-ligand motif in 
JAG1; this prompted the hypothesis that the Notch-DSL pathway is bidirectional (Ascano, 
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Beverly, & Capobianco, 2003). Bidirectional signaling in this case indicates that even though 
activation of the Notch pathway is receptor-ligand dependent, the intracellular domains (ICDs) 
of each receptor and ligand regulate transcription independently. JAG1 and other Notch ligands 
undergo similar processing and proteolytic cleavage to release their respective ICDs. The JAG1 
intracellular domain (JICD) has been identified to activate activator protein-1 (AP-1)-mediated 
transcription (Duryagina, et al., 2013), and inhibit NICD mediated transcription (Metrich, et al., 
2015). The delta-like ligand (DLL) intracellular domain (DICD) was also able to mediate TGFb-
Activin signaling through binding to Smads (Hiratochi, et al., 2007), and was also inhibited by 
the NICD (Jung, et al., 2011). However, even though Notch-independent DSL signaling has been 
reported and established, its physiological relevance in tumorigenesis has yet to be identified. 
The Notch pathway does not act independently. Rather, it is part of a complex network of 
many signaling pathways that are interconnected (Borggrefe & Liefke, 2012). As an example, 
the Notch pathway has been identified to be modulated by Wnt signaling (Jin, et al., 2009) and 
HIF-1a (Gustafsson, et al., 2005). Table 2 identifies various Notch-interacting partners that 
either inhibit or activate Notch signaling. Within this intricate network are feedback loops, which 
are essential for establishing limitations of Notch signaling during development (Kim, et al., 
2011; Fischer & Gessler, 2007). Notch signaling regulates itself by activating the transcription of 
regulatory factors that are direct Notch target genes such as hairy enhancer of split 1 (HES1) 
(Takebayashi, et al., 1994). These regulatory factors are what establish the positive- and 
negative-feedback mechanisms in Notch signaling, which can be classified based on the stages 
they act on within the pathway (Figure 9). The first stage that direct feedback regulators act on is 
the initiation of the Notch response. The genes that code for the Notch receptors, Notch1 and  
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Table 2. Notch-interacting Partners 
There are many interacting factors that can alter the stability and the composition of the activator 
complex, which precisely regulates the Notch signaling output. HIF-1a = Hypoxia Inducible 
Factor 1a, JICD = JAG1 Intracellular Domain, RUNX2 = Runt Related Transcription Factor 2, 
RUNX3 = Runt Related Transcription Factor 3, NICD = Notch Intracellular Domain, MAML = 
Mastermind-like, - = Notch Inactivation, + = Notch Activation. 
 
 
 
 
 
 
 
 
Notch-interacting Partners
Interacting Protein Partner Notch Signaling 
Effect
β-catenin
(Jin, et al., 2009)
NICD +
HIF-1α
(Gustafsson, et al., 
2005)
NICD +
JICD
(Kim, et al., 2011)
NICD -
p300
(Oswald, et al., 2001)
NICD/MAML +
RUNX2
(Ann, et al., 2011)
NICD -
RUNX3
(Gao, et al., 2010)
NICD -
Smad
(Takizawa, Ochiai, 
Nakashima, & Taga, 
2003)
NICD +
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Figure 9. Notch Target Genes that Act as Positive- and Negative-feedback Regulators for 
the Notch Signaling Pathway 
Direct feedback regulators can be classified based on what stages of Notch signaling they can 
modulate. (A) The initiation phase of Notch signaling (Pin1 and cis-inhibition). (B) NICD and 
corresponding transcription complex levels and stability (Numb and JICD). (C) Co-regulation 
gene expression by binding to N-Box (suppressing DNA regions) and E-Box (enhancing DNA 
regions) sequences of Notch target genes (HES1 and c-myc). NICD = Notch Intracellular 
Domain, JICD = JAG1 Intracellular Domain, Pin1 = Prolyl-cis/trans Isomerase 1, CSL = RBP-
Jk/Su(H)/Lag-1, MAML = Mastermind-like, HES1 = Hairy Enhancer of Split 1, c-myc = V-myc 
Avian Myelocytomatosis Viral Oncogene Homolog, PDZ = PSD-95/Dlg/ZO-1, Ub = Ubiquitin. 
Green Arrows = Positive-feedback Loops, Red Arrows = Negative-feedback Loops. 
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Notch3, and Notch ligand receptors JAG1 and DLL1 were found to be regulated by the Notch 
pathway itself (Weng, et al., 2006; Weerkamp, et al., 2006; Chen, et al., 2010; Qian, et al., 2009). 
The increased expression of these Notch receptors and ligands acts to promote a positive- 
feedback loop. However, even though increasing expression of these receptors promotes Notch 
signaling on the adjacent cell, the same receptors act as a negative regulator on the originating 
cell; a cellular process coined cis-inhibition (del Álamo, Rouault, & Schweisguth, 2011). Nuclear 
inhibition has been observed through studying the JICD. After the JICD is released from the 
receptor, it translocates to the nucleus and binds the NICD, where it inhibits Notch signaling by 
promoting its proteasomal degradation via FBXW7 (Kim, et al., 2011). Therefore, the 
intracellular functionality of the JICD serves as an additional negative-feedback loop. A form of 
positive-feedback at the initiation step is increased expression of the Notch target gene prolyl-
cis/trans-isomerase 1 (Pin1) (Rustighi, et al., 2009). Once expressed, Pin1 interacts with the 
Notch1 receptor at the membrane and helps promote cleavage by g-secretase, which stimulates 
the release of the NICD. Therefore, increased Pin1 expression results in elevated Notch1 activity 
and transcriptional output. 
Direct feedback regulators also play a role in modulating the amount and stability of 
NICD. While at the membrane or shortly after release, NICD can interact with Notch target gene 
product Numb (Figure 9). Numb acts as a negative-feedback regulator by interacting with the 
NICD and induces ubiquitination via the E3 ligase Itch, which stimulates the ubiquitination and 
proteasomal degradation of the NICD (Rebeiz, Miller, & Posakony, 2011) (Figure 9). This 
negative-feedback regulator results in the reduction of the total amount of NICD present in the 
cell and nucleus, hence reducing its transcriptional output. Runt related transcription factor 2 
(RUNX2) also acts as negative regulator by inhibiting Notch1 signaling during osteoblast 
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differentiation by binding the NICD and inducing its degradation (Ann, et al., 2011). Other 
Notch target genes are transcription factors that can transmit the Notch signal to further 
downstream target genes. Some well-known examples of Notch target genes that encode 
transcription factors include: HES1, hairy enhancer of split 5 (HES5), and HES related family 
bHLH transcription factor with YRPW motif 1 (HEY1), which are DNA binding transcription 
factors that act through transcriptional elements to induce or suppress the expression of target 
genes (Fischer & Gessler, 2007). These enhancer and repressor regions are present in many 
Notch target genes and there have been several reports showing that Notch target genes can be 
repressed by HES1, including the HES1 gene itself. This feedback loop was identified as an 
“incoherent network logic” by Krejcí et al. to signify Notch as a signaling pathway that induces 
its target genes along with repressors for those target genes, which could serve a purpose to 
create a temporary window of responsiveness after Notch activation (Krejcí, Bernard, Housden, 
Collins, & Bray, 2009). Collectively, these positive- and negative-feedback loops play a major 
role in modulating the Notch pathway and are essential to convert these modulations into 
versatile biological outcomes. 
2.2. Physiological Functions of Notch Signaling: Immunity, Inflammation, Hematopoiesis, 
and Development 
Recent evidence has established that Notch signaling is associated with immunity and 
inflammation because of its activity in several inflammatory diseases including rheumatoid 
arthritis (RA) (Ando, et al., 2003), atherosclerosis (Fung, et al., 2007), and primary biliary 
cirrhosis (Geisler & Strazzabosco, 2015). Expression of Notch receptors and ligands was 
detected in RA synovial tissues, and excessive activation of Notch1 was observed in synoviocyte 
cultures from RA patients (Nakazawa, et al., 2001). Therefore, it has been predicted that the 
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Notch pathway is activated in RA and may modulate the severity of the disease. However, 
although the association between Notch signaling and inflammation is supported by a copious 
amount of literature, the mechanisms by which Notch regulates inflammation is poorly 
understood. Under inflammatory conditions, Notch signaling can be promoted by stimuli from 
two different sources, exogenous agents such as pathogens and/or endogenous factors such as 
inflammatory cytokines.  
Regarding pathogenic infections, macrophages (Palaga, et al., 2008) and dendritic cells 
(DCs) (Cheng & Gabrilovich, 2008; Gentle, Rose, Bugeon, & Dallman, 2012; Cheng, Nefedova, 
Miele, Osborne, & Gabrilovich, 2003) express toll-like receptors (TLRs) that enable them to 
respond rapidly to coordinate innate and adaptive immune responses. TLRs are a single 
membrane-spanning, non-catalytic receptor class of proteins that play a key role in the innate 
immune system and are usually expressed on sentinel cells that recognize structurally conserved 
molecules, such as macrophages and DCs. Concurrently, macrophages and DCs also 
constitutively express Notch ligands and receptors on their cellular membrane that respond to 
Notch signaling (Cheng, Nefedova, Corzo, & Gabrilovich, 2007; Shang, Smith, & Hu, 2016). 
There is plenty of evidence that TLRs can modulate Notch signaling by inducing expression of 
Notch receptors as well as Notch ligands JAG1, DLL1, and DLL4 (Fung, et al., 2007; Foldi, et 
al., 2010; Monsalve, et al., 2009). By enhancing the expression of Notch receptors and ligands, 
TLR signaling indirectly promotes Notch activation in a manner that is predicted to be dependent 
on de novo protein synthesis (Palaga, et al., 2008; Hu, et al., 2008). These observations support a 
binary model where signal 1 represents tonic signaling and signal 2 represents acute TLR 
signaling (Shang, Smith, & Hu, 2016). This binary model allows us to understand that: 1) resting 
macrophages show basal levels of the NICD because of constitutive expression of Notch 
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receptors and ligands, 2) activation of Notch target gene expression occurs rapidly once triggered 
by TLR stimulation, which circumvents the requirement for activation via receptor-ligand 
induction, and 3) signal 1 or signal 2 alone is necessary but not sufficient for robust Notch target 
gene expression in macrophages. Therefore, the cooperation of both signaling pathways is 
required for optimal activation. However, it is important to note that the mechanism that couples 
acute TLR signaling to Notch pathway activation is currently unknown.  
Inflammatory cytokines such as TNFa and interleukin-1b (IL-1b) are essential for host 
defense against a plethora of pathogens and are present during innate and immune responses. 
However, these cytokines can become detrimental and pathogenic under conditions with 
uncontrolled inflammation and in autoimmune diseases when the expression of these cytokines 
becomes dysregulated. In RA, it is well established that TNFa plays a key role in RA 
pathogenesis and is currently validated as a drug target in the treatment of RA. Coincidently, in 
RA synovial fibroblasts, TNFa induces transcription of Notch1, Notch4, and JAG2 via 
activation of the nuclear factor-kB (NF-kB)-inhibitor of NF-kB subunit a (IKKa) signaling 
pathway, which in turn promotes NICD nuclear translocation (Ando, et al., 2003). Another 
example of TNFa-induced Notch activation is observed in osteoclast precursors, where Notch 
signaling is activated by TNFa and as a result inhibits osteoclastogenesis and enhances TNFa-
mediated inflammatory bone resorption in a feedback manner (Zhao, Grimes, Li, Hu, & 
Ivashkiv, 2012). Therefore, TNFa appears to function as a promoter of Notch signaling in 
various cell types. IL-1b is reported to induce expression of Notch target gene HES1 in 
chondrocytes via Notch1 activation (Ottaviani, et al., 2010). In addition, TGFb has also been 
identified to directly induce HES1 expression in several cell types (Ostroukhova, et al., 2006). 
While there are multiple cytokines that positively regulate Notch signaling, interferon-g (IFNg) 
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functions as a negative regulator of Notch signaling (Hu, et al., 2008) and was observed in 
human macrophages, where IFNg suppressed transcription of Notch target genes by TLR and 
Notch ligands. However, the precise mechanism of how this occurs has not been identified. 
Hematopoiesis is the developmental process where pluripotent hematopoietic stem cells 
(HSCs) produce progeny that undergo proliferation and differentiation as a response to both cell-
bound factors and cytokines in a positive and negative manner, which results in the production of 
mature blood cells of various lineages. The Notch signaling pathway modulates the interactions 
between HSCs (which express all four Notch receptors) and bone marrow stromal cells (which 
express various Notch ligands) in the developing immune system (Bigas, Martin, & Milner, 
1998). It is important to understand the role of Notch signaling in myeloid cell development and 
differentiation, even though there are some discrepancies regarding the mechanism(s) involved. 
One collection of evidence was able to demonstrate that Notch signaling is vital in the 
maintenance of progenitor cells and blocking terminal differentiation of myeloid cells (Shang, 
Smith, & Hu, 2016) and was supported when retroviral transduction of activated Notch1 
intracellular domain (NICD1) in 32D myeloid progenitor cells inhibited the differentiation of 
mature granulocytes in response to granulocyte colony-stimulating factor (G-CSF) but not 
granulocyte macrophage colony-stimulating factor (GM-CSF), without affecting the proliferation 
of undifferentiated cells. Interestingly, the Notch2 intracellular domain (NICD2) inhibited 
differentiation of 32D cells in response to GM-CSF but not G-CSF (Milner, et al., 1996; Bigas, 
Martin, & Milner, 1998), which suggests that even though both Notch1 and Notch2 inhibited 
myeloid differentiation, there may be independent functions taking place in HSCs depending on 
the specific differentiation signal involved. Over-expression of HES1 resulted in a similar 
phenotype and, in addition, also blocked erythroid differentiation (Lam, Ronchini, Norton, 
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Capobianco, & Bresnick, 2000; Kumano, et al., 2001). On the other hand, Notch has been shown 
to be required for differentiation of mature myeloid cells. Schroeder & Just were able to 
demonstrate that conditional expression of the NICD in 32D cells decreased self-renewal and 
enhanced granulocyte differentiation through JAG1 activity in a transcriptionally active form of 
RBP-Jk (Schroeder & Just, 2000).  
It was more recently demonstrated by Klinakis et al. that Notch modulated early HSC 
differentiation in vivo. In a mouse model, Notch signaling was inhibited by targeting g-secretase 
complex member nicastrin, and resulted in excessive accumulation of granulocyte and or 
monocyte progenitors in the blood, spleen, and liver; which is diagnostic of the induction of 
chronic myelomonocytic leukemia (CMML)-like disease (Klinakis, et al., 2011). Gene 
expression analysis was able to reveal that the Notch pathway regulates a myelomonocytic-
specific gene signature by suppressing gene expression via HES1. Furthermore, in samples from 
CMML patients, somatic mutations were identified in multiple components of the Notch 
pathway such as nicastrin, MAML and Notch2, suggesting a potentially tumor-suppressive role 
for Notch signaling in addition to its involvement in early HSC differentiation (Shang, Smith, & 
Hu, 2016). 
Notch signaling is remarkably pleiotropic. There is not a cell or tissue that is not affected 
by cell fate choices regulated by Notch signaling (Hori, Sen, & Artavanis-Tsakonas, 2013). With 
regard to developmental signaling, the consequences of either activating or inhibiting Notch is 
strictly context-specific. For example, the same Notch signal in one circumstance can promote 
proliferation while another can result in apoptosis (Hori, Sen, & Artavanis-Tsakonas, 2013). 
Therefore, how Notch signaling is incorporated with other signaling pathways in the context of a 
particular cellular physiology will ultimately dictate how Notch activity affects cell fate. Even 
41 
though there are a lot of spatial and temporal complexities intertwined within the dynamics of 
this pathway, cis-inhibition is the hallmark of Notch-regulated cell fate and lateral specification 
(Greenwald, 1998). Cis-inhibition describes the mechanism by which cells that are in the process 
of adopting one particular cell fate influence the fate of the neighboring cell. Due to this pathway 
being so evolutionarily conserved, most eukaryotic lineages rely on cis-inhibition. One classic 
example of the developmental action of Notch is the case of neuroblast differentiation in 
Drosophila embryo. In neuroblast differentiation, a cell that is about to become a neuroblast 
prevents its adjacent neighbors from adopting the same fate and has two important implications 
to consider when regarding morphogenesis: 1) Notch signaling helps in the separation of specific 
lineages from a field of developmentally equivalent cells and 2) is a crucial mechanism that 
specifies borders between cellular fields (Bray, 2006). 
Stem cells exist in most embryonic and adult organisms and are defined as cells having 
the ability for self-renewal. Stem cells also have the ability to generate all cell types of a given 
organ. During the developmental process, stem cells give rise to all lineages of tissues, but in 
adults they are responsible for maintaining tissue homeostasis in damaged tissue (Liu, Sato, 
Cerletti, & Wagers, 2010). Therefore, the balance between self-renewal and differentiation is 
under tight regulation to allow for proper development to occur and avoid excessive growth, 
which could potentially lead to cancer. Conditional gain- and loss-of-function studies 
demonstrated that Notch regulates quiescence and cell cycle exit in neuronal stem cells. 
Chapouton et al. showed that high Notch activity maintained neuronal stem cells in a quiescent 
state but inhibiting Notch signaling resulted in increased neuronal stem cell division followed by 
differentiation, which in turn depletes the neuronal stem cell population (Chapouton, et al., 
2010). Once again, this study suggests that cis-inhibition may act as the mechanism that 
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generated the results. Similar results were obtained in mice with conditional ablation of RBP-Jk 
in the adult brain, where all neuronal stem cells differentiated into transit-amplifying cells and 
neurons. As a result, transient neurogenesis was increased but later depleted the neuronal stem 
cell population and neurogenesis was completely lost (Ehm, et al., 2010). These results indicate 
that the Notch pathway is an absolute necessity for the maintenance of neuronal stem cells and 
for the proper control of neurogenesis in both embryonic and adult brains.   
2.3. JAG1-dependent Notch Signaling in Cancer 
The Notch pathway is increasingly attracting attention as a new target for cancer 
treatments considering that ligand-induced Notch signaling has been shown to promote cancer 
progression (Li, Masiero, Banham, & Harris, 2014). Even though Notch inhibitors such as GSIs 
are currently undergoing clinical trials and have been extensively researched, targeting Notch 
ligands provides a more attractive option due to 1) their more restricted expression, 2) better-
defined functions and 3) lower mutation rates in cancer. JAG1 is the most extensively researched 
Notch ligand, is over expressed in various cancer types, has been linked with poor prognosis, and 
plays a vital role in several functions of tumor biology.   
JAG1 is a member of the DSL family that encodes a Type I transmembrane receptor 
protein. The extracellular portion of this receptor contains a calcium-binding (C2) domain at the 
N-terminus that binds to the phospholipid bilayer once undergoing glycosylation to modulate 
JAG1-dependent Notch activation (Cordle, et al., 2008; Whiteman, et al., 2013) (Figure 10). The 
DSL binding domain is located below the C2 domain which is responsible for binding Notch 
receptors; this domain was also recently discovered to bind cluster of differentiation 46 (CD46) 
receptor to regulate T-cell functionality (Le Friec, et al., 2012) (Figure 10). Following the DSL 
binding domain are multiple highly conserved EGF repeats (human JAG1 consists of 16 EGF  
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Figure 10. The JAG1 Ligand Receptor and its Roles in Cancer Biology  
JAG1 is a type I transmembrane receptor protein. The extracellular portion of the receptor 
consists of a C2 phospholipid recognition domain, DSL-binding domain, 16 EGF repeats and a 
CRD. JAG1 can be cleaved by ADAM upon binding to the NOTCH receptor and then undergoes 
a second cleavage by 𝛾-secretase to release the JICD. The JICD contains a PDZ-ligand binding 
motif that is responsible for the intrinsic bidirectional signaling induced by JAG1. In cancer and/ 
or in stromal cells, JAG1 induces tumor cell growth and inhibits apoptosis. JAG1 also plays a 
key role in cancer stem cell maintenance and promotes metastasis. In the tumor 
microenvironment, JAG1 was also linked to promoting tumor angiogenesis and increasing the 
Treg cell population to inhibit tumor-specific immunity. The genes that are listed along the arrow 
leading to their corresponding role in cancer biology are regulated in a JAG1-dependent manner 
either in a direct or indirect manner. Genes represented in green are increased by JAG1 while the 
genes decreased by JAG1 are represented in red. DSL = Delta/Serrate/Lag-1, EGF = Epidermal 
Growth Factor, C2 = Calcium-binding, CRD = Cysteine-rich Domain, JICD = JAG1 Intracellular 
Domain, PDZ = PSD95/Dlg/ZO-1, ADAM = A-Disintegrin and Metalloproteinase, avb3-
integrin = Integrin av and Integrin b3,  IL-2 = Interleukin-2, IL-6 = Interleukin-6, IL-10 = 
Interleukin-10, IL-17 = Interleukin-17, CD44 = Cluster of Differentiation 44, CD34 = Cluster of 
Differentiation 34, µPA = Urokinase-type Plasminogen Activator, MMP2 = Matrix 
Metallopeptidase 2, MMP9 = Matrix Metallopeptidase 9, DLL4 = Delta-like Ligand 4, Bcl-2 = 
B-cell Lymphoma-2, c-myc = V-myc Avian Myelocytomatosis Viral Oncogene Homolog, 
Foxp3 = Forkhead Box P3, PDGFR-β = Platelet-derived Growth Factor Receptor–β, RUNX3 = 
Runt Related Transcription Factor 3, SOX2 = Sex Determining Region Y (SRY) Box 2, ZEB1 = 
Zinc-finger E-box Binding Homeobox 1, OX40L = Tumor Necrosis Factor Receptor, 
Superfamily Member 4. 
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repeats) (Figure 10). The DSL family is classified in the JAG- or DLL-subgroups, but the 
defining motif that determines the JAG1-subgroup is the presence of a cysteine-rich domain 
(CRD) between the EGF-repeats and transmembrane domain (Luca, et al., 2017; Chillakuri, et 
al., 2013). The intracellular domains of DSL proteins vary in length and are not conserved in the 
primary amino acid sequence. Additionally, the JICD contains a PDZ-ligand binding domain 
located at the C-terminal end of the JAG1 receptor (Ascano, Beverly, & Capobianco, 2003; 
LaVoie & Selkoe, 2003) (Figure 10). The JICD is released after undergoing cleavage by ADAM 
and g-secretase upon binding to the Notch receptor. Upon this release, the JICD induces intrinsic 
bidirectional signaling in the JAG1 expressing cell (Lu, et al., 2013) (Figure 8). Furthermore, 
JAG1-dependent Notch signaling is directly implicated in tumor growth by maintaining CSC 
populations (Simões, et al., 2015), promoting cell survival (Purow, et al., 2005), inhibiting 
apoptosis (Wang, et al., 2010a), and influencing cell proliferation (Cohen, et al., 2010) as well as 
metastasis (Leong, et al., 2007). Additionally, JAG1 can also affect cancer tumors indirectly by 
interacting with components of the tumor microenvironment to promote angiogenesis (Chen, et 
al., 2016) and T-cell regulation (Kumar, et al., 2017). Considering that the focus of this 
dissertation is based on the regulation of the Notch ligand receptor JAG1, this section will 
primarily focus on JAG1-dependent Notch signaling and its roles in cancer biology as well as its 
potential as a therapeutic target in breast cancer. Figure 10 depicts a synopsis of this section and 
contains an overview of the structure of JAG1 along with a summary of its roles in both direct 
and indirect regulation of gene expression for various functions in cancer biology. 
2.3.1. Angiogenesis 
Angiogenesis is the growth of new blood vessels from existing ones and is a 
physiological process that normally takes place during embryonic development and wound 
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healing (Carmeliet & Jain, 2011). Angiogenesis is also a hallmark function of cancer 
progression, as this process allows the tumor to receive nutrients (Hanahan & Weinberg, 2000). 
Notch ligands expressed on endothelial cells can interact with their respective receptors on 
endothelial and perivascular cells, smooth muscle cells, and pericytes, which are involved in 
multiple stages of blood vessel formation from initial sprouting until maturation of the blood 
vessel (Sainson & Harris, 2008). JAG1 has been proven to promote endothelial cell proliferation 
and sprouting and inhibit DLL4-dependent Notch signaling in endothelial cells (Kofler, et al., 
2011). Therefore, inhibition of JAG1 reduces sprouting angiogenesis, while increased expression 
suppresses DLL4-dependent signaling to promote sprouting angiogenesis.  
When it comes to vascular smooth muscle cell coverage of blood vessels and maintaining 
the interaction between endothelial cells and perivascular cells, JAG1 is indispensable. High et 
al. showed that the expression of JAG1 in endothelial cells is required for vascular smooth 
muscle development because its knockout from the endothelium induced defects in vascular 
smooth muscle turned out to be fatal (High, et al., 2008) due to JAG1-mediated increases in 
integrin av and integrin b3 (avb3-integrin), which confers activity to von Willebrand Factor 
(VWF). The activation of VWF is important for maintaining smooth muscle adhesion and vessel 
maturation (Scheppke, et al., 2012). It was shown by Liu et al. that Notch3-expressing 
perivascular cells can also be induced by JAG1-expressing endothelial cells (Liu, Kennard, & 
Lilly, 2009). As a result, the upregulation of JAG1 expression on perivascular cells induces an 
auto-regulatory loop that promotes pericyte maturation and angiogenesis. This auto-regulatory 
loop is important, considering that inhibition of Notch signaling by Notch3 or JAG1 knockdown 
abrogates angiogenesis. The platelet-derived growth factor (PDGF) signaling pathway functions 
to promote angiogenesis when endothelial cells secrete the ligand platelet-derived growth factor-
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b (PDGF-b) (Kofler, et al., 2011). Interestingly, the platelet-derived growth factor receptor-b 
(PDGFR-b) has been shown to be a direct target gene of JAG1-induced Notch activation (Liu, 
Kennard, & Lilly, 2009).  
In the case of tumor associated blood vessels, JAG1 has been reported to be highly 
expressed in blood vessels that are in contact with brain and ovarian tumors (Lu, et al., 2007). In 
head and neck squamous cell carcinoma (HNSCC) tumors, growth factors such as human growth 
factor (HGF) and TGFa are secreted from the tumor and, in an autocrine and or juxtacrine 
fashion, upregulate the expression of JAG1 via the MAPK pathway. As a result, JAG1 then 
stimulates endothelial sprouting, promoting angiogenesis and tumor growth in the mouse model 
(Zeng, et al., 2005). Moreover, JAG1 expression has a positive correlation with micro-vessel 
formation in HNSCC. The pro-angiogenic role of JAG1 has also been reported in ovarian cancer 
models because silencing JAG1 expression in stromal cells significantly reduced tumor 
microvascular density and neoplastic growth (Steg, et al., 2011). Overall, this data suggests that 
inhibiting the JAG1 pathway could be beneficial to cancer patients, even in the absence of 
tumoral JAG1 expression due to its role in the promotion of angiogenesis. 
2.3.2. Cancer Stem Cells 
 Even though CSCs were discussed extensively in the previous chapter, this section will 
cover the functionality of JAG1-dependent Notch signaling in the CSC population. Due to the 
significance of the Notch pathway in normal stem cell biology, treatment using GSIs in cancer 
patients to inhibit all Notch signaling factors (pan-Notch ablation) resulted in intolerable levels 
of GI toxicity (Imbimbo, 2008). Unlike the DLL1 and DLL4 Notch ligands, JAG1 was found to 
be dispensable for the homeostatic maintenance of normal intestinal stem cells (Pellegrinet, et 
al., 2011) suggesting that targeting JAG1 specifically is likely to have less GI side-effects. 
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Considering we know that Notch signaling is important for both CSC maintenance and self-
renewal (Wang, Li, Banerjee, & Sarkar, 2009; Espinoza, Pochampally, Xing, Watabe, & Miele, 
2013), several studies indicated that JAG1 is functionally linked to “stemness” in cancer and 
appears to be the primary ligand that drives Notch signaling in the CSC population (Patrawala, et 
al., 2005; Harrison, et al., 2010). 
In breast cancer, it was shown that high levels of JAG1 promote mammosphere formation 
in vitro by mediating the pro-cancer effects of Notch3 (Sansone, et al., 2007a), interleukin-6 (IL-
6) (Sansone, et al., 2007b), carbonic anhydrase IX (CAIX) (Lock, et al., 2013) and NF-kB 
(Yamamoto, et al., 2013). In a mouse model, deletion of lunatic fringe (Lfng), an N-
acetylglucosamine transferase that prevents JAG1-dependent Notch activation, induced basal-
like breast cancer with higher JAG1 activity and enhanced the CSC proliferation (Xu, et al., 
2012). JAG1 is also involved in CSC biology in other tumor types such as glioblastoma (Zhu, et 
al., 2011), lymphoma (Cao, et al., 2014), and colorectal cancer (Lu, et al., 2013). Overall, these 
observations indicate that JAG1 is a vital inducer of the CSC phenotype in different types of 
cancer, which suggests its targeting could suppress CSCs. 
2.3.3. Epithelial-Mesenchymal Transition (EMT), Invasion, and Metastasis 
Metastasis is a complex process with multiple steps that gives tumor cells the ability to 
invade the surrounding tissue and to colonize distant organs; both are key features of cancer 
aggressiveness. To escape their local environment, epithelial cells can exploit a reversible 
developmental process called the epithelial-mesenchymal transition (EMT) (Hanahan & 
Weinberg, 2011). EMT is a phenotypic switch that converts epithelial cells into motile 
mesenchymal-like cells, which requires epithelial cells to undergo a spectrum of changes that 
reduce their adhesion to other cells and increase their migratory process. EMT is essential during 
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embryonic development and in tissue repair (Kong, Li, Wang, & Sarkar, 2011), but a large body 
of evidence indicates that it contributes to the early stages of tumor metastasis. Notch signaling 
has been extensively studied in this context and several reports describe JAG1 involvement in 
EMT, invasion, and metastasis in breast cancer and other cancer types (Espinoza, Pochampally, 
Xing, Watabe, & Miele, 2013). Leong et al. demonstrated that JAG1-induced Notch signaling in 
breast cancer could inhibit the epithelial phenotype by increasing expression of EMT master-
regulator SLUG, which in turn promoted tumor growth and metastasis (Leong, et al., 2007). 
JAG1 was also shown to be integrated with TGFb-induced EMT in mammary gland cells 
(Zavadil, Cermak, Soto-Nieves, & Böttinger, 2004). Moreover, JAG1 increases the migratory 
and invasive behavior of TNBC cells through the induction of urokinase-type plasminogen 
activator (µPA), a well-established marker of recurrence and metastasis (Shimizu, et al., 2011). 
Lastly, JAG1 has been identified to be involved in the tissue specificity of breast cancer 
dissemination, as was described to play a vital role in metastasis to the bone and brain (Sethi, 
Dai, Winter, & Kang, 2011; Xing, et al., 2013). 
JAG1 was also described to promote EMT in other cancer types such as 1) cervical 
cancer, where JAG1 expression positively correlated with induction of PI3K-mediated EMT 
(Veeraraghavalu, et al., 2005), in 2) hepatocellular carcinoma, where JAG1 was reported to 
suppress the expression of tumor suppressor runt related transcription factor 3 (RUNX3) 
(Tanaka, et al., 2012), and in 3) drug resistant pancreatic cancer, where JAG1-Notch2 signaling 
promoted several EMT transcription factors such as Snail, Slug, and zinc-finger E-box binding 
homeobox 1 (ZEB1) (Wang, et al., 2009). In prostate cancer, JAG1 was able to promote invasive 
and migratory functions through the NF-kB signaling pathway (Wang, et al., 2010a). Lastly, in 
colon cancer, JAG1 mediated apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1) pro-
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tumorigenic functions and induced expression of metastatic markers matrix metallopeptidase 2 
(MMP2) and matrix metallopeptidase 9 (MMP9) (Kim, et al., 2013; Dai, et al., 2014). As a 
whole, JAG1-dependent Notch signaling appears to be implicated in various steps of EMT, 
invasion, and metastasis, which was demonstrated in several tumor types and further promotes 
the interest of JAG1 as a therapeutic target to inhibit tumor cell invasiveness and metastasis. 
2.3.4. Proliferation, Cell Cycle Regulation, Drug Resistance, and Survival 
JAG1 regulates basic cellular functions such as cell cycle progression, proliferation, 
apoptosis, and cell survival. In several types of cancer, JAG1 was shown to induce tumor cell 
growth and to promote cell cycle progression. For example, Cohen et al. showed that JAG1 can 
directly regulate the cell cycle by identifying CCND1 as a direct target of JAG1-dependent 
Notch activation in breast cancer cells (Cohen, et al., 2010). The same observation was also 
demonstrated in colon cancer where JAG1-dependent Notch signaling induced the expression of 
CCND1, cyclin E (CCNE), and c-myc (Dai, et al., 2014). In prostate cancer, JAG1 promoted 
cyclin-dependent kinase 2 (CDK2) activity while repressing p27, a cell cycle suppressor (Zhang, 
et al., 2006). Similar proliferative promoting functionality has also been reported in glioma 
(Purow, et al., 2005), myeloma (Jundt, et al., 2004), and ovarian cancer (Choi, et al., 2008; Steg, 
et al., 2011). Knowing the role of JAG1 in cell proliferation, it is not surprising that JAG1 is 
indicated as the Notch ligand that exerts anti-apoptotic functions. Evidence for the anti-apoptotic 
functions of JAG1 was produced by Wang et al. who demonstrated that JAG1 suppressed 
apoptosis by activating serine-threonine protein kinase (Akt), mechanistic target of rapamycin 
(mTOR), and NF-kB signaling pathways in glioma cells and by upregulating Bcl-2 (Wang, et al., 
2010a). In regard to drug resistance, JAG1 prevented chemotherapy-induced apoptosis in 
lymphoma with respect to doxorubicin (Cao, et al., 2014), taxanes with ovarian cancer (Steg, et 
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al., 2011), breast cancer with tamoxifen (Simões, et al., 2015), and pancreatic cancer with 
gemcitabine (Wang, et al., 2009). The chemo-protective effects of JAG1 represent a key finding 
as it highlights the opportunity to treat drug resistant cancers via combination therapy that 
includes inhibition of JAG1-dependent Notch signaling through the potential use of monoclonal 
antibodies or small molecules. 
2.3.5. T-cell Regulation 
The tumor microenvironment is a vital component for cancer growth and survival. There 
is a plethora of immune cells that are found within close proximity of tumors that include T-
cells, DCs, macrophages and neutrophils. However, there are very few natural killer cells 
present, which are extremely effective in killing tumor cells (Whiteside, 2008). It is important to 
note that in many cancer types, there is an increased concentration of T-regulatory (Treg) cells 
that can suppress immune responses that are tumor-specific, which in turn allows tumor cells to 
evade tumor surveillance (Strauss, et al., 2007). Treg cells in combination with myeloid-derived 
suppressor cells and cytokines help foster and maintain a favorable immunosuppressive tumor 
microenvironment that supports tumor growth (Whiteside, 2008).  
JAG1-induced Notch activation plays an important role in the induction and expansion of 
Treg cells in the tumor microenvironment, which involves cross-talk between tumor cells and 
DCs. JAG1-Notch3 signaling has been identified to stimulate tumor necrosis factor superfamily 
receptor 4 (OX40L) in order to initiate Treg cell induction and expansion (Gopisetty, et al., 
2013), while JAG1 expression in antigen presenting cells induces antigen-specific Treg cells. 
Furthermore, the maturation of DCs via JAG1 is what promotes the survival and proliferation of 
Treg cells (Bugeon, Gardner, Rose, Gentle, & Dallman, 2008). JAG1-induced Notch activation 
may also have an impact on CD46 T-cell activation, which was demonstrated by Le Friec et al. 
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by identifying a new interaction between JAG1 and CD46 (Le Friec, et al., 2012). CD46 is a 
ubiquitously expressed human type I transmembrane glycoprotein that is currently identified as a 
complement regulatory protein and cell-entry receptor (Le Friec, et al., 2012). The activation of 
CD46 on CD4+ T-cells was shown to regulate the expression of Notch as well as its ligands. 
Furthermore, JAG1 was identified as an additional physiological ligand for CD46, as the JAG1 
binding site of CD46 overlaps with that of Notch receptors. Therefore, targeting JAG1-
dependent Notch signaling may promote the eradication of tumor cells by augmenting the effects 
of cancer chemotherapeutics and by bolstering the capability of the immune system to destroy 
cancer cells.  
2.3.6. A Synopsis of JAG1-Notch Signaling in Breast Cancer 
To date, there are multiple lines of evidence that establish Notch signaling in the 
involvement of breast cancer development, maintenance and metastasis (Takebe, Nguyen, & 
Yang, 2014). Over expression of Notch1, Notch3, and Notch4-activated ICDs caused aggressive 
and metastatic mammary tumors in mice (Kofler, et al., 2011; Simões, et al., 2015), while active 
forms of Notch1 and Notch4 receptors induce transformation of both normal human and murine 
mammary epithelial cells (Leong, et al., 2007). Additionally, loss of Numb, a negative regulator 
of Notch signaling, is found to be associated with higher grade and poorer prognosis in breast 
cancer (Chen, et al., 2016), while suppression of Notch activity via Notch3 and CSL knockdown 
promotes cancer cell apoptosis and inhibits tumor cell growth (Liu, Kennard, & Lilly, 2009).  
It is important to note that unlike in T-cell acute lymphoblastic leukemia (T-ALL), which 
normally stems from Notch1 gene mutations (Vlierberghe & Ferrando, 2012), the induction of 
Notch signaling in breast cancer, as well as others, is mainly associated with ligand-dependent 
methods of activation. Studies currently indicate that JAG1 is the most prominent ligand 
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involved in excessive activation of Notch signaling in breast cancer as both messenger RNA 
(mRNA) and protein are over expressed in breast cancer and these higher expressions are 
established indicators of poor prognosis (Dickson, et al., 2007; Reedijk, et al., 2005; Buckley, et 
al., 2013). Therefore, it is critical to identify methods and or natural cellular mechanisms that 
inhibit or reduce JAG1 expression as a means for the treatment and prevention of various 
cancers. 
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CHAPTER 3 
THE ARYL HYDROCARBON RECEPTOR (AHR): A MULTI-FACETED 
TRANSCRIPTION FACTOR 
3.1. A Brief History and Introduction to AHR Biology 
During the Vietnam War, US and allied military sprayed approximately 77 million liters 
of tactical herbicide (Yi & Ohrr, 2014). Agent Orange was the most commonly used agent and 
was contaminated with 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD). In animals, TCDD is a 
lipophilic environmental toxicant that acts as a potent multisite carcinogen and has been shown 
to disrupt multiple endocrine pathways (Vanden Heuvel & Lucier, 1993; Sycheva, et al., 2016; 
Rappe, 1990). Later, it was discovered that TCDD binds its cognate cytoplasmic ligand-activated 
transcription factor, the aryl hydrocarbon receptor (AHR). TCDD is very stable and highly 
selective for the AHR, making it the ideal ligand for discovering AHR-regulated genes and 
pathways. To date, most TCDD effects have been reported to be mediated via the AHR and 
changes in gene expression. Although TCDD is best known for inducing developmental and 
immune toxicity, there are many reports showing that it also modulates several cancer processes 
(Warner, et al., 2011) including cell invasion (Hall, et al., 2010), movement (Zhang, et al., 2012), 
and proliferation (Zhang, et al., 2009). 
Since the Vietnam War and over the past 50 years, there have been advances in 
understanding the role of the AHR in both cancerous and normal tissue. The industrial revolution 
during the twentieth century promoted extremely rapid growth in the mass production of various 
plastic and metal materials. As a result, increased chemical waste production led to increased risk 
of exposure to potentially hazardous environmental pollutants/toxicants. Chemical spills and 
accidental exposure to polycyclic halogenated aromatic hydrocarbons (PHAHs) or polycyclic 
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aromatic hydrocarbons (PAHs) have unveiled a wide array of detrimental health effects, which 
has been and is continuing to be extensively studied by researchers (Zack & Suskind, 1980; 
Collins, Bodner, Aylward, Wilken, & Bodnar, 2009). In 1949, one of the earliest PAH/PHAH 
chemical spills occurred in Nitro WV, about 40 miles from Marshall University, and industrial 
workers that manufactured Agent Orange were exposed to the AHR agonist TCDD. Aside from 
being a carcinogen, exposure to TCDD resulted in chloracne, liver disease, ischemic heart 
disease, and even death in some workers (Collins, Bodner, Aylward, Wilken, & Bodnar, 2009). 
However, the exact mechanism by which TCDD causes toxicity in humans is still unclear. 
The discovery of benzpyrene hydroxylase was a result of some of the earliest research 
with PAHs (Conney, Miller, & Miller, 1957). Benzpyrene hydroxylase was an enzyme named 
due to its ability to form hydroxylated products of 3,4-benzpyrene, but it was quickly renamed 
aryl hydrocarbon hydroxylase (AHH) because several PAHs induced its activity (Nebert & 
Bausserman, 1971; Gielen & Nebert, 1971). During the 1970s, there were numerous studies 
showing that there was a direct correlation between activated AHH and increased cytochrome 
P450, family 1 subfamily A member 1 (CYP1A1) activity; and that this response varied between 
different mouse strains, specifically C57BL/6 and DBA/2 mice (Nebert & Bausserman, 1970). 3-
Methylcholanthrene (3-MC) was able to stimulate increases in AHH activity in C57BL/6 mice 
more effectively than DBA/2 mice. Researchers wondered whether diminished AHH activity in 
DBA/2 mice in response to 3-MC was due to these mice having a genetic defect, or whether they 
express a PAH/PHAH receptor with reduced binding affinity (Poland, Glover, Robinson, & 
Nebert, 1974). Researchers used radioactive TCDD to discover that it accumulated highly in the 
liver of C57BL/6 mice, where it bound a receptor leading to induction of AHH activity (Poland, 
Glover, & Kende, 1976). In DBA/2 mice, the levels of radio-labeled TCDD in liver extracts were 
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much lower, supporting the previous theory that they express a receptor with reduced binding 
affinity. These radioactive TCDD experiments allowed the Nebert lab to dub this newly 
identified receptor, the AHR (Okey, et al., 1979). During this time, it was also determined that 
the AHH and CYP1A1 were one and the same; CYP1A1 will be used henceforth to refer to this 
important enzyme (Okey, 2007). 
The Bradfield group validated the hypothesis that DBA/2 mice expressed an altered AHR 
that was proposed in the 1970s when they cloned the AHR in 1992. These studies revealed that 
reduced AHR ligand affinity was due to an altered AHR ligand binding domain in DBA/2 mice 
(Burbach, Poland, & Bradfield, 1992). When the AHR coding sequences from the DBA/2 and 
C57BL/6 were compared, two critical alterations were noted: 1) the AHR had undergone a 
substitution (valine instead of alanine) at position 375 and 2) a T to C mutation in the stop codon 
was observed in the DBA/2 mouse strain (Ema, et al., 1994). The mutated stop codon causes a 
lengthening of the carboxy-terminus in the mature AHR protein in DBA/2 mice resulting in a 
ligand-binding domain with lowered ligand binding affinity (Ema, et al., 1994). The major 
advances in AHR biology, after these initial findings were discovered, was made possible by 
uncovering the canonical AHR signaling pathway and will be discussed in the next section. 
3.2. The Canonical AHR Signaling Pathway 
When the AHR is activated by a ligand such as TCDD, it becomes a transcription factor 
by moving into the nucleus to regulate the expression of various genes (Figure 11). In the 
cytoplasm, the inactive AHR is bound with two HSP90 proteins (Chen, Singh, & Perdew, 1997) 
(Figure 11). These HSP90 proteins function as chaperones to prevent degradation of the AHR as 
well as for steroid hormone receptors (Pratt & Toft, 1997) (Figure 11). The inactivated AHR 
complex also contains a third protein, which was identified as hepatitis B Virus X-associated  
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Figure 11. The Canonical AHR Signaling Pathway 
Ligands diffuse through the cellular membrane and bind to the cytosolic AHR complex, which in 
turn exposes the NLS. The activated AHR complex is then translocated into the nucleus where 
the ARNT displaces chaperone proteins and binds the AHR, resulting in AHR-ARNT dimers 
that bind to and activate transcription from gene promoters that contain DREs such as various 
CYP450s. Activation of CYP450s can result in metabolism of exogenous and endogenous AHR 
ligands. The AHRR lacks a transactivation domain and exerts negative-feedback regulation on 
the AHR pathway through its competition for ARNT proteins and formation of inactive AHRR-
ARNT transcriptional complexes on DREs. Following transcription, AHR is exported and 
degraded by the proteasome in the cytoplasm. NLS = Nuclear Localization Sequence, AHRR = 
Aryl Hydrocarbon Receptor Repressor, AHR = Aryl Hydrocarbon Receptor, XAP2 = Hepatitis B 
Virus X-associated Protein 2, HSP90 = Heat-shock Protein 90, ARNT = Aryl Hydrocarbon 
Receptor Nuclear Translocator, DRE = Dioxin Response Element, OH = hydroxyl group, 
CYP450s = Cytochrome P450s. Red Arrows = Post-activation. 
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protein 2 (XAP2) (Carver & Bradfield, 1997; Meyer, Pray-Grant, Vanden Heuvel, & Perdew, 
1998). However, the function of XAP2 has not been determined. Later research showed that p23 
was also part of the inactive AHR complex in the cytoplasm, and it was identified to help 
maintain AHR stability (Figure 11). This inactive AHR complex serves to keep the AHR from 
entering the nucleus by concealing the AHR nuclear localization sequence (NLS) in the absence 
of ligand (Petrulis, Hord, & Perdew, 2000; Kazlauskas, Poellinger, & Pongratz, 1999; Petrulis, 
Kusnadi, Ramadoss, Hollingshead, & Perdew, 2003). Once TCDD binds to the AHR, a 
conformational change occurs in the complex that exposes the NLS of the AHR and translocates 
the activated complex into the nucleus (Jain, Dolwick, Schmidt, & Bradfield, 1994) (Figure 11). 
Once the complex enters the nucleus, XAP2 and p23 are released and the AHR binds to the 
ARNT with its bHLH motif (Rowlands, McEwan, & Gustafsson, 1996) (Figure 11). As a result, 
the ARNT keeps the AHR in the nucleus and induces the release of the HSP90 chaperones, 
leading to the activation of gene expression via the TCDD-AHR-ARNT complex (Figure 11). 
Canonical AHR signaling stimulates the expression of genes involved in phase I and 
phase II drug metabolism, such as CYP1A1 and cytochrome P450, family 1 subfamily B 
member 1 (CYP1B1) (Korashy, Abuohashish, & Maayah, 2013). In the liver, these 
monooxygenase enzymes are important for “first pass” metabolism where a large portion of 
drugs and xenobiotics are bio-transformed via hydroxylation in order to aid in the excretion and 
elimination of various compounds by increasing their solubility in water (Meyer, 1996). 
Cytochrome P450s 1A1 and 1B1 have been highly associated with cancer. CYP1A1 has been 
shown to regulate breast cancer proliferation and survival as well as initiate cancer growth by 
converting toxicants such as benzo[a]pyrene (B[α]P) into genotoxic agents (Rodriguez & Potter, 
2013; Schwarz, Kisselev, Cascorbi, Schunck, & Roots, 2001). Silencing of CYP1A1 resulted in 
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decreased colony formation, proliferation, and CCND1 levels as well as inducing cell cycle 
arrest and apoptosis in human breast cancer cells (Rodriguez & Potter, 2013). CYP1B1 has been 
coined as a “universal tumor marker” due to its over-expression in many tumor types, including 
lung, breast, and colorectal tumors (Murray, et al., 1997). CYP1B1 has been shown to convert 
estrogen into genotoxic metabolites like 4-hydroxyestradiol to initiate tumor formation. 
Glutathione-S-transferases (GSTs) are phase II enzymes whose expression is also induced by 
TCDD via AHR activation (Li, Seidel, Pritchard, Wolf, & Friedberg, 2000; Schrenk, Stüven, 
Gohl, Viebahn, & Bock, 1995). GSTs aid in the detoxification of xenobiotics by catalyzing the 
conjugation with GSH (Ketterer, Coles, & Meyer, 1983). Specific polymorphisms in the genes 
that encode the GST enzyme superfamily have been reported to be linked with resistance to 
chemotherapy in tumors (McIlwain, Townsend, & Tew, 2006). 
The AHR and ARNT target genes possess a unique sequence in a specific region of DNA 
called dioxin response elements (DREs). The specific consensus DNA sequence for the TCDD-
AHR binding complex (5’-TGCGTGA-3’) was first identified in the CYP1A1 gene promoter, 
which lies upstream and proximal to the transcription start site (TSS). The function of the DREs 
is to confer transcriptional activation to TCDD-AHR target genes upon binding TCDD-
stimulated AHR-ARNT complexes (Denison, Fisher, & Whitlock, 1988). In addition to AHR-
ARNT, TCDD also stimulates the recruitment of transcriptional cofactors to DREs in TCDD-
AHR target genes including acetyltransferase p300 (Beischlag, Luis Morales, Hollingshead, & 
Perdew, 2008; Beischlag, et al., 2002), CBP (Bedford & Brindle, 2012), nuclear receptor co-
activator 1 (NCOA-1) (Spencer, et al., 1997) and brahma-related gene 1 (BRG1) (Trotter & 
Archer, 2008). These transcriptional cofactors stimulate gene expression by promoting histone 
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acetylation and inducing chromatin to assume a confirmation that is more conducive to active 
transcription (Spencer, et al., 1997).    
The discovery of DREs was a landmark moment in AHR biology and gave way for the 
identification of other genes regulated by TCDD, such as ATP binding cassette sub-family G 
member 2 (ABCG2) (Tan, et al., 2010) and aldehyde dehydrogenase 1, family member A3 
(ALDH1A3) (Marcato, et al., 2011; Contador-Troca, et al., 2015). The transporter ABCG2 
promotes the efflux of drugs from tumor cells while ALDH1A3 is overexpressed in BCSCs and 
has been identified as a prognostic marker (Marcato, et al., 2011). The transcriptional regulation 
of CYP1A1 (Rodriguez & Potter, 2013), CYP1B1 (Murray, et al., 1997), ABCG2 (Tan, et al., 
2010), ALDH1A3 (Marcato, et al., 2011) has been shown to play roles in several different types 
of cancer, indicating that a better understanding of AHR signaling could provide new insights 
into the modulation of several cancers including breast cancer. One of the objectives in this 
dissertation was to use genome-wide RNA-sequencing (RNA-seq) analysis to identify novel 
TCDD-AHR regulated genes that could play important roles in the regulation of breast cancer 
progression. My findings revealed that stimulating human MCF7 breast cancer cells with TCDD 
for 6 hours induced changes in the expression of 660 genes including: CYP1A1, CYP1B1, 
ABCG2 and ALDH1A3. This novel result indicates that TCDD-AHR signaling may modulate 
breast cancer initiation and progression by inducing changes in the expression of a large set of 
genes that regulate various cancer processes. Indeed, my RNA-seq results provided the impetus 
to investigate a novel hypothesis in this dissertation by which TCDD-AHR signaling modulates 
breast cancer progression by regulating the JAG1-Notch1 pathway. As detailed in chapters 1 and 
2, the JAG1-Notch signaling pathway is an embryonic pathway that also promotes breast cancer 
progression.   
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3.3. Non-canonical AHR Signaling  
Although the canonical AHR signaling pathway is important, AHR activation can also 
alter gene expression by cross-talking with other important transcription factors. The AHR has 
also been shown to cross-talk with the ER (Matthews & Gustafsson, 2006), NF-kB (Denison, 
Soshilov, He, DeGroot, & Zhao, 2011; Vogel, et al., 2014), and HIF-1a (Vorrink & Domann, 
2014) to modulate estrogen, inflammatory and hypoxia signaling, respectively.  
There are various ways that the AHR can cross-talk with transcription factors, but the 
interaction between the AHR and ER has been the most extensively studied (Figure 12). 
Experiments studying long-term TCDD exposure in female Sprague Dawley rats were the first to 
suggest that the AHR and ER signaling pathways cross-talk, because it was identified that TCDD 
inhibited the growth of estrogen responsive mammary and uterine tumors (Kociba, et al., 1978). 
Other reports have shown that TCDD inhibited estrogen-stimulated increases in the expression of 
ER target genes (Safe & Wormke, 2003). There are several mechanisms by which TCDD-AHR 
signaling influences estrogen signaling (Figure 12). The first mechanism is mediated by 
CYP1A1-induced metabolism of estrogen upon exposure to TCDD. As noted earlier, CYP1A1 
reduces estrogen by promoting its metabolism (Spink, et al., 1992) (Figure 12). Other recent 
findings have identified that TCDD-activated AHR signaling stimulates increases in ER 
ubiquitination and degradation (Wormke, et al., 2003) as well as inhibits estrogen-stimulated 
gene expression by binding to inhibitory DREs (iDREs) in the promoter regions of ER target 
genes (Krishnan, Porter, Santostefano, Wang, & Safe, 1995) (Figure 12). Because the AHR and 
ER share common transcriptional co-activators, they have been reported to compete for a limited 
pool of transcriptional co-activators, which can lead to reductions in ER transcriptional activity  
61 
 
Figure 12. Mechanisms of AHR-ER Crosstalk 
(A) AHR activation upregulates CYP450 expression and promotes estrogen metabolism. (B) 
Activation of AHR squelches co-activator proteins preventing them from binding with ER 
transcriptional complexes. (C) Activated AHR-ARNT complexes can bind to iDREs in ER target 
genes to silence expression. (D) The AHR targets ER for proteasomal degradation. ER = 
Estrogen Receptor, AHR = Aryl Hydrocarbon Receptor, ARNT = Aryl Hydrocarbon Receptor 
Nuclear Translocator, DRE = Dioxin Response Element, ERE = Estrogen Response Element, 
iDRE = Inhibitory Dioxin Response Element, HSP90 = Heat Shock Protein 90, XAP2 = 
Hepatitis B Virus X-associated Protein 2. 
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(Brunnberg, et al., 2003) (Figure 12). TCDD has also been reported to mimic estrogen signaling 
by promoting the recruitment of unliganded ER to the estrogen response element (ERE) in ER 
target genes (Brunnberg, et al., 2003).  
TCDD has also been reported to crosstalk with the NF-kB pathway (Tian, 2009; 
Beischlag, Luis Morales, Hollingshead, & Perdew, 2008; Kim, et al., 2000; Salisbury & Sulentic, 
2015). The NF-kB canonical pathway is induced by pro-inflammatory cytokines, IL-6 and TNFa 
(Yamamoto, et al., 2013; Hayden & Ghosh, 2008; Kolasa, Houlbert, Balaguer, & Fardel, 2013) 
(Figure 13). IL-6, by activating its cognate receptor, induces the phosphorylation of inhibitor of 
NF-kB (IκB) by the inhibitor of NF-kB kinase (IκBK) complex, leading to its ubiquitination and 
subsequent degradation by the 26S proteasome (Hayden & Ghosh, 2008) (Figure 13). The V-Rel 
avian reticuloendotheliosis viral oncogene homolog A (RelA)-p50 complex is then free to 
translocate to the nucleus to activate the transcription of target genes (Hayden & Ghosh, 2008; 
Bash, et al., 1999) (Figure 13). TNFa induces a non-conical NF-kB pathway, which results in 
the activation of IkB by NF-kB Inducing Kinase (NIK) (Yamamoto, et al., 2013) (Figure 13). 
The formation of the NIK-IkB-p100 complex leads to the phosphorylation of the p100 subunit 
(Hayden & Ghosh, 2008) (Figure 13) and results in 26S proteasome-dependent processing of 
p100 to p52. The production of p52 leads to the activation of the V-Rel avian 
reticuloendotheliosis viral oncogene homolog B (RelB)-p52 heterodimer that targets a distinct 
NF-κB element and induces the transcription of target genes (Vogel & Matsumura, 2009) (Figure 
13). The AHR crosstalks with the NF-kB pathway by binding to RelA and forms an inactivated 
AHR-RelA dimer that perturbs RelA-stimulated transcription (Salisbury & Sulentic, 2015; Tian, 
2009) (Figure 13). The AHR has also been reported to bind to RelB, forming an active AHR-
RelB heterodimer that increases the transcriptional activity of AHR-RelB response  
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Figure 13. Canonical and Non-canonical Pathways of NF-κB Signaling Modulated by AHR  
A) The canonical pathway is induced by cytokines such as IL-6. The activation results in the 
phosphorylation of IκB by the IκBK complex, leading to its ubiquitylation and subsequent 
degradation by the 26S proteasome. The RelA-p50 complex is free to translocate to the nucleus 
to activate the transcription of target genes. B) The non-canonical pathway results in the 
activation of IκBK by the NIK after stimulation by cytokines. The formation of the NIK-IκB-
p100 complex leads to the phosphorylation of the p100 subunit and results in 26S proteasome 
dependent processing of p100 to p52 and leads to the activation of the RelB-p52 complex that 
target distinct NF-κB elements and induce the transcription of target genes. C) Direct protein 
binding between the AHR and RelA was proposed to induce repressive effects that are mediated 
by formation of transcriptionally inactive AHR-RelA heterodimers that also reduced the 
concentration of available nuclear AHR and RelA necessary for normal AHR- and NF-κB- 
mediated gene expression. In contrast to RelA, direct interactions between the TCDD-activated 
AHR and RelB also occur and were reported to produce an active AhR-RelB heterodimer 
complex that could bind to a specific AHR-RelB DNA recognition site and stimulate 
transcription of inflammatory genes. AHR = Aryl Hydrocarbon Receptor, XAP2 = Hepatitis B 
Virus X-associated Protein 2, HSP90 = Heat-shock Protein 90, RelA = V-Rel Avian 
Reticuloendotheliosis Viral Oncogene Homolog A, RelB = V-Rel Avian Reticuloendotheliosis 
Viral Oncogene Homolog B, IκB = Inhibitor of NFkB, IκBK = Inhibitor of NF-κB Kinase, Ub = 
ubiquitin, NIK = Nuclear Factor κB-inducing Kinase, TNFα = Tumor Necrosis Factor α, IL-6 = 
Interleukin-6, LPS = Lipopolysaccharide, p = phosphate group. 
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elements in specific pro-inflammatory genes such as interleukin 8 (IL-8) (Vogel & Matsumura, 
2009; Vogel, et al., 2014; Vogel, et al., 2007) (Figure 13). 
The AHR has also been seen to cross-talk with HIF-1a (Vorrink & Domann, 2014) 
(Figure 14). Oxygen is essential for aerobic organisms and is an important component of many 
cellular processes such as aerobic metabolism and energy homeostasis (Majmundar, Wong, & 
Simon, 2010). The amount of available oxygen in tissues can become reduced under certain 
physiological conditions or disease states. The key players that regulate the adaptive responses to 
hypoxia are the hypoxia-inducible factors. HIF-1a, one of the main regulators of the hypoxic 
response, is a transcription factor that also requires the ARNT protein as a dimerization partner 
(Kewley, Whitelaw, & Chapman-Smith, 2004). Under normal oxygen (normoxic) conditions, 
HIF-1a undergoes hydroxylation via prolyl hydroxylase domain (PHD) proteins and then 
subsequently ubiquinated by the von Hippel-Lindau tumor suppressor gene product (pVHL) 
before undergoing proteasomal degradation (Déry, Michaud, & Richard, 2005; Ohh, et al., 2000) 
(Figure 14). However, hypoxic conditions stabilize HIF-1a, and this transcription factor induces 
gene expression by forming a heterodimer with the ARNT (Kewley, Whitelaw, & Chapman-
Smith, 2004) (Figure 14). In cancer, the activation of HIF-1a-ARNT signaling can maintain and 
promote the self-renewal capacity of GSCs by promoting the Notch signaling pathway (Qiang, et 
al., 2012). The high binding-affinity of the ligand-activated AHR to ARNT proteins compete 
against HIF-1α for a limited pool of ARNT proteins and other co-activators, which in turn can 
negatively impact the activity of HIF-1a (Vorrink & Domann, 2014) (Figure 14). 
3.4. TCDD-induced Negative-feedback Loops that Limit AHR Signaling 
There are two TCDD-induced negative-feedback loops that limit AHR signaling (Figure 
15). Soon after its induction by TCDD, the AHR is ubiquitinated and then degraded by the  
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Figure 14. Crosstalk at the AHR-ARNT-HIF-1α Signaling Node  
Normoxic conditions lead to HIF-1α hydroxylation and degradation. HIF-1α proteins are 
hydroxylated by PHD proteins, ubiquinated by pVHL and ultimately degraded via the 
proteasome. In contrast, hypoxic environments cause HIF-1α stabilization and translocation to 
the nucleus. In the nucleus, HIF-1α binds to the ARNT to induce transcription of HRE-
containing genes. The AHR is quiescent in the cytoplasm until ligand binding occurs, which 
initiates translocation to the nucleus. In the nucleus, the AHR binds to the ARNT to induce 
transcription of DRE-containing genes. AHR = Aryl Hydrocarbon Receptor, XAP2 = Hepatitis B 
Virus X-associated Protein 2, HSP90 = Heat-shock Protein 90, ARNT = Aryl Hydrocarbon 
Receptor Nuclear Translocator, DRE = Dioxin Response Element, HRE = Hypoxic Response 
Element, HIF-1α = Hypoxia Inducible Factor 1α, PHD = Prolyl Hydroxylase Domain, pVHL = 
von Hippel-Lindau Tumor Suppressor Gene Product, OH = Hydroxyl Group, Ub = Ubiquitin, O2 
= Oxygen. 
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Figure 15. Mechanisms of Inhibition for AHR 
(A) The activated AHR binds the ARNT and co-activators to regulate expression of target genes 
containing DREs and induce expression of the AHRR. The AHRR protein competes with ARNT 
proteins for binding the AHR, which prevents active AHR complex formation and binding to 
DREs to regulate gene expression. (B) AHR signaling can also be inhibited through proteasomal 
degradation via CUL4B and other ubiquinating enzymes. AHR = Aryl Hydrocarbon Receptor, 
ARNT = Aryl Hydrocarbon Nuclear Translocator, RBX1 = Ring Box 1, DDB1 = Damaged 
DNA Binding Protein 1, Ub = Ubiquitin, CUL4B = Cullin 4B, ER = Estrogen Receptor, TBL3 = 
Transducin Beta Like 3, DRE = Dioxin Response Element, AHRR = AHR Repressor. Red 
Arrows = Post-activation. 
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proteasome (Ma & Baldwin, 2000) (Figure 15). The proteins that mediate the ubiquitination of 
TCDD-induced AHR include: cullin 4B (CUL4B), ring box 1 (RBX1) and damaged DNA 
binding protein 1 (DDB1), which are recruited by AHR in response to TCDD (Morales & 
Perdew, 2007) (Figure 15). Interestingly, TCDD-induced AHR also promotes the ubiquitination 
of the ER and the AR, which in part explains how TCDD inhibits estrogen and androgen 
signaling (Ohtake, Fujii-Kuriyama, & Kato, 2009) (Figure 15). The second TCDD-induced 
negative-feedback loop that limits AHR signaling involves the AHR repressor (AHRR) (Figure 
15).    
The AHRR and AHR contain a bHLH motif and, therefore, AHRR proteins can bind to 
ARNT proteins (Evans, et al., 2008) (Figure 15). TCDD induces the transcription and expression 
of the AHRR, which in turn removes ARNT proteins from the AHR and suppresses AHR 
activity (Mimura, Ema, Sogawa, & Fujii-Kuriyama, 1999) (Figure 15). However, other reports 
suggest that AHRR binds directly to DREs in AHR target genes, which also inhibits AHR 
activity (Hahn, Allan, & Sherr, 2009) (Figure 15). Thus, the primary mechanism by which 
TCDD-induced AHRR exerts its negative feedback inhibition on AHR signaling is still not clear; 
however, it is clear that AHRR suppresses TCDD-induced AHR signaling.   
3.5. Physiological Roles of AHR: Immunity, Development, and Reproduction  
For reasons detailed in the previous paragraphs, the historical role of AHR has been 
linked with TCDD and TCDD-induced toxicity. However, the development of AHR-null mice 
during the 1990s showed that the AHR has significant activity in mice not treated with TCDD. 
Indeed, AHR-null mice exhibited defects in immunity, proper organ development, and 
reproduction. For instance, AHR-null mice showed decreased lymphocyte accumulation in the 
spleen and lymph nodes compared to wild-type mice, but not the thymus (Fernandez-Salguero, 
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Hilbert, Rudikoff, Ward, & Gonzalez, 1996; Schmidt, Su, Reddy, Simon, & Bradfield, 1996; 
Andreola, et al., 1997). This suggested that AHR signaling has a role in innate immunity. Further 
investigation into the role of the AHR in immunity has identified that different AHR ligands 
have different effects on T-cells. For instance, TCDD and the endogenous AHR ligand 
kynurenine promote the activity and differentiation of T-cells into Treg cells, which in turn 
suppresses immune responses and favors the growth of tumors (Mezrich, et al., 2010; Quintana, 
et al., 2008). However, the endogenous AHR ligand 6-formylindolo [3,2-b] carbazole (FICZ) 
stimulates the differentiation of naïve T-cells into pro-inflammatory T-helper 17 (Th17) cells and 
this exacerbates immune responses (Veldhoen, et al., 2008). Some dietary AHR ligands such as 
indolo [3,2-b] carbazole (ICZ) and 3,3-diindolylmethane (DIM) have also been shown to play a 
role in the immune response (Veldhoen & Brucklacher-Waldert, 2012). Indole-3-carbinol (I3C) 
is a dietary AHR ligand that comes from cruciferous vegetables and is converted by stomach 
acid to the products ICZ and DIM, which then act as high affinity AHR ligands in the gut. As a 
result, ICZ- and DIM-activated AHR helps maintain gut microflora, intraepithelial lymphocytes, 
interleukin-22 (IL-22) expression and Th17 cell activity (Veldhoen & Brucklacher-Waldert, 
2012). These studies and observations allowed researchers to establish that there are AHR-
dependent roles in developmental and functional immunity.  
The liver expresses the highest levels of the AHR compared with all other tissues 
(Dolwick, Schmidt, Carver, Swanson, & Bradfield, 1993). The liver of AHR-null mice is smaller 
and exhibits thickening, and fibrosis of the portal vein compared with wild-type mice, suggesting 
that proper liver development is AHR-dependent (Schmidt, Su, Reddy, Simon, & Bradfield, 
1996). Further work has fostered a hypothesis by which the observed diminished liver growth in 
AHR-null mice is attributed to significant inflammatory changes in the bile ducts (cholangitis) 
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compared to wild-type mice (Fernandez-Salguero, et al., 1995). Although the activation of the 
AHR by endogenous ligands is important for proper development of the liver, its activation by 
TCDD causes developmental and endocrine toxicity. For instance, TCDD dramatically reduced 
ovarian follicle number and size in female Holtzman rats, which provided a mechanism that 
explains why TCDD reduces fecundity in female rats (Heimler, Trewin, Chaffin, Rawlins, & 
Hutz, 1998). In a rodent model, other teratogenic effects include blocked ovulation (Li, Johnson, 
& Rozman, 1995), atypical release of FSH and LH (Li, Johnson, & Rozman, 1997) as well as 
development of cleft palate and kidney deficiencies in offspring (Mimura, et al., 1997). Work 
comparing wild-type mice with AHR-null mice has confirmed that TCDD-induced toxicity is 
mediated through AHR signaling. Mouse studies have revealed that AHR has a role in mammary 
development and function, including pregnancy-associated changes in the mouse mammary 
gland and in utero mammary gland development. More specifically, AHR-null mice exhibit 
improper mammary development compared to wild-type mice, including reductions in mammary 
gland size and less mammary gland terminal end buds, which are the proliferative structures 
found at the tips of ducts (Mimura, et al., 1997). This result suggests that normal development 
and proliferation in the mammary gland could be dependent on endogenous AHR ligands. 
3.6. AHR Signaling and Cancer  
There have been numerous reports linking AHR signaling to cancer biology and a high 
degree of complexity has emerged with pro-tumorigenic and anti-tumorigenic activities of the 
AHR in studies using cell culture and in vivo models of malignancy (Murray, Patterson, & 
Perdew, 2014). Whether the AHR promotes or inhibits the initiation or progression of cancer is 
dependent on the ligand it binds. Consequently, there are tumor promoting AHR ligands as well 
as tumor suppressive AHR ligands. The activity of these ligands are also cancer specific. The 
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AHR modulates these tumor-promoting and -suppressing pathways in different cancer types and 
this seemingly indecisive role of AHR in cancer has been attributed to 1) differences in cancer 
models, 2) species differences, 3) different AHR ligands having different (and opposite) effects 
in cancer and 4) that AHR exhibits promiscuous binding with multiple ligands that have different 
chemical structures (Denison, Soshilov, He, DeGroot, & Zhao, 2011). The importance of 
defining whether the AHR is tumor promoting or tumor suppressing in each cancer type has 
important implications for drug development, because AHR antagonism may work well for some 
cancers, and AHR agonism may work better for other cancers. The following section will 
provide a balanced discussion of the tumor-promoting and -suppressing roles for the AHR in 
cancer. Although the AHR has been proposed to bind hundreds of ligands, I will focus my 
discussion on the best characterized AHR ligands in cancer, which are shown in Table 3 and 4. 
There are multiple cases and studies identifying AHR signaling promotes tumorigenic 
activity. Overexpression of the AHR and constitutively active AHR signaling is common in 
breast and prostate cancer, as well as other cancers (Shin, Sánchez-Velar, Sherr, & Sonenshein, 
2006; Kolluri, Jin, & Safe, 2017; Schlezinger, et al., 2006). Moreover, the AHRR has also been 
identified as a tumor suppressor (Zudaire, et al., 2008). Overexpression of the AHR in normal 
human mammary cells induces malignant traits such as increased EMT (Barretina, et al., 2012; 
Brooks & Eltom, 2011), a cellular process where cells lose adhesion to each other in preparation 
to invade and or migrate. Endogenous AHR ligands that are products of tryptophan metabolism 
such as kynurenine and kynurenic acid have also been identified to promote tumor survival by 
suppressing the immune response through autocrine and paracrine mechanisms (Opitz, et al., 
2011; DiNatale, et al., 2010; D’Amato, et al., 2015). CYP1B1, a known AHR gene target, has 
also been identified to be highly expressed in metastatic tumors compared to healthy tissue and  
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Table 3.  AHR Agonists that Possess Anti-cancer Effects 
 
 
 
 
 
 
 
 
 
AHR Agonists that Possess Anti-cancer Effects
Source AHR Agonists Cell Lines that Exhibited 
Anti-Cancer Effects
Xenobiotic
Polycyclic Halogenated Aromatic Hydrocarbons
(PHAHs):
• TCDD
Pharmaceuticals:
• Tranilast
• Omeprazole
• LNCaP
• MCF7
• SKBR3
• MDA-MB-
231
• BT474
• T47D
• Panc-1
• MiaPaCa2
• MCF7
• MDA-MB-231
• Panc-1
• MiaPaCa2
• MCF7
• MDA-MB-
231
Dietary
Flavonoids:
• Quercetin
• Kaempferol
Indoles:
• Indole-3-carbinol (I3C)
• 3,3’-Diindoylmethane (DIM)
• MCF7
• HL60
• CCRF-CEM
• MCF7
• PaCa-2
• Panc-1
• MCF7
• MDA-MB-231
• MDA-MB-468
• MCF7
• MDA-MB-231
• SKBR3
• T47D
Endogenous
Tryptophan Metabolites:
• 2-(1’H-indole-3’-carbonyl)-thiazole-4-
carboxylic acid methylester (ITE)
• HCCLM3
• OVVAR-3
• SKOV-3
• HepG2
• LNCaP
• U87
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Table 4. The Molecular Structures of AHR Agonists that Promote Anti-cancer Effects 
 
Molecular Structures of AHR agonists that Promote Anti-cancer Effects
AHR Agonist Molecular Structure
TCDD
Tranilast
Omeprazole
Quercetin
Kaempferol
Indole-3-carbinol
3,3’-Diindolylmethane
2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid 
methylester (ITE)
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has been identified as a metastatic marker in lung, colon, prostate, and breast cancer (Murray, et 
al., 1997; Murray, Melvin, Greenlee, & Burke, 2001). Elevated CYP1B1 levels promote the 
synthesis of the genotoxic metabolite 4-hydroxyestradiol and increases chemo-resistance by 
metabolizing certain chemotherapy agents into inactive metabolites (Li, Seidel, Pritchard, Wolf, 
& Friedberg, 2000).  
TCDD is considered as both a complete epigenetic carcinogen and a potent tumor 
promoter through sustained AHR activation (Safe, 1990; Poland & Knutson, 1982). However, 
whether TCDD is a tumor promoter or a tumor suppressor is dependent on the cancer. For 
instance, TCDD inhibits the proliferation of ER-positive breast cancer cells, because it inhibits 
estrogen signaling (Hanieh, 2015; Wang, Wyrick, Meadows, Wills, & Vorderstrasse, 2011). 
TCDD has also been reported to inhibit the proliferative, migratory and invasive activity of 
breast cancer cells that are of the TNBC subtype (Zhang, et al., 2009; Hall, et al., 2010). The 
application of TCDD to TNBC cells induced decreases in the expression of sex-determining 
region Y (SRY)-box 4 (SOX4), which is a transcription factor that promotes metastatic behavior 
of breast cancer cells (Hanieh, 2015). TCDD suppressed the expression of SOX4 by inducing the 
expression of the microRNA-212/132 cluster, which directly targets SOX4 (Hanieh, 2015). 
Although TCDD is too toxic to be used for cancer treatments, finding that TCDD inhibits the 
aggressiveness of TNBC cells suggests that increasing the activity of AHR with a non-toxic 
AHR ligand could be a new way to treat this disease.   
With regard to non-toxic AHR ligands (Tables 3 and 4), dosing rodents with the dietary 
AHR ligand I3C inhibited the growth of mammary (Wu, et al., 2010; Tin, Park, Sundar, & 
Firestone, 2014) and cervical (Qi, Anderson, Chen, Sun, & Auborn, 2005) tumor xenografts 
without causing toxicity. In addition to mammary and cervical cancer, I3C has also been reported 
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to suppress prostate cancer progression in vivo (rodent models) by promoting cell cycle arrest 
and increasing apoptosis (Chinni & Sarkar, 2002). The search for endogenous AHR ligands led 
to the purification and characterization of an endogenous ligand with high affinity and 
selectively for AHR, known as 2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid 
methylester (ITE) (Song, et al., 2002; Henry, Bemis, Henry, Kende, & Gasiewicz, 2006). ITE 
was purified from porcine lung. Recent reports indicate that ITE has anticancer activity that is 
attributed to its function as an AHR ligand (Wang, et al., 2013). The application of ITE to glioma 
cancer cells inhibited the expression of octamer-binding protein 4 (OCT4), which encodes a 
transcription factor that plays a key role in embryonic development and stem cell pluripotency 
(Cheng, et al., 2015). Upregulation of OCT4 in adult tissues promotes tumorigenesis. Therefore, 
finding that ITE inhibited OCT4 provided a new insight into how this endogenous AHR ligand 
inhibited the stem cell-like cancer cells in glioblastoma. Importantly, in contrast to TCDD, ITE is 
not toxic when tested in rodent models (Nugent, et al., 2013). The dosing of mice with ITE, 
however, suppressed the growth of glioblastoma tumor grafts in nude mice, indicating that this 
endogenous AHR ligand has anti-cancer activity in vivo (Cheng, et al., 2015).   
The anti-inflammatory drug tranilast functions as an AHR ligand and it has been reported 
to inhibit mammary cancer in mice (Rogosnitzky, Danks, & Kardash, 2012). Interestingly, 
tranilast inhibits the BCSC population in vivo and in vitro models at pharmacologically relevant 
concentrations (200 micromolar (µM)) (Prud’homme, et al., 2010). Further work showed that 
knockdown of AHR prevented the effects of tranilast, indicating that this anti-inflammatory drug 
inhibits breast cancer by activating AHR (Prud’homme, et al., 2010). The translation of AHR 
ligands for breast cancer therapy into the clinic mandates the identification of non-toxic AHR 
ligands that have anti-cancer activity in vivo and a complete understanding of the pathways that 
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are regulated by AHR ligands. In this regard, my work in this dissertation has identified for the 
first time that the non-toxic AHR ligand ITE inhibits TNBC cell aggressiveness by reducing the 
levels of JAG1 and NICD, which are known to promote breast cancer progression.  
3.7. Current Problematic Observation and Overall Hypothesis 
Although there are various AHR ligands that have been shown to promote various anti-
cancer effects, the mechanism(s) by which they occur have yet to be determined or fully 
characterized. As a result, the controversy of utilizing non-toxic AHR ligands as a potential 
therapy along with current chemotherapy regimens is still prominent, unless a more concrete 
mechanism behind the anti-cancer effects is proposed. Characterizing the mechanism that 
promotes these anti-cancer effects via non-toxic AHR ligands may also shed light on specific 
proteins or signaling pathways that may also be considered to be novel therapy targets for the 
treatment of cancer. It is also important to note that investigating the changes in JAG1 levels in 
the presence of known anti-cancer AHR ligands can provide important insight on how the 
expression of JAG1 in cancer cells as well as changes in cell migration and invasion are altered 
in a ligand-dependent manner in cancer cells (Hall, et al., 2010). Therefore, I hypothesize that 
non-toxic AHR ligands can induce anti-cancer effects through regulating the expression of JAG1 
and the Notch signaling pathway.   
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CHAPTER 4 
METHODS FOR STUDYING AHR SIGNALING 
4.1. Materials 
The purpose of this introductory methods section is to provide a brief overview of the 
methods that were used in this dissertation. MCF7 (ER-positive), T47D (ER-positive) MDA-
MB-231 (ER-negative) breast cancer cells were purchased from ATCC (Manassas, VA). MDA-
MB-157 (ER-negative) cells were generously provided by Dr. Ruth Keri (Case Western 
Reserve). TCDD in dimethyl sulfoxide (DMSO) (155µM) was purchased from Cambridge 
Isotopes Laboratory (Andover, MA). ER status of these cell lines were determined via western 
blot. The AHR agonist ITE was purchased from Tocris Bioscience (San Diego, CA). The TCDD 
antagonist CH-223191 was purchased from Sigma-Aldrich (St. Louis, MO). Non-targeting 
siRNA (cat # D-001810-01-20), ON-TARGET plus human siRNA against AHR (cat # J-004990-
08-0010) and JAG1 (cat # J-011060-11-0005) were purchased from GE Dharmacon (Lafayette, 
CO). Dulbecco’s Modified Eagle Medium (DMEM)/High glucose with L-glutamine and sodium 
pyruvate, fetal bovine serum (FBS), phosphate buffer saline (PBS), penicillin/streptomycin, and 
DMSO were purchased from Thermo Fisher Scientific (Pittsburgh, PA). Sodium dodecyl sulfate 
(SDS), 30% acrylamide/bis solution, ammonium persulfate, Tween-20, b-mercaptoethanol 
(BME) and polyvinylidene difluoride (PVDF) membranes were obtained from BIO-RAD 
(Hercules, CA).  
4.2. RNA-sequencing 
RNA-sequencing (RNA-seq) analysis was based on four biological replicates in each 
experimental group. For TCDD stimulation, MCF7 (ER-positive) cells were plated at 250,000 
cells/milliliter (mL) on 35 millimeter (mm) cell culture plates in DMEM containing 10% FBS 
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(DMEM/FBS (10%)) and were grown for 24 hours before being serum starved in phenol red-free 
DMEM for 16 hours prior to treatment. Cells were then treated with TCDD (100 nanomolar 
(nM)) for 6 hours. Total RNA purification kits (Qiagen, Valencia, CA) were used to extract total 
RNA. RNA sample quality was assessed using Bioanalyzer RNA Nano chips (Agilent); all RNA 
samples had an RNA Integrity Number (RIN) greater than or equal to 8. The RIN is an algorithm 
for assigning integrity values to RNA measurements and assigns an electropherogram a value of 
1 to 10, with 10 being the least degraded. RNA-seq libraries were prepared from 1 microgram 
(µg) of total RNA using a TruSeq RNA Prep Kit (Illumina Inc., San Diego, CA). RNA-seq was 
performed using an Illumina HiSeq1000 in a 2 x 100 base paired end design yielding a minimum 
of 50 million reads per sample. Differentially expressed genes were identified at a False 
Discovery Rate (FDR) of 5%. For pathway analysis, TCDD-regulated genes (TRGs) expressed 
as a ratio of TCDD/DMSO were loaded into Ingenuity Pathway Analysis (IPA) software 
(Ingenuity Systems, Redwood City, CA). The IPA Core Analysis tool was used to identify 
significant associations between TRGs and pathways. We configured the core analysis to report 
Benjamini-Hochberg corrected p-values. 
4.3. Cell Culture and Treatments 
Cell lines were maintained at 37°C with 5% carbon dioxide (CO2). Cells were grown in 
DMEM/FBS (10%) and 1% pencillin/streptomyocin. Cells were plated onto 35mm tissue culture 
plates in DMEM/FBS (10%) at a cell density of 250,000 cells per plate 24 hours prior to 
treatment. The medium containing ITE (10µM) was reapplied to cells every 12 hours, based on 
the findings of a prior report showing that ITE induces its maximal effect at 10µM, and it has to 
be applied to cells every 12 hours based on its stability in cell culture (Cheng, et al., 2015; 
Henry, Bemis, Henry, Kende, & Gasiewicz, 2006). The medium containing TCDD (10nM or 
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100nM) was applied once to cells, because TCDD is stable in cell culture. The AHR antagonist 
CH-223191 (10µM) was applied 1 hour prior to treatment with ITE or TCDD.   
4.4. Short-interfering RNA (siRNA): Gene Knockdown Experiments 
Gene specific siRNA were used to knockdown the expression of specific genes to 
evaluate their function. A concentration of 200,000 cells/mL in DMEM/FBS (10%) were mixed 
directly with 100nM of siRNA that was either non-targeting (control), JAG1-targeting or AHR-
targeting. Transfection reagent (3 microliters (µL)) (Lipofectamine RNAi Max, Life 
Technologies) was then added and plated onto 35mm tissue culture plates. After 36 hours, cells 
were treated with vehicle, TCDD (10nM, 24 hours), or ITE (10uM, 72 hours). Treatments were 
removed, and total cellular RNA or protein was extracted with RNA-purification kits (Qiagen 
RNeasy) or 2× Laemmli sample lysis buffer, respectively. In some experiments, total RNA was 
isolated using TRI-reagent in accordance with protocols provided by the manufacturer (Sigma 
Aldrich).  
4.5. mRNA Analysis: Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR)  
Total RNA was extracted using RNA purification columns (Qiagen). Reverse 
transcription was performed on 300 nanograms (ng) of RNA using cDNA synthesis kits (Applied 
Biosystems (Foster City, CA)) in accordance with the suppliers’ instructions. StepOnePlus 
(Applied Biosystems) was used to take quantitative polymerase chain reaction (qPCR) 
measurements. Amplifications were carried out using SYBR green master mixes (Applied 
Biosystems) according to the manufacturer’s protocols. Samples were run in triplicate, and the 
average normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was quantitated 
using the 2−ΔΔCT formula. CYP1A1 and GAPDH primers have been published (Tomblin & 
Salisbury, 2014). JAG1 primers used were: forward 5′-GAGCCCGGCCTCCTTTTATT, reverse 
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5′-GCGTCATTGTGTTACCTGCG. 
4.6. Protein: Western Blotting 
Cells were scraped in 300uL of 2x SDS sample buffer to isolate total cellular 
extract. Proteins were heat denatured and then separated by SDS/polyacrylamide gel 
electrophoresis (PAGE) followed by transfer to a PVDF membrane. Equal protein loading 
(~15µg/sample) was confirmed by western blotting. Blots were incubated overnight at 4°C in 
primary antibody followed by a 1 hour incubation in secondary antibody at room temperature. 
Antibodies from Cell Signaling Technology were: JAG1 (IC4) (1:1000), AHR (D5S6H) 
(1:1000), Cleaved-NICD (D3B8) (1:1000), HES1 (D6P2U) (1:1000), Snail (C15D3) (1:1000), 
rabbit-HRP (1:10,000) and mouse-HRP (1:10,000). GAPDH antibody was purchased from 
Millipore (Cat #MAB374). Densitometry was calculated with ImageLab PC-based software 
(Biorad). 
4.7. Functional Assay: Scratch Analysis 
Scratch assays were conducted with MDA-MB-231 cells. Cells were first seeded into 12-
well plates at a concentration of 50,000 cells per well and were grown for 24 hours in 
DMEM/FBS (10%) and 1% pencillin/streptomyocin. Cells were then rinsed with PBS solution 
and treated with vehicle or 10µM ITE every 12 hours for 5 days in DMEM containing 1% FBS 
(DMEM/FBS (1%)). After 5 days, a scratch was made in each well with a pipette tip. The media 
was then aspirated to remove floating cells, then vehicle or 10µM ITE treated complete media 
was reapplied. The scratches were photographed at 0 hour and at 24 hours using the Lycia 
Microscope. The exposed surface area of the plates was measured using ImageJ analysis 
software. Regarding ITE (10µM) treatments, cells were grown and treated in the same manner as 
detailed in section 4.3, except ITE treatments, which continued for five days before the scratch 
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was made; ITE treatments were reapplied every 12 hours for five days. As for JAG1 siRNA 
transfections, JAG1 knockdown cells were scratched and incubated for 12 hours; cells were 
photographed at 0 hours and 24 hours. 
4.8. Functional Assay: Boyden Chamber 
Cells were plated on 35mm tissue culture plates in DMEM/FBS (10%) and 1% 
penicillin/streptomycin for 24 hours prior to treatment. After cells were treated with vehicle or 
10µM ITE in DMEM/FBS (10%) and 1% penicillin/streptomycin every 12 hours for the 
indicated number of days, they were detached from tissue culture plates (using trypsin) and 
counted. Cells were immediately transferred to cell invasion chambers in DMEM at a 
concentration of 50,000 cells/well. Chambers filled with cells were then incubated in 24-well 
tissue culture plates containing DMEM/FBS (10%) as the chemoattractant for 36 hours. Each 
experiment included a negative control in which chambers filled with cells were incubated with 
DMEM lacking FBS. Following the 36h incubation in the presence of DMSO vehicle or 10µM 
ITE, a cotton swab removed non-adherent cells that were not invasive. Invasive cells were 
stained with crystal violet for 10 minutes at room temperature and then rinsed gently with tap 
water. Stained cells were then incubated in DMSO for 10 minutes with orbital shaking to extract 
crystal violet. Cell lysates were measured at 560 nanometers (nm) for invasive activity. For the 
indicated siRNA experiments, the cell invasion was assayed 48 hours after transfection. Boyden 
cell invasion chambers were purchased from ThermoFisher Scientific. 
4.9. Statistical Analysis 
The Tukey’s post-hoc test was used to determine statistically significant differences 
among groups following one-way analysis of variance (ANOVA). One-tailed, unpaired t-tests 
with confidence intervals of 95% were used to determine statistically significant differences 
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between two groups. All studies were conducted in triplicate. 
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5.1. Abstract 
The AHR is a ligand-activated transcription factor that binds pollutants, therapeutic 
drugs, and endogenous ligands. The AHR is expressed in all breast cancer subtypes and it can 
switch the aggressiveness of breast cancer cells from low to high depending on the ligand that it 
binds. JAG1 is a Notch receptor ligand that is overexpressed in TNBC and promotes breast 
cancer progression in part by increasing the migratory and invasive activity of TNBC cells. The 
regulation of JAG1 by the AHR in ER-positive and ER-negative breast cancer cells by two AHR 
ligands (TCDD and ITE) was investigated in this report in order to determine the anti-metastatic 
roles of AHR activation. TCDD is the prototype AHR ligand, and ITE is a non-toxic endogenous 
AHR ligand with anti-cancer activity. IPA revealed a significant association between TRGs and 
cell movement. Experiments involving siRNA-directed knockdown of AHR confirmed TCDD-
stimulated decreases in JAG1 required AHR expression. TCDD-induced reductions in JAG1 
were also inhibited by the AHR antagonist CH-223191. The non-toxic AHR ligand ITE also 
reduced JAG1 by activating the AHR in breast cancer cells, as confirmed by AHR knockdown 
experiments. RNA-seq findings coupled with published TCDD-stimulated AHR-chromatin 
immunoprecipitation (ChIP)-sequencing (ChIP-seq) results suggest that ligand-activated AHR 
reduces the expression of JAG1 by increasing the expression of HES1. HES1 is a direct AHR 
target gene and is also known as a JAG1 suppressor. MDA-MB-231 cells are TNBC cells that 
are highly migratory and invasive, and these cancer cell attributes were significantly inhibited by 
ITE. We reduced JAG1 with targeting siRNA, and the outcome mirrored ITE by suppressing 
TNBC cell migration and invasive activity. Collectively, these findings are the first showing that 
ITE is a tumor-suppressing AHR ligand in TNBC cells in part because it reduces JAG1 
expression.   
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5.2. Introduction 
The AHR mediates tumor-promoting and -suppressing pathways in different cancer types 
(Safe, Lee, & Jin, 2013; Murray, Patterson, & Perdew, 2014). The seemingly indecisive role of 
the AHR in cancer, sometimes tumor-promoting, other times tumor-suppressing, has been 
attributed to differences in cancer models, species differences and the receptor’s promiscuous 
binding with multiple ligands that have different chemical structures including: halogenated 
polycyclic hydrocarbons (i.e. TCDD), polycyclic aromatic hydrocarbons (i.e. benzo[a]pyrene), 
tryptophan-derived ligands (i.e. kynurenine) and indole glucosinolates (i.e. indole-3-carbinol) 
(Denison, Soshilov, He, DeGroot, & Zhao, 2011; Murray, Patterson, & Perdew, 2014). The 
industrial byproduct TCDD is the prototype AHR ligand, whose combined stability and 
selectivity for the AHR exceeds all other AHR ligands (Denison, Soshilov, He, DeGroot, & 
Zhao, 2011). Gene expression changes induced by TCDD, therefore, reflect the purest AHR 
response that can be obtained by RNA-seq. The AHR is a cytoplasmic protein that binds HSP90 
(Perdew, 1988; Kazlauskas, Sundstrom, Poellinger, & Pongratz, 2001), XAP2 (Carver & 
Bradfield, 1997; Meyer, Pray-Grant, Vanden Heuvel, & Perdew, 1998) and the co-chaperone 
protein p23 (Kazlauskas, Poellinger, & Pongratz, 1999). The binding of TCDD to the AHR 
induces AHR translocation from the cytoplasm to the nucleus where it forms a heterodimer with 
the ARNT (Denison, Soshilov, He, DeGroot, & Zhao, 2011; Beischlag, Luis Morales, 
Hollingshead, & Perdew, 2008). Primary TCDD-stimulated AHR target genes harbor inducible 
DREs that confer transcriptional activity to TCDD target genes upon their binding to AHR 
activated complexes (Beischlag, Luis Morales, Hollingshead, & Perdew, 2008).   
TNBC cells fail to express ER, PR and HER2 (Foulkes, Smith, & Reis-Filho, 2010). 
Absence of these three receptors make TNBC more difficult to treat, because there are no 
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targeting therapies for this breast cancer subtype (Foulkes, Smith, & Reis-Filho, 2010). The 
AHR, however, is expressed in all TNBC cells studied to date (Zhang, Liu, Wang, & Zhang, 
2016; Tomblin, et al., 2016; Hall, et al., 2010). Further, TCDD signaling reduces the 
aggressiveness of TNBC cells by suppressing their proliferation (Zhang, Liu, Wang, & Zhang, 
2016), promoting their differentiation (Hall, et al., 2010) and suppressing their invasive activity 
(Zhang, et al., 2012). This is contrary to the AHR ligand kynurenine where it is known to 
promote the survival of TNBC cells by suppressing anoikis pathways (D’Amato, et al., 2015). 
Thus, AHR may increase or decrease the aggressiveness of TNBC cells depending on which 
ligand it binds. The effects of ITE, a nontoxic endogenous AHR ligand, (Henry, Bemis, Henry, 
Kende, & Gasiewicz, 2006; Song, et al., 2002) has not been investigated in breast cancer cells. 
However, the known anti-cancer activity of ITE in other types of cancer (Cheng, et al., 2015; 
Wang, et al., 2013) motivated us to test its effects on breast cancer cells.   
The Notch signaling pathway has also been implicated in breast cancer progression. 
There are five Notch receptor ligands (JAG1, JAG2 and DLL1, DLL3, and DLL4); however, 
JAG1 is the predominant tumor-promoting Notch receptor ligand in breast cancer (Li, Masiero, 
Banham, & Harris, 2014; Previs, Coleman, Harris, & Sood, 2015). Upon binding JAG1, the 
Notch receptor undergoes two proteolytic cleavage events (Borggrefe & Liefke, 2012) that 
release the NICD (Bray, 2006). Following its release, the NICD translocates to the nucleus and 
binds to the transcription factor RBP-Jk (Borggrefe & Oswald, 2009), which induces the 
exchange of corepressors for coactivators at RBP-Jk and this in turn stimulates increases in the 
transcription of NICD gene targets (Bray, 2006).  
In this report, we performed an RNA-seq analysis to identify TRGs in MCF-7 breast 
cancer cells and identified 660 TRGs. HES1 was identified as a direct AHR target gene that 
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functions as a transcriptional repressor and a regulator of neurogenesis. HES1 is also a 
downstream target gene of the Notch signaling pathway and has been identified to suppress the 
expression of Notch receptor ligands, JAG1 and DLL1, as a negative-feedback regulatory 
mechanism. Interestingly, JAG1 which is associated with breast cancer recurrence and poor 
breast cancer outcome (Reedijk, et al., 2005; Dickson, et al., 2007; Buckley, et al., 2013), was 
one of the 660 TRGs. Because JAG1 is associated with poor breast cancer outcomes (Buckley, et 
al., 2013; Li, Masiero, Banham, & Harris, 2014), we investigated its regulation by two AHR 
ligands, TCDD and ITE, in order to determine if the anti-cancer effects of AHR activation was 
due to regulating JAG1 expression. Our results are the first to show that TCDD and ITE reduce 
JAG1 expression in breast cancer cells and confirm that JAG1 is critical for TNBC cell 
migratory and invasive activity.    
5.3. Materials and Methods 
5.3.1 Materials 
 MCF7 (ER-positive), T47D (ER-positive) MDA-MB-231 (ER-negative) breast cancer 
cells were purchased from ATCC (Manassas, VA). MDA-MB-157 (ER-negative) were 
generously donated by Ruth Keri (Case Western University). TCDD in DMSO was purchased 
from Cambridge Isotopes Laboratory (Andover, MA). The AHR antagonist CH-223191 was 
purchased from Sigma-Aldrich (St. Louis, MO). The AHR ligand ITE was purchased from 
Tocris Bioscience (Bristol, United Kingdom). Non-targeting siRNA (D-001810-01-20), ON-
TARGET plus siRNA against AHR (J-004990-08-0010) and JAG1 (J-011060-11-0005) were 
purchased from GE Dharmacon (Lafayette, CO). DMEM/High glucose with L-glutamine and 
sodium pyruvate, FBS, PBS, penicillin/streptomycin, DMSO, and Lipofectamine RNAiMAX 
were purchased from Fisher Scientific (Pittsburgh, PA). SDS, 30% acrylamide/bis solution, 
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ammonium persulfate, Tween-20, BME and PVDF membranes were obtained from BIO-RAD 
(Hercules, CA).   
5.3.2 Cell Culture, siRNA-mediated Gene Knockdown and CH-223191 
 Cells were cultured in DMEM/FBS (10%) and 1% penicillin/streptomycin at 37°C with 
5% CO2. For TCDD (10nM, 24 hours) and ITE (10µM, 72 hours) stimulation, 250,000 MCF7 
(ER-positive), T47D (ER-positive), MDA-MB-231 (ER-negative), and MDA-MB-157 (ER-
negative) cells were plated on 35mm tissue culture plates in DMEM/FBS (10%) and grown to 
~90% confluency. Cells treated with ITE had the media and treatments replenished every 12 
hours over the course of three days to compensate for the metabolism of ITE (Cheng, et al., 
2015; Henry, Bemis, Henry, Kende, & Gasiewicz, 2006). Transient transfection with siRNA was 
performed as described in our previous publications (Tomblin & Salisbury, 2014; Tomblin, et 
al., 2016). In brief, cell suspensions (200,000 cells/mL) were mixed with 100nM of the indicated 
siRNA with 3µL of Lipofectamine RNAiMAX in DMEM/FBS (10%) for ~20 minutes. Cells 
were then immediately plated on 35mm tissue culture plates in DMEM/FBS (10%) and cultured 
for 48 hours before the indicated treatments. Previous reports have shown that CH-223191 is an 
AHR antagonist that selectively antagonizes AHR ligands with structures similar to TCDD 
(Kim, et al., 2006; Zhao, Degroot, Hayashi, He, & Denison, 2010). Cells were treated with the 
indicated concentrations of TCDD or ITE in the absence of presence of 10µM CH-223191 for 
the indicated periods of time followed by western blot analysis of GAPDH (loading control), 
JAG1, AHR, Cleaved-NICD, and HES1.   
5.3.3 TCDD RNA-sequencing 
RNA-seq was conducted as described in our previous report (Salisbury, et al., 2014). 
Briefly, RNA-seq analysis was based on four biological replicates in each experimental group. 
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Total RNA purification kits (Qiagen, Valencia, CA) were used to extract total RNA. RNA 
sample quality was assessed using Bioanalyzer RNA Nano chips (Agilent); all RNA samples had 
an RIN greater than or equal to 8. RNA-seq libraries were prepared from 1µg of total RNA using 
a TruSeq RNA Prep Kit (Illumina Inc., San Diego, CA). RNA-seq was performed using an 
Illumina HiSeq1500 in a 2 x 100 base paired end design yielding a minimum of 50 million reads 
per sample. Differentially expressed genes were identified at a FDR of 5% as detailed in our 
prior report (Salisbury, et al., 2014). Raw reads and processed data (un-normalized and 
normalized read counts by gene) were deposited in the Gene Expression Omnibus (GEO) at the 
National Center for Biotechnology Information and are accessible via accession number 
GSE98515. For pathway analysis, TRGs are expressed as a ratio of TCDD/DMSO were loaded 
into IPA software (Ingenuity Systems, Redwood City, CA). Of the 660 TRGs identified by 
RNA-seq, 536 were mapped to known functions and pathways by Ingenuity Pathway Analysis 
(IPA, Qiagen Bioinformatics). The IPA Core Analysis tool was used to identify significant 
associations between TRGs and curated pathways. To account for testing the TRGs against 
multiple pathways, we configured IPA Core Analysis to report Benjamini-Hochberg corrected p-
values. 
5.3.4. RT-qPCR 
Total RNA was extracted using RNA purification columns (Qiagen). Reverse 
transcription was performed on 300ng of RNA using cDNA synthesis kits (Applied Biosystems 
(Foster City, CA)) in accordance with the suppliers’ instructions. Quantitative PCR (qPCR) was 
conducted with the StepOnePlus (Applied Biosystems) using SYBR green master mix (Applied 
Biosystems) in accordance with the suppliers’ protocols. Samples were run in triplicate and the 
average was normalized to GAPDH loading control. Relative changes in gene expression was 
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quantitated using the 2−ΔΔCT formula. We have published the GAPDH primer sequences 
(Salisbury, et al., 2014). JAG1 primers used were: forward 5′-GAGCCCGGCCTCCTTTTATT, 
reverse 5′-GCGTCATTGTGTTACCTGCG.   
5.3.5. Western Blotting 
Cells were rinsed with PBS and total cellular extract was isolated in SDS sample buffer 
(40% glycerol, 8% SDS, 5% BME, 0.04% bromophenol blue in tris-hydrochloride (Tris-HCl), 
pH 6.8). Proteins were heat denatured and then separated by SDS/PAGE followed by transfer to 
a PVDF membrane, then blocked with milk (5%) in PBS with 0.05% Tween-20 (PBST). Blots 
were incubated overnight at 4°C while rocking in primary antibody followed by an incubation 
period of 90 minutes in secondary antibody at room temperature. Blots were then rinsed five 
times (5 minutes per rinse) with PBST. Protein targets were detected via chemiluminescence 
(Millipore, Billerica, MA). JAG1 (1C4), AHR (D5S6H), Cleaved-NICD (D3B8), and HES1 
(D6P2U) antibodies were purchased from Cell Signaling Technology (Danvers, MA). GAPDH 
antibody was purchased from Millipore (Cat #MAB374). Primary antibodies were diluted 1:1000 
in PBST. Secondary antibodies were diluted 1:10000 in PBST. ChemiDoc MP Imaging System 
was used to quantify band density and acquire western blot images. 
5.3.6. Scratch Migration Assay  
Cells were plated on 12-well tissue culture plates at a concentration of 50,000 cells per 
well and grown to ~90% confluency prior to treatment. After cells were treated with vehicle or 
10µM ITE in DMEM/FBS (1%) every 12 hours for five days, a scratch was made in each well 
with a pipette tip. Media was then aspirated to removed floating cells, then vehicle or 10µM ITE 
was reapplied in DMEM/FBS (1%). The scratches were photographed at 0 hours and at 24 hours 
post scratch using the Lycia Microscope. The exposed surface area of the plates was measured 
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using ImageJ analysis software. For the indicated siRNA experiments, cell migration was 
assayed ~48 hours after transfection.    
5.3.7. Boyden Chamber Invasion Assay 
Cells were plated on 35mm tissue culture plates in DMEM/FBS (10%) for 24 hours prior 
to treatment. After cells were treated with vehicle or 10µM ITE in DMEM/FBS (10%) every 12 
hours for the indicated number of days, they were detached from tissue culture plates (using 
trypsin) and counted. Cells were immediately transferred to cell invasion chambers in DMEM at 
a density of 100,000 cells per 500µL. Chambers filled with cells were then incubated in 24-well 
tissue culture plates containing DMEM/FBS (10%) as the chemoattractant for 36 hours. Each 
experiment included a negative control in which chambers filled with cells were incubated with 
DMEM lacking FBS. Following the incubation period in the presence of vehicle (DMSO) or 
10µM ITE, a cotton swab was used to remove non-adherent cells that were not invasive. Invasive 
cells were stained with crystal violet for 10 minutes at room temperature and then rinsed gently 
with deionized water. Stained cells were then incubated in DMSO for 10 minutes with orbital 
shaking to extract crystal violet. Cell lysates were measured at 560nm for invasive activity. For 
the indicated siRNA experiments, the cell invasion was assayed 48 hours after transfection. 
Boyden cell invasion chambers were purchased from ThermoFisher Scientific.  
5.3.8. Statistics 
The Tukey’s Post-Hoc test was used to determine statistically significant differences 
among groups following an ANOVA. One-tailed, unpaired t tests with confidence intervals of 
95% were used to determine statistically significant differences between two groups. 
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5.4. Results 
5.4.1. TCDD RNA-seq 
 
We have recently shown that treating MCF7 cells with 10nM TCDD for 6 hours changed 
the expression of 137 genes (Tomblin, et al., 2016). Here, we have analyzed gene expression 
changes in MCF7 cells treated with 100nM TCDD for 6 hours compared with vehicle controls. 
Even though the 100nM TCDD concentration may not be consistent with human exposure, the 
purpose behind the analysis of 100nM TCDD concentrations was to identify robust AHR-
regulated target genes in order to elucidate novel AHR-dependent transcriptional mechanisms. 
This new differential expression-sequencing analysis identified 660 genes that were regulated by 
100nM TCDD, including a high representation of genes regulated by 10nM TCDD (123) and 
genes uniquely regulated by 100nM TCDD (537) (Figure 16). We performed gene expression 
analyses in IPA to identify biological functions that were most significant to the published TRG 
and new TRG gene sets. Pathway analysis of the published TRGs (123 genes) revealed 
enrichment in functions regulated by TCDD, such as cell cycle (Puga, et al., 2000), cell death 
and survival (Bekki, et al., 2015), lipid metabolism (Bui, Solaimani, Wu, & Hankinson, 2012; 
Yang, Solaimani, Dong, Hammock, & Hankinson, 2013) and drug metabolism (Nebert & 
Dalton, 2006) (Table 5), while the new TRGs (537 genes) were enriched in pathways associated 
with other aspects of breast cancer (Table 6). These included cell morphology (Diry, et al., 
2006), cell assembly and organization, cell-to-cell signaling, cell development and cellular 
movement (Hall, et al., 2010; Zhang, et al., 2012), signifying a potential broader role for TCDD 
in breast cancer.  
TRGs can be roughly divided into two groups. One group is directly regulated by TCDD 
via the AHR binding to DREs, and the other group is indirectly regulated by TCDD because the  
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Figure 16. Comparison of Published 10nM TRGs with the More Extensive List of 100nM 
TRGs  
Analysis of the 100nM TRGs showed enrichment for published TRGs (123) (Tomblin, et al., 
2016) and new TRGs (537). Genes from the 10nM TCDD-treated MCF7 cells are highly 
represented in the 100nM TCDD-treated MCF7 cells gene set.  
 
 
 
 
 
 
 
 
 
 
123
100 nM TCDD
RNA-seq
10 nM TCDD 
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Table 5. IPA Biofunctions Associated with 123 TRGs from 10nM and 100nM TCDD-
treated MCF7 Cells 
Biofunctional analysis was conducted on the 123 overlapped genes to identify if there are any 
associated biofunctions related to cancer biology. Column 1 identifies the biofunctional category 
that IPA linked to the 123 TRGs. Column 2 shows the range of B-H corrected p-values for the 
biofunction in a given category and the strength of biofunctional association is ordered from top 
to bottom. Cancer-related biofunctions found in this table include cell morphology, cell death 
and survival, cell-to-cell signaling, cell movement, cell cycle, cell development, cell growth and 
proliferation, and cell assembly and organization. Column 3 identifies the number of genes 
within the dataset to be associated within the given biofunctional category.  
 
 
 
 
 
IPA Biofunctions Associated with 123 Published TRGs from 
10nM and 100nM TCDD-treated MCF7 Cells
Category *B-H p-value # TRGs
Cell Cycle 1.34E-03-2.79E-02 18
Cell Death and Survival 3.03E-03-2.79E-02 32
Lipid Metabolism 5.18E-03-2.79E-02 13
Small Molecule Biochemistry 5.18E-03-2.79E-02 26
Cell Morphology 5.31E-03-2.79E-02 30
Cell Function and Maintenance 5.31E-03-2.79E-02 23
Gene Expression 6.8E-03-2.79E-02 12
Carbohydrate Metabolism 7.54E-03-2.79E-02 12
Drug Metabolism 7.54E-03-2.79E-02 9
Energy Production 7.54E-03-2E-02 7
*p-values are calculated by Fishers exact test and corrected for multiple testing by the 
Benjamini-Hochberger p-values (B-H) method (B-H p-value). Column 2 shows the range of 
B-H corrected p-values for the biofunction in a given category.
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Table 6. IPA Biofunctions Associated with 537 Uniquely Regulated Genes from 100nM 
TCDD-treated MCF7 Cells  
Biofunctional analysis was conducted on the 537 regulated genes from the 100nM TCDD-treated 
MCF7 cells in order to identify if there are any associated biofunctions related to cancer biology. 
Column 1 identifies the biofunctional category that IPA linked to the 123 TRGs. Column 2 
shows the range of B-H corrected p-values for the biofunction in a given category and the 
strength of biofunctional association is ordered from top to bottom. Column 3 identifies the 
number of genes within the dataset to be associated within the given biofunctional category. 
Cancer-related biofunctions found in this table include cell morphology, cell assembly and 
organization, cell-to-cell signaling, cell development, cell growth and proliferation, and cellular 
movement. Because this biofunctional analysis contained categories that were more relevant to 
cancer biology compared to the 123 overlapped gene set (Table 5), bioinformatic and genomic 
analysis was conducted with the 100nM TCDD gene set.  
 
 
IPA Biofunctions Associated with 537 Uniquely Regulated Genes from 
100nM TCDD-treated MCF7 Cells
Category *B-H p-value # TRGs
Cell Morphology 1.14E-06-1.31E-02 111
Cell Assembly and Organization 1.14E-06-9.46E-03 81
Cell Function and Maintenance 1.14E-06-9.46E-03 114
Cell-To-Cell Signaling 4.87E-06-1.31E-02 66
Cell Development 1.1E-05-1.44E-02 128
Cell Growth and Proliferation 1.1E-05-1.31E-02 120
Amino Acid Metabolism 1.45E-05-3E-03 18
Post-Translational Modification 1.45E-05-1.28E-03 41
Small Molecule Biochemistry 1.45E-05-1.44E-02 46
Cellular Movement 2.63E-04-1.38E-02 83
*p-values are calculated by Fishers exact test and corrected for multiple testing by the 
Benjamini-Hochberger p-values (B-H) method (B-H p-value). Column 2 shows the range of 
B-H corrected p-values for the biofunction in a given category.
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gene does not possess DREs; however, they are part of the TCDD pathway. Previously, 2,594 
TCDD-stimulated AHR binding sites were identified in MCF7 cells by ChIP-seq (Lo & 
Matthews, 2012). We overlapped these published 2,594 TCDD-AHR binding sites (Lo & 
Matthews, 2012) with our complete TRGs set and identified that 189 genes were common 
between the two groups (Figure 17). The 189 shared genes represent probable direct TCDD-
stimulated AHR gene targets (Table 7), while the remaining 471 TRGs are regulated indirectly 
by TCDD-stimulated AHR activation. IPA biological function analysis of the primary 189 TRGs 
showed enrichment in functions downstream of TCDD including gene expression, cell cycle 
(Barhoover, Hall, Greenlee, & Thomas, 2010; Puga, et al., 2000; Marlowe, Knudsen, 
Schwemberger, & Puga, 2004), cell death and survival (Bekki, et al., 2015), cell morphology 
(Diry, et al., 2006), cell-to-cell signaling, cellular movement (Hall, et al., 2010; Zhang, et al., 
2012), cellular development and cell assembly and organization, all of which provide insight into 
how TCDD may act in breast cancer (Table 8). 
We filtered this list to binding sites that appeared less than 5000 bases upstream of an 
annotated TSS in order to identify direct AHR target genes. This analysis identified 224 genes 
that had TCDD-stimulated AHR binding sites identified by ChIP-Seq (Lo & Matthews, 2012) 
less than 5 kilobases (Kb) upstream of their TSS. We compared this list of 224 genes with our 
complete list of TRGs (660) and identified that 41 were common (Figure 18). The 41 shared 
genes represent gene targets where the TCDD-AHR binding site is within 5Kb of the TSS (Table 
9), while the remaining 619 TRGs are regulated either indirectly by TCDD-AHR or the TCDD-
AHR binding site is greater than 5Kb of the TSS.  
Next, an IPA upstream regulator analysis was used to determine if genes within the 
100nM TRG set (660 genes) were regulated through a common upstream regulator (Table 10).  
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Figure 17. Comparison of Published 100nM TRGs with TCDD-stimulated AHR Binding 
Sites Identified by ChIP-seq in MCF7 Cells 
To better understand AHR-ARNT signaling in breast cancer cells, Lo et al. used chromatin 
immunoprecipitation linked to high-throughput sequencing to identify AHR and ARNT binding 
sites across the genome in TCDD-treated MCF-7 cells (Lo & Matthews, 2012). They identified 
2594 AHR-bound regions, which were overlapped with the 100nM TRGs analysis to determine 
any potential direct AHR target genes. This overlap identified 189 genes that are directly bound 
by AHR when stimulated by TCDD which are displayed in Table 7. 
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Table 7. The 189 TRGs that Overlap with Reported TCDD-stimulated AHR-ChIP-seq 
from Lo & Matthews (2012) 
 
 
 
 
 
 
 
 
 
The 189 TRGs that Overlap with Reported TCDD-stimulated AHR-ChIP-seq from Lo & Matthews (2012)
Gene 
Name
*Fold 
Change Gene Name
*Fold 
Change Gene Name
*Fold 
Change 
Gene 
Name
*Fold 
Change Gene Name
*Fold 
Change Gene Name
*Fold 
Change 
CYP1A1 713.9 TMTC2 2.5 ELF4 2.0 TUFT1 1.6 CCDC88C 1.4 CD47 1.3
CYP1B1 12.5 TNFRSF11B 2.4 FAM198B 1.9 RRS1 1.6 LPP 1.4 FREM2 1.3
DRD1 8.0 NEDD9 2.4 FAM110B 1.9 PKP1 1.6 SIPA1L2 1.4 NPEPPS 1.3
PITPNM2 6.7 C1orf116 2.4 PRDM16 1.8 LRIG3 1.6 ABCC5 1.4 GMNN 1.3
STRA6 6.0 ITPR1 2.3 PHEX 1.8 INPP4B 1.6 SIPA1L3 1.4 C4orf32 1.3
TRPM6 5.8 TSKU 2.3 ATP1B1 1.8 NEK6 1.5 FARP1 1.4 SSBP2 1.3
LMCD1 5.5 ZIC2 2.3 SLC16A14 1.8 FRMD4A 1.5 TRAFD1 1.4 RCC2 1.3
SLC7A5 5.0 DNMBP 2.2 DLL1 1.8 DDIT4 1.5 PDZRN3 1.4 TRIO 1.3
ALDH1A3 4.2 STC2 2.2 FOSL2 1.8 PSPC1 1.5 RAP1GAP 1.4 PARP4 1.3
ABCG2 4.2 AGPAT9 2.2 GAD1 1.8 GLI3 1.5 MSX2 1.4 SPTBN1 1.3
HAR1A 3.8 PYGL 2.2 HES1 1.8 IL1RAPL2 1.5 NR3C1 1.4 MED13L 1.3
NCCRP1 3.8 ATP9A 2.2 NRP1 1.8 ADAP1 1.5 USP3 1.4 SLC4A7 1.3
RUNX2 3.8 FAM84A 2.2 SAMD12 1.8 NADK 1.5 CDC25B 1.4 MYO6 1.3
HAR1B 3.7 CABLES1 2.2 C9orf3 1.8 DSP 1.5 MEIS1 1.4 TRPS1 1.2
BMF 3.6 SALL4 2.2 AHRR 1.7 SOS1 1.5 MTMR2 1.4 HBP1 0.8
HAR1A 3.6 LEKR1 2.2 SLC2A11 1.7 REL 1.5 IER5 1.4 HDAC5 0.8
ST3GAL1 3.4 NFE2L2 2.2 SLC27A2 1.7 GDF15 1.5 SPAG17 1.4 MYB 0.8
GLDN 3.3 HS6ST3 2.1 RUNX1 1.7 EGFR 1.5 RIOK1 1.4 GPRC5A 0.8
RND1 3.2 GPR115 2.1 KLF7 1.7 IGF1R 1.5 PIK3C2B 1.4 KITLG 0.8
LEF1 3.1 VIPR1 2.1 ZFHX3 1.7 NHS 1.5 ROCK2 1.3 TESK2 0.8
FAM105A 3.0 LRP5 2.1 SCARA5 1.7 C15orf39 1.5 TSHZ2 1.3 KIAA1467 0.7
TIPARP 3.0 ADAM12 2.1 VDR 1.7 SPRED2 1.5 LPHN2 1.3 FAM5B 0.7
C9orf169 3.0 CLSTN2 2.1 SHISA2 1.7 GPR157 1.5 CPEB4 1.3 AGR3 0.7
MAPRE2 2.9 NBPF1 2.0 TMEM120B 1.6 HOXC11 1.5 GNL3 1.3 CSRNP1 0.7
SYT12 2.8 KIAA1549 2.0 ACOXL 1.6 PTPRJ 1.5 QSOX1 1.3 LYN 0.7
TTC39B 2.8 PPARG 2.0 TNS3 1.6 DOCK5 1.5 PSD3 1.3 NPY1R 0.7
PLEKHF1 2.7 WNK2 2.0 PRPS1 1.6 CARD10 1.5 ARHGEF10L 1.3 SLC30A1 0.7
MCOLN2 2.6 WSCD1 2.0 ZBTB7C 1.6 SPIRE2 1.5 PAK2 1.3 RBM24 0.7
HECW2 2.6 RARRES1 2.0 TDH 1.6 BMPR1B 1.4 SYDE2 1.3 GSC 0.6
EDC3 2.6 DUSP10 2.0 TIMP3 1.6 JARID2 1.4 EHD4 1.3 MAF 0.6
HEY1 2.5 SLC16A7 2.0 SNX25 1.6 CUX1 1.4 BOD1 1.3 TP73 0.5
TMEM45B 2.5 TPCN1 1.6 DPP9 1.3
*RNA-fold change expression values from 100 nM TCDD-treated MCF7 cells compared with vehicle expressed as a ratio/vehicle 
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Table 8. IPA Biofunctions Associated with 189 Primary TRGs from the 100nM TCDD-
treated MCF7 Cells Overlapped with ChIP-seq Analysis from Lo & Matthews (2012)  
Biofunctional analysis was conducted on the 189 primary TRGs in order to identify if there are 
any associated biofunctions related to cancer biology. Column 1 identifies the biofunctional 
category that IPA linked to the 189 TRGs. Column 2 shows the range of B-H corrected p-values 
for the biofunction in a given category and the strength of biofunctional association is ordered 
from top to bottom. Cancer-related biofunctions found in this table include cell morphology, cell 
death and survival, cell-to-cell signaling, cell movement, cell cycle, cell development, cell 
growth and proliferation, and cell assembly and organization. Column 3 identifies the number of 
genes within the dataset to be associated within the given biofunctional category.  
 
 
 
 
 
IPA Biofunctions Associated with 189 Primary TRGs from the 100nM TCDD-treated 
MCF7 Cells Overlapped with ChIP-seq Analysis from Lo & Matthews (2012)
Category *B-H p-value # TRGs
Cell Morphology 3.83E-06-1.37E-02 60
Cell Death and Survival 2.58E-05-8.62E-03 63
Cell-To-Cell Signaling 2.66E-05-1.14E-02 33
Cell Movement 3.15E-05-1.36E-02 53
Cell Cycle 3.33E-05-1.41E-02 46
Cell Development 3.84E-05-1.29E-02 69
Gene Expression 8.38E-05-7.81E-03 50
Cell Function and Maintenance 1.2E-04-1.37E-02 63
Cell Growth and Proliferation 3.41E-04-1.17E-02 70
Cell Assembly and Organization 1.48E-03-1.37E-02 39
*p-values are calculated by Fishers exact test and correct for multiple testing by the 
Benjamini-Hochberger p-values (B-H) method (B-H p-value). 
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Figure 18. Comparison of Published 100nM TRGs with TCDD-stimulated AHR Binding 
Sites Identified by ChIP-seq Less than 5Kb Upstream of their TSS 
The identified 2594 AHR-bound regions via ChIP-seq analysis (Lo & Matthews, 2012) were 
filtered down to genes that contained AHR-binding sites within 5Kb of the TSS, in order to 
determine bonafide direct AHR target genes. This analysis identified 224 genes that met the 
criteria and were then overlapped with the 100nM TCDD RNA-seq to determine what genes may 
be directly targeted by AHR within our gene set. This overlap identified 41 genes that are 
directly bound by AHR and are within 5Kb of the transcription start site which are displayed in 
Table 9. 
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Table 9. The 41 Genes Within the 100nM TCDD RNA-seq Data Set with an AHR Binding 
Site Within 5Kb of the TSS in MCF7 Cells 
 
 
The 41 Genes Within the 100nM TCDD RNA-seq Data Set with an 
AHR Binding Site Within 5Kb of the TSS in MCF7 Cells
Gene Name *Fold Change Gene Name *Fold Change
CYP1A1 713.9 RUNX1 1.7
CYP1B1 12.5 VDR 1.7
LMCD1 5.5 PRPS1 1.6
ABCG2 4.2 LSMEM1 1.6
NCCRP1 3.8 TUFT1 1.6
C9orf169 3.0 DDIT4 1.5
SYT12 2.8 ADAP1 1.5
RNF224 2.8 NADK 1.5
PLEKHF1 2.7 SOS1 1.5
TMTC2 2.5 REL 1.5
AC018816.3 2.4 IGF1R 1.5
ITPR1 2.3 CARD10 1.5
ZIC2 2.3 USP3 1.4
SALL4 2.2 CPEB4 1.3
PPARG 2.0 DPP9 1.3
FAM198B 1.9 FREM2 1.3
SLC34A3 1.8 SSBP2 1.3
GAD1 1.8 SYBU 0.7
HES1 1.8 RBM24 0.7
NRP1 1.8 TP73 0.5
SLC2A11 1.7
*RNA-fold change expression values from TCDD-treated MCF7 cells 
compared with vehicle expressed and a ratio/vehicle
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Table 10. IPA Upstream Regulators Associated with 100nM TRGs (660) 
An IPA upstream regulator analysis was conducted to identify transcription factors and other 
upstream molecules that may be responsible for gene expression changes observed. Column 1 
indicates the transcription factors and or small molecules that IPA predicted to be associated with 
the 100nM TCDD TRGs. Column 2 uses the activation z-score algorithm to predict IPA 
upstream regulator activity, which is determined by comparing reported gene responses to a 
given upstream regulator to the observed expression changes in 100nM TRGs. Column 3 shows 
the strength of overlap and is ordered from top to bottom, based on the calculated p-value by the 
Fisher exact test. Column 4 shows the number of TRGs in the RNA-seq 100nM TCDD dataset 
that are within the gene network under a specific IPA-upstream regulator. Column 5 indicates the 
total number of genes in the network under a specific IPA upstream regulator pathway.  
 
 
 
 
 
IPA Upstream Regulators Associated with 100nM TRGs (660)
Upstream 
Regulator
Predicted
Activation 
State
*p-value of 
Overlap
Target Genes 
in Dataset
Number of Genes 
in the Network
Beta-estradiol 1.8E-12 87 203
PGR 5.4E-10 26 199
SOX2 2E-09 27 131
Progesterone Activated 1.6E-08 37 184
TP63 3.2E-08 28 182
TNF 7.4E-08 73 219
Valproic Acid 3.5E-07 29 170
Estrogen Receptor 3.7E-07 20 179
Fulvestrant 4.4E-07 21 185
NOTCH1 Activated 5.1E-07 20 163
AHR Activated 6.1E-06 22 162
TCDD Activated 8.3E-05 21 155
*p-value of overlap are calculated by Fisher exact test
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This analysis revealed that TRGs were significantly enriched under the following upstream 
regulators: beta-estradiol (endogenous hormone), PR (ligand-activated transcription factor), SRY 
box 2 (SOX2) (transcription factor), progesterone (endogenous hormone), tumor protein 63 
(TP63) (transcription factor), tumor necrosis factor (TNF) (cytokine), valproic acid (chemical 
drug), ER (ligand-activated transcription factor), fulvestrant (chemical drug), Notch1 
(transcription factor), AHR (ligand-activated transcription factor) and TCDD (chemical toxicant) 
(Table 10). Of the 37 TRGs in the progesterone pathway, 21 exhibited patterns of expression 
consistent with activation of progesterone signaling activity (Table 10). For Notch1, the pattern 
of expression of 13 of the 20 TRGs was consistent with activation of the Notch1 pathway (Table 
11).  
In ER-expressing breast cancer cells (e.g. MCF7 and T47D), TCDD increases: 1) 
posttranscriptional downregulation of the ER (Wormke, et al., 2003), 2) the binding of the AHR 
to inhibitory dioxin response elements (iDREs) that perturb the binding of ER and associated 
transcriptional activators to ER target genes (Krishnan, Porter, Santostefano, Wang, & Safe, 
1995), 3) the co-recruitment of AHR and ER complexes to the promoters of AHR and ER target 
genes (Beischlag & Perdew, 2005; Matthews, Wihlen, Thomsen, & Gustafsson, 2005) and 4) the 
recruitment of receptor interacting protein 140 (RIP140) (negative transcriptional regulator) to 
certain ER target genes that are suppressed by TCDD-stimulated AHR signaling (Madak-
Erdogan & Katzenellenbogen, 2012). Based on the findings of these prior reports, identifying 
that 87 of 203 beta-estradiol target genes are TRGs is not surprising. Finally, TRGs were 
significantly enriched within the AHR (20 of 162 AHR network genes) and TCDD pathways (21 
of 155 TCDD network genes), which is consistent with cells being treated with TCDD. The IPA-
predicted AHR activation and TCDD activity was based in part on the induction of canonical 
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TCDD-stimulated AHR target genes CYP1A1 (~ 714-fold) (Spink, et al., 1998), CYP1B1 
(~12.5-fold) (Spink, et al., 1998) and ALDH3A1 (~ 4.2-fold) (Vasiliou, Reuter, Williams, Puga, 
& Nebert, 1999) in TCDD-treated cells compared with controls (Table 7). 
The 20 TRGs that are grouped under the IPA-defined Notch1 network are shown in Table 
11. Overlap analysis with predicted direct TCDD-AHR regulated genes (Table 7) shows that half 
of the genes within the Notch1 network were predicted direct TCDD-AHR gene targets and the 
other half were indirect TCDD-AHR gene targets that did not bind the AHR (Table 11). The 
predicted direct TCDD-AHR gene targets that are also Notch1 network genes include RUNX2 
(Hilton, et al., 2008), v-rel avian reticuloendotheliosis viral oncogene homolog (c-Rel) (Cheng, 
et al., 2001), PPARg (Sciaudone, Gazzerro, Priest, Delany, & Canalis, 2003), MYC proto-
oncogene (myc) (Weng, et al., 2006), lymphoid enhancing factor 1 (LEF1) (Spaulding, et al., 
2007), IGF-1R (Eliasz, et al., 2010), HEY1 (Borggrefe & Liefke, 2012), HES1 (Borggrefe & 
Liefke, 2012), EGFR (Baumgart, et al., 2010), and DLL1 (Jaleco, et al., 2001). Overlap analysis 
with TCDD-stimulated AHR regulated genes that have TCDD-AHR binding sites within 5Kb of 
the TSS (Table 9) shows that four TRGs that meet these criteria are within the Notch1 network. 
Those genes include c-Rel (Cheng, et al., 2001), PPARg (Sciaudone, Gazzerro, Priest, Delany, & 
Canalis, 2003), IGF-1R (Eliasz, et al., 2010), and HES1 (Borggrefe & Liefke, 2012) (Table 9). 
The group of 10 Notch1 network genes that are regulated by TCDD-AHR through an indirect 
mechanism included JAG1 (Table 9). JAG1 is the predominant Notch receptor ligand in TNBC 
that is also implicated in breast cancer progression (Reedijk, et al., 2005; Dickson, et al., 2007; 
Cohen, et al., 2010). Because JAG1 is clinically linked to breast cancer progression (Dickson, et 
al., 2007; Reedijk, et al., 2005) (Figure 10), we investigated the mechanism by which TCDD 
reduces the expression of JAG1. 
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Table 11. TRGs (100nM) that are IPA-determined Notch1 Regulated Genes 
According to the IPA upstream regulator analysis, Notch1 was predicted to be activated based on 
the gene expression changes present within the 100nM TRGs (660) and shows 20 genes that are 
downstream of the Notch signaling pathway to be affected in the presence of TCDD. Column 1 
shows the name of the 100nM TRG. Column 2 is the predicted activation state of Notch 
signaling based on the direction of gene expression change. Column 3 shows the fold change of 
TRGs. Column 4 shows if the gene is a direct AHR target gene based from overlapping 100nM 
TCDD RNA-seq with TCDD-AHR ChIP-seq (Table 5). Column 5 identifies primary TRGs that 
bind to TCDD-AHR binding sites within 5Kb of transcription start site (Table 7). 
 
 
 
 
TRGs (100 nM) that are IPA-determined Notch1 Regulated Genes
Genes in Dataset Predicted State of 
Activation
Expression Log 
Ratio of TRGs
Predicted TRG TRG Within 5Kb 
of TSS
RUNX2 Activated 1.914 Yes No
REL Activated 0.567 Yes Yes
PPARG Activated 1.021 Yes Yes
NCF1 Activated -0.518 No No
MYC Activated 0.881 Yes No
LEF1 Activated 1.645 Yes No
IGFBP3 Activated -0.628 No No
IGF1R Activated 0.56 Yes Yes
HEY1 Activated 1.336 Yes No
HES1 Activated 0.852 Yes Yes
EGFR Activated 0.561 Yes No
DKK1 Activated -0.729 No No
CHST1 Activated -1.005 No No
MYCL Inhibited -0.568 No No
CAD Affected 0.586 No No
DLL1 Affected 0.872 Yes No
ITGA6 Affected -0.399 No No
JAG1 Affected -0.336 No No
LFNG Affected -0.678 No No
WNT5A Affected 1.998 No No
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5.4.2. TCDD Reduces JAG1 mRNA in MCF7 Cells 
 In an effort to confirm the RNA-seq analysis, we treated MCF7 cells with DMSO or the 
indicated concentrations of TCDD for 6 hours. The relative mRNA levels of JAG1 normalized to 
GAPDH loading control were determined by RT-qPCR. We verified that JAG1 expression was 
reduced by TCDD and found that 10nM and 100nM TCDD treatment significantly reduced 
JAG1 mRNA (by ~40%) in MCF7 cells after 6 hours of treatment (Figure 19).  
5.4.3. TCDD Reduces JAG1 Protein but Activates Notch Signaling in MCF7 Cells  
 After establishing that TCDD significantly reduced JAG1 mRNA levels after 6 hours in 
MCF7 cells, we sought to determine if TCDD also reduced the levels of JAG1 protein and 
whether changes in the levels of JAG1 were correlated with changes in the activity of the Notch 
signaling pathway. We, therefore, treated MCF7 cells with 10nM TCDD for 24 hours and 
extracted total cellular protein to analyze by western blot (Figure 20). We probed blots with 
JAG1, AHR, and HES1 antibodies. The activation of Notch signaling induces the proteolysis of 
the Notch receptor, and this releases the NICD, which functions as a transcription factor that 
activates Notch target genes like HES1 (Borggrefe & Liefke, 2012). We, therefore, also probed 
blots with an antibody that specifically recognizes activated cleaved-NICD as the readout for 
changes in Notch signaling. The western blot signals for JAG1, AHR, HES1, and cleaved-NICD 
were normalized to GAPDH. We have shown in prior reports that GAPDH is a suitable loading 
control for western blots analysis because its levels are not changed in response to AHR ligands 
(Salisbury, et al., 2014).  
The western blot findings showed that after 24 hours TCDD significantly reduced the 
levels of AHR protein compared with vehicle (Figure 20). The observed reduction in AHR in 
response to TCDD is consistent with prior reports that have shown that TCDD-activated AHR is  
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Figure 19. TCDD Decreases JAG1 mRNA Levels in MCF7 Cells  
MCF7 cells were treated with vehicle or the indicated concentrations of TCDD for 6 hours. The 
relative mRNA levels of JAG1 normalized to GAPDH loading control were determined by RT-
qPCR (as detailed in the Material and Methods). Results shown are the means ± standard error 
margin (SEM) of three independent experiments. Significant reductions by TCDD are indicated 
by *P < 0.05.  
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Figure 20. TCDD Decreases JAG1 Protein Levels but Activates the Notch Signaling 
Pathway in MCF7 Cells 
MCF7 cells were treated with vehicle or 10nM TCDD for 24 hours. Total cellular protein was 
isolated and subjected to western blot analysis. Blots were probed with the indicated antibodies. 
Levels of JAG1, AHR, Cleaved-NICD, and HES1 were normalized to GAPDH. Results shown 
are the means ± SEM of three independent experiments. Significant changes in expression by 
TCDD are indicated by *P < 0.05 or **P<0.01. 
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ubiquitinated and then degraded by the proteasome and that this regulation is a negative-
feedback loop in the TCDD signaling pathway (Ma & Baldwin, 2000). We also observed TCDD-
stimulated reductions in the levels of JAG1 protein (Figure 20), which is consistent with our 
RNA-seq and RT-qPCR results showing that TCDD reduced the expression of JAG1 mRNA. 
We hypothesized that TCDD-induced reductions in JAG1 would lead to the attenuation of Notch 
signaling, because JAG1 is a Notch receptor ligand. The findings, however, revealed that TCDD-
stimulated a robust increase in the levels of NICD (Figure 20). This result indicates that in ER-
expressing MCF7 cells, TCDD is sufficient to activate the Notch pathway, even when the levels 
of JAG1 protein are reduced in response to TCDD (Figure 20). To further investigate whether 
TCDD-stimulated increases in the NICD have a functional impact in MCF7 cells, we evaluated 
the expression of HES1, which is a direct Notch target gene (Borggrefe & Liefke, 2012). In 
accordance with the observed increases of cleaved-NICD levels in response to TCDD, we 
identified that TCDD stimulated HES1 expression in MCF7 cells (Figure 20). Collectively, these 
results indicate that TCDD is sufficient to increase Notch signaling, because it induced cleaved-
NICD levels and promoted the expression of the Notch target gene, HES1. TCDD, however, 
reduced the expression of the Notch receptor ligand JAG1 at the level of mRNA and protein.     
5.4.4. TCDD Reduces JAG1 mRNA in MDA-MB-231 Cells 
 We sought to further investigate the regulation of JAG1 and Notch signaling by TCDD in 
MDA-MB-231 TNBC cells.  The impetus for including MDA-MB-231 cells in our TCDD 
analysis stems from prior reports showing that the JAG1-Notch pathway is more active in TNBC 
compared with ER-positive breast cancer. We first evaluated the levels of JAG1 mRNA, and the 
findings showed that treating MDA-MB-231 cells with 10nM TCDD for 24 hours significantly 
reduced the levels of JAG1 mRNA compared with cells treated with vehicle (Figure 21). 
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Figure 21. TCDD Decreases JAG1 mRNA Levels in MDA-MB-231 Cells 
MDA-MB-231 cells were treated with vehicle or 10nM TCDD for 6 hours. The relative mRNA 
levels of JAG1 normalized to GAPDH loading control was determined by RT-qPCR (as detailed 
in the Material and Methods). Results shown are the means ± SEM of three independent 
experiments. Significant reductions by TCDD are indicated by *P < 0.05. 
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 5.4.5. TCDD Reduces JAG1 Protein and Inhibits Notch Signaling in MDA-MB-231 
 Cells 
 Having established that TCDD significantly reduces the expression of JAG1 mRNA, we 
sought to investigate whether this prototype AHR ligand also reduces the levels of JAG1 protein 
in MDA-MB-231 cells. The western blot findings showed that 10nM TCDD (24 hours) 
significantly reduced the levels of JAG1 protein in MDA-MB-231 cells, which is similar to what 
we had observed in MCF7 cells (Figure 22). Next, we investigated Notch signaling activity by 
measuring the cleaved-NICD levels by western blot in MDA-MB-231 cells treated with vehicle 
or 10nM TCDD (24 hours). In accordance with prior reports, the levels of cleaved-NICD were 
high in control MDA-MB-231 cells (Figure 22). This result indicates that MDA-MB-231 cells 
exhibit constitutive Notch signaling under basal conditions, which is different than what we 
observed in MCF7 cells. As shown in Figure 20, control MCF7 cells do not express cleaved-
NICD under basal conditions. The western blot findings also revealed that TCDD-stimulated 
reductions in levels of cleaved-NICD in MDA-MB-231 cells (Figure 22). Collectively, these 
results indicate that TCDD-activated AHR signaling reduces JAG1 and cleaved-NICD levels in 
the TNBC MDA-MB-231 cell line. 
5.4.6. AHR Mediates TCDD-stimulated Reductions in JAG1 and Cleaved-NICD in 
MDA-MB-231 Cells 
We performed AHR knockdown experiments in MDA-MB-231 cells to determine 
whether this receptor mediates TCDD-induced downregulation of JAG1. Control cells were 
transfected with control siRNA that was non-targeting. As anticipated, TCDD significantly 
reduced JAG1 protein (by ~ 44%) in control cells (Figure 23A). Western blot analysis of cells 
transfected with AHR-targeting siRNA revealed that AHR was significantly reduced (by ~ 95%) 
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Figure 22. TCDD Decreases JAG1 Protein Levels and Inhibits the Notch Signaling 
Pathway in MDA-MB-231 Cells 
MDA-MB-231 cells were treated with vehicle or 10nM TCDD for 24 hours. Total cellular 
protein was isolated and subjected to western blot analysis. Blots were probed with the indicated 
antibodies. Levels of JAG1, AHR, Cleaved-NICD, and HES1 were normalized to GAPDH. 
Results shown are the means ± SEM of three independent experiments. Significant changes in 
expression by TCDD are indicated by *P < 0.05 or ***P<0.001. 
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Figure 23. AHR Mediates TCDD-stimulated Reductions of JAG1 in MDA-MB-231 Cells  
A) Control cells were transfected with non-targeting short interfering RNA and AHR knockdown 
cells were transfected with AHR-targeting siRNA. Forty-eight hours after transfection, cells 
were treated with vehicle or 10nM TCDD for 24 hours. B) Control cells were treated with 
vehicle or 10nM TCDD. CH-223191 groups were treated with 10µM CH-223191 in the absence 
or presence of 10nM TCDD for 24 hours. Total cellular protein was isolated and subjected to 
western blot analysis. Blots were probed with the indicated antibodies. Levels of AHR and JAG1 
were normalized to GAPDH. Data shown are the means ± SEM of three independent 
experiments. Significant reductions by TCDD or AHR-targeting siRNA are indicated by * P < 
0.05. 
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compared to control cells, indicating that our approach to knocking down AHR was highly 
effective (Figure 23A). We observed that cells with AHR knockdown were unresponsive to 
TCDD-stimulated reductions in JAG1, indicating that the suppressive effect of TCDD on JAG1 
expression is dependent on AHR activation (Figure 23A). The observed reduction in AHR 
protein in response to TCDD in control cells (Figure 23A) is mediated by a posttranscriptional 
mechanism that increases the ubiquitination of AHR, which in turn causes AHR to be degraded 
by the proteasome (Wormke, et al., 2003; Pollenz, 2002). The AHR antagonist CH-223191 is 
reported to selectively antagonize the binding of halogenated polycyclic aromatic hydrocarbons 
(e.g. TCDD) to AHR (Zhao, Degroot, Hayashi, He, & Denison, 2010) and allows us to test if 
TCDD binding to AHR reduces the expression of JAG1. The findings showed that CH-223191 
prevented TCDD-stimulated reductions in JAG1 protein (Figure 23B) and supports our 
hypothesis that TCDD reduces JAG1 by binding to and activating the AHR. 
5.4.7. ITE Reduces JAG1 in MCF7 and T47D Cells 
 TCDD inhibits the growth and proliferation of ER-positive breast cancer cells by 
antagonizing estrogen signaling (Ohtake, Fujii-Kuriyama, & Kato, 2009). However, there are no 
reports indicating that TCDD or other AHR ligands modulate the JAG1-Notch pathway in ER-
positive breast cancer cells. Considering that a recent report has shown that increases in JAG1 
plays a role in tamoxifen resistance in ER-positive breast cancer (Simões, et al., 2015), we 
further investigated the regulation of JAG1-Notch signaling by AHR in MCF7 and T47D breast 
cancer cells. To this end, we stimulated MCF7 and T47D cells with the non-toxic endogenous 
AHR ligand ITE then assayed JAG1 and cleaved-NICD levels by western blot. Cells were 
treated with vehicle or 10µM ITE every 12 hours for three days. Our rationale for treating cells 
every 12 hours with 10µM ITE was based on a prior report showing that ITE exerts its maximal 
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effect at this concentration and that cells must be replenished with ITE every 12 hours due to its 
rapid metabolism by cells (Cheng, et al., 2015; Henry, Bemis, Henry, Kende, & Gasiewicz, 
2006). The western blot results showed that ITE induced downregulation of AHR protein levels, 
which is consistent with our expectation that ITE is functioning as an AHR ligand in ER-positive 
breast cancer cells (Ohtake, Fujii-Kuriyama, & Kato, 2009) (Figure 24). As noted earlier, 
downregulation of AHR protein in response to an AHR ligand is mediated by the ubiquitination 
of AHR, followed by degradation of AHR by the proteasome (Ma & Baldwin, 2000). The levels 
of JAG1 protein in MCF7 and T47D cells treated with ITE were significantly lower compared 
with cells treated with vehicle (Figure 24). Thus, our findings show that TCDD and ITE decrease 
JAG1 in ER-expressing MCF7 and T47D cells. Next, we analyzed the amount of cleaved-NICD, 
and the results showed that ITE stimulated increases of cleaved-NICD levels in MCF7 cells 
compared with the control group (Figure 24). Considering that HES1 is a direct Notch target 
gene, we questioned whether ITE, by inducing NICD, also promoted the expression of HES1. 
The findings showed that ITE did indeed increase the levels of HES1 compared with cells treated 
with vehicle (Figure 24). Collectively, these results suggest that TCDD and ITE decrease JAG1, 
but are sufficient to activate Notch signaling in ER-positive breast cancer cells. These results are 
the first to show that the AHR signaling pathway cross-talks with the JAG1-Notch signaling 
pathway in ER-positive breast cancer cells. 
5.4.8. ITE Reduces JAG1 in MDA-MB-231 and MDA-MB-157 Cells 
Considering that the JAG1-Notch pathway has been shown to promote the progression of 
TNBC, we questioned whether the non-toxic AHR ligand ITE reduces JAG1 expression and 
suppresses Notch signaling in TNBC cells. To this end, we applied vehicle (DMSO) or ITE  
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Figure 24. ITE Decreases JAG1 Protein Levels but Activates the Notch Signaling Pathway 
in ER-positive Breast Cancer Cells 
MCF7 and T47D cells were treated with vehicle or 10µM ITE every 12 hours for 3 days. Total 
cellular protein was isolated and subjected to western blot analysis. Blots were probed with the 
indicated antibodies. Levels of JAG1, AHR, Cleaved-NICD, and HES1 were normalized to 
GAPDH. Results shown are the means ± SEM of three independent experiments. Significant 
changes in expression by ITE are indicated by * P < 0.05 or ** P<0.01. 
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(10µM) to MDA-MB-231 cells every 12 hours for 1, 3 and 5 days to investigate whether it 
reduces JAG1 expression in TNBC cells. We found that the levels of JAG1 protein were 2-fold 
higher in vehicle-treated cells on day 5 compared with day 1 (Figure 25). Conversely, ITE 
reduced JAG1 protein on day 1 (by~40%), day 3 (by ~ 50%) and day 5 (by ~ 63%) compared 
with vehicle-treated controls (Figure 25). Based on these results, we also tested whether ITE 
treatment would reduce JAG1 mRNA. The mRNA results mirrored the protein findings, showing 
that JAG1 mRNA levels increased by day 5 compared with day 1 in control cells, and that JAG1 
mRNA levels were significantly reduced by ITE on day 3 and day 5 compared with vehicle-
treated controls (Figure 25). Collectively, these data indicate that ITE reduces JAG1 mRNA, 
which may in turn lead to reductions in JAG1 protein. To determine if ITE reduces JAG1 in 
another TNBC cell line, we applied ITE (10µM) to MDA-MB-157 cells every 12 hours for 3 
days and measured the levels of JAG1 protein. We also treated MDA-MB-231 cells as a positive 
control based on our prior data showing that ITE reduced JAG1 in this TNBC cell line (Figure 
25).  
Similar to MDA-MB-231 cells, we found that JAG1 expression was also reduced in 
MDA-MB-157 cells in the ITE-treated group compared to the control group (Figure 26). We also 
tested whether ITE inhibited Notch signaling by measuring the levels of cleaved-NICD by 
western blot analysis. The results showed that ITE decreased the amount of cleaved-NICD 
present in both MDA-MB-231 and MDA-MB-157 cells (Figure 26). To investigate whether the 
observed reductions in cleaved-NICD levels correlated with a decrease in the levels of a Notch 
target gene, we probed blots with HES1 antibody. The findings showed that the levels of HES1 
were reduced in MDA-MB-231 and MDA-MB-157 breast cancer cells in response to ITE 
(Figure 26). Based on these findings, we postulate that ITE-stimulated AHR signaling reduces  
117 
 
 
Figure 25. ITE Reduces JAG1 mRNA and Protein in MDA-MB-231 Cells 
MDA-MB-231 cells were treated with vehicle or ITE every 12 hours for 1, 3 and 5 days. Total 
cellular protein was isolated and western blot analysis was performed. Blots were probed with 
JAG1 and GAPDH. Levels of JAG1 were normalized to GAPDH. Relative mRNA levels of 
JAG1 normalized to GAPDH loading control was determined by RT-qPCR (as detailed in the 
Material and Methods). Data shown are the means ± SEM of three independent 
experiments. Significant increases on Day 5 compared with Day 1 are indicated by # P < 
0.05. Significant decreases by ITE are indicated by * P < 0.05 or ** P<0.01. 
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Figure 26. ITE Decreases JAG1 Protein Levels and Inhibits the Notch Signaling Pathway 
in MDA-MB-231 and MDA-MB-157 Cells 
MDA-MB-231 and MDA-MB-157 cells were treated with vehicle or 10µM ITE every 12 hours 
for 3 days. Total cellular protein was isolated and subjected to western blot analysis. Blots were 
probed with the indicated antibodies. Levels of JAG1, AHR, Cleaved-NICD, and HES1 were 
normalized to GAPDH. Results shown are the means ± SEM of three independent experiments. 
Significant reductions by ITE are indicated by *P < 0.05, **P<0.01, or ***P<0.001. 
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JAG1, which leads to reductions in cleaved-NICD levels and the expression of the Notch target 
gene HES1 in TNBC cells. 
5.4.9. AHR Mediates ITE-stimulated Reductions in JAG1, Cleaved-NICD, and HES1 
 Because ITE is an AHR ligand, we postulated that AHR knockdown cells would not 
respond to ITE. To investigate this postulate, we transfected MDA-MB-231 cells with non-
targeting siRNA or AHR-targeting siRNA. Cells were then treated with vehicle or 10µM ITE 
every 12 hours for 3 days. We found a significant reduction in the levels of JAG1 and AHR 
protein in the control cells transfected with non-targeting siRNA in response to ITE compared 
with vehicle (Figure 27). We observed that cells transfected with AHR-targeting siRNA were not 
responsive to ITE-stimulated reductions in JAG1, indicating that the suppressive effect of ITE on 
JAG1 expression is transmitted through the AHR (Figure 27). Moreover, the findings showed 
that siRNA-mediated knockdown of the AHR restored the levels of cleaved-NICD in ITE-treated 
cells to that observed in control cells treated with vehicle (Figure 27). 
Collectively, these results suggest that ITE-activated AHR signaling reduces the 
expression of JAG1 and inhibits Notch signaling. We reasoned that reductions in JAG1 and 
cleaved-NICD levels in response to ITE in control cells (transfected with non-targeting siRNA) 
would lead to reductions in the levels of HES1. We, therefore, probed blots with HES1 antibody, 
and the findings showed that ITE reduced the levels of HES1 in control cells, but not in the AHR 
knockdown cells (Figure 27). Collectively, these data suggest that ITE-activated AHR signaling 
suppresses JAG1-Notch-HES1 signaling in TNBC MDA-MB-231 cells.  
 As discussed in section 5.3.6., the AHR antagonist CH-223191 preferentially inhibits the 
binding of TCDD to AHR; however, it does not inhibit the binding of non-halogenated AHR 
ligands to the AHR (Zhao, Degroot, Hayashi, He, & Denison, 2010). Because ITE is a non-  
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Figure 27. AHR Knockdown Indicates ITE-stimulated Suppression of JAG1 Expression in 
MDA-MB-231 Cells is AHR-dependent 
Control cells were transfected with non-targeting siRNA and AHR knockdown cells were 
transfected with AHR-targeting siRNA. Forty-eight hours after transfection, cells were treated 
with vehicle or 10µM ITE every 12 hours for 3 days. Total cellular protein was isolated and 
subjected to western blot analysis. Blots were probed with the indicated antibodies. Levels of 
JAG1, AHR, Cleaved-NICD, and HES1 were normalized to GAPDH. Data shown are the means 
± SEM of three independent experiments. Significant reductions by TCDD or AHR-targeting 
siRNA are indicated by *P < 0.05, **P<0.01, or ***P<0.001. 
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halogenated AHR ligand, we expected that it would not be antagonized by CH-223191. We 
assessed the levels of JAG1 protein in MDA-MB-231 cells treated with ITE in the absence or 
presence of CH-223191 and the results showed that this particular AHR antagonist does not 
block ITE-mediated downregulation of the AHR or JAG1 (Figure 28). This selective-antagonism 
is consistent with a prior report showing that CH-223191 selectively antagonizes TCDD, but not 
other types of AHR ligands including ITE (Zhao, Degroot, Hayashi, He, & Denison, 2010). This 
observed selectivity of CH-223191 for TCDD also suggests that ITE and TCDD reduce JAG1 by 
activating the AHR through different binding sites on the AHR.     
5.4.10. Tranilast Reduces JAG1 in MDA-MB-231 Cells 
In addition to investigating the mechanism of how TCDD induces decreases in JAG1 
expression, I have addressed how the non-toxic AHR agonist ITE also regulated JAG1 
expression in breast cancer cells (Figure 24-28). Therefore, we performed AHR knockdown 
experiments in MDA-MB-231 cells to determine whether this receptor mediates both TCDD- 
and ITE-induced downregulation of JAG1 (Figures 23, 27-28). We observed that AHR 
knockdown cells were unresponsive to both TCDD- and ITE-stimulated reductions in JAG1, 
indicating that the suppressive effects of TCDD and ITE on JAG1 expression is dependent on 
AHR activation. We questioned whether there are any other AHR ligands that have been known 
to promote anti-cancer effects in breast cancer cells that can also reduce expression of JAG1 and 
have clinical relevance. To answer this question, we treated MDA-MB-231 cells with tranilast to 
see if it reduces JAG1 expression. Tranilast is a non-toxic AHR ligand that possesses clinical 
relevance because it is a daily medication that targets inflammatory signaling to treat various 
allergy symptoms and was shown to inhibit MDA-MB-231 cell growth and metastasis in vivo 
(Prud’homme, et al., 2010). However, the mechanism behind the anti-cancer effects of tranilast  
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Figure 28. AHR Antagonism via CH-229131 does not Inhibit ITE-stimulated Suppression 
of JAG1 in MDA-MB-231 Cells 
Control cells were treated with vehicle or 10µM ITE every 12 hours for 3 days. CH-223191 
groups were treated with 10µM CH-223191 in the absence or presence of 10µM ITE every 12 
hours for 3 days. Total cellular protein was isolated and subjected to western blot analysis. Blots 
were probed with the indicated antibodies. Levels of AHR and JAG1 were normalized to 
GAPDH. Data shown are the means ± SEM of three independent experiments. Significant 
reductions by ITE or CH-229131 are indicated by *P < 0.05.  
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has yet to be determined. We applied tranilast (200µM) to MDA-MB-231 cells every 24 hours 
for 1, 3 and 5 days to investigate whether it reduces JAG1 expression in TNBC cells. We found 
that the levels of JAG1 protein were significantly higher in vehicle-treated cells on day 5 
compared with day 1 (Figure 29). Conversely, tranilast significantly reduced JAG1 on day 3 (by 
~ 65%) and day 5 (by ~ 75%) compared with vehicle-treated controls (Figure 29). This data 
reveals tranilast as another AHR ligand that promotes anti-cancer effects due to decreasing JAG1 
expression and is critically important because it adds clinical relevance to this newly discovered 
mechanism. 
5.4.11. Invasive and Migratory Studies with ITE and JAG1 Knockdown in MDA-
MB-231 Cells 
 Because JAG1 has been reported to be important for the invasive and migratory activity 
of MDA-MB-231 cells (Shimizu, et al., 2011), we sought to determine whether these MDA-MB-
231 processes are inhibited by ITE. To determine the effect of ITE on cell migration, we treated 
cells with vehicle or ITE every 12 hours for 5 days and then used a pipette tip to make an 
artificial gap in the confluent cell mass and monitored their capacity to migrate over the gap. We 
found a significant decrease in the migration of cells treated with ITE compared with those 
treated with vehicle (40% versus 85% of cells treated with ITE and vehicle, respectively, filled 
the gap) (Figures 30A and 30B). We also predicted that ITE would suppress the ability of MDA-
MB-231 cells to invade through a matrigel-based basement membrane towards a chemoattractant 
gradient provided by 10% FBS. We first determined whether MDA-MB-231 cells could invade 
through the matrigel-based basement membrane towards medium supplemented with 10% FBS 
as the chemoattractant. We observed significant increases (by ~ 155%) in the migration of 
control cells towards 10% FBS compared with cell culture medium lacking FBS (Figure 30C).  
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Figure 29. Tranilast Inhibits the Expression of JAG1 in MDA-MB-213 Cells at 1, 3, and 5 
Days 
MDA-MB-231 cells were treated with vehicle or tranilast every 24 hours for 1, 3 and 5 days. 
Total cellular protein was isolated and western blot analysis was performed. Blots were probed 
with JAG1 and GAPDH. Levels of JAG1 were normalized to GAPDH. Data shown are the 
means ± SEM of three independent experiments. Significant increases on Day 5 compared with 
Day 1 are indicated by #P < 0.05 Significant decreases by ITE are indicated by *P < 0.05, **P< 
0.01, and ***P<0.001. 
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Figure 30. ITE by inhibiting JAG1 Reduces the Migratory and Invasive Activity of MDA-
MB-231 Cells 
A) Image of the scratch at 0 hours and 24 hours. B-C) Cells were treated with vehicle (DMSO) 
or 10 µM ITE every 12 h for 5 days prior to the indicated assay. D-F) Control cells were 
transfected with non-targeting siRNA. JAG1 knockdown cells were transfected with JAG1-
targeting siRNA. The indicated assays were performed 48 hours after transfection. D) Total 
protein was subjected to western blot analysis and blots were probed with indicated antibodies. 
JAG1 was normalized to GAPDH. B-F) Data shown are means ± SEM of at least 3 independent 
experiments. Significant increase by 10% FBS is indicated by #P < 0.05. Significant reductions 
by ITE or JAG1-targeting siRNA are indicated by * and $P < 0.05, respectively  
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Introduction of ITE resulted in a significant decrease (by ~ 40%) in the invasive activity of cells 
compared with control cells (Figure 30C).   
We hypothesized that if ITE inhibits MDA-MB-231 migration by reducing JAG1, then 
reducing JAG1 with JAG1-targeting siRNA should be sufficient to suppress the invasive and 
migratory activity of MDA-MB-231 cells. Measuring the levels of JAG1 in MDA-MB-231 cells 
transfected with JAG1-targeting siRNA showed that JAG1 protein was significantly reduced (by 
~ 95%) compared with control cells transfected with non-targeting siRNA, indicating that our 
JAG1 knockdown approach was valid (Figure 30D). We observed that the cells with JAG1 
knockdown had defects that mirrored cells treated with ITE, namely reductions in migratory and 
invasive activity compared with control cells transfected with non-targeting siRNA (Figures 30E 
and 30F). Our finding that ITE treatment mimics the loss of migratory and invasive activity of a 
JAG1 knockdown suggests that ITE affects the behavior of these TNBC cells by reducing JAG1. 
5.5. Discussion 
The findings of this study have provided the first evidence for crosstalk between ligand-
activated AHR signaling and JAG1-Notch signaling pathways in ER-positive and ER-negative 
breast cancer cells. Considering that the JAG1-Notch pathway has been shown to promote the 
aggressiveness of breast cancer, our findings suggest that modulating the activity of AHR with 
AHR ligands could be a novel way to suppress breast cancer progression. This discovery is 
therefore novel and provides a new perspective into the mechanism(s) by which ligand-activated 
AHR signaling inhibits breast cancer hallmarks including cell proliferation, invasion and 
migration (Zhang, et al., 2009; Hall, et al., 2010; Zhang, et al., 2012). We have expanded our 
previous list of TRGs (137) in MCF7 cells and found that this more extensive list of TRGs (660) 
is significantly enriched in pathways, which represent new TCDD effects on breast cancer 
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development (i.e. cell-to-cell communication) (Table 5 and 6). Interestingly, the new TRGs (660) 
were significantly enriched in cell movement pathways (Table 6 and 8), which supports and 
extends prior reports showing that TCDD regulates the migratory and invasive activity of breast 
cancer cells (Zhang, et al., 2012; Hsu, et al., 2007). 
It is important to also point out that the ability of ITE to reduce JAG1 expression in 
breast cancer cells indicates that ITE could be an effective AHR ligand for the treatment of this 
disease (Figures 24-28). Because the survival of the CSC population is dependent on JAG1-
Notch4 signaling (Harrison, et al., 2010; Simões, et al., 2015), it suggests that ITE could target 
this population of highly tumorigenic cells by targeting JAG1. JAG1 expressed in breast cancer 
activates Notch signaling in bone, which induces pathways that make bone more amenable to 
breast cancer cell invasion and therefore metastasis (Sethi, Dai, Winter, & Kang, 2011). Future 
studies of the role of ITE in these areas of breast cancer research (CSC and metastasis) may lead 
to new possibilities in the treatment of both ER-positive and ER-negative breast cancer.  
This research also acknowledges that AHR activation has a different outcome in ER-
positive breast cancer cells, as the Notch pathway was shown to be activated in the presence of 
TCDD and ITE (Figures 20 and 24). However, the Notch pathway that is activated in ER-
positive breast cancer cells may result in a different physiological outcome (i.e. cell morphology) 
compared to JAG1-dependent Notch activation due to JAG1 having the ability to regulate gene 
expression independent of the NICD via its intracellular domain (JICD) (Ascano, Beverly, & 
Capobianco, 2003). Therefore, further research is required to identify unique direct JICD-gene 
targets that may play a role in the promotion of metastatic behavior and CSC maintenance in 
breast cancer. 
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5.5.1. Potential Mechanisms by which TCDD and ITE Differentially Regulate Notch 
Signaling in ER-negative and ER-positive Breast Cancer Cells 
 Our results showing that TCDD and ITE increase the levels of cleaved-NICD and HES1 
in MCF7 cells suggest that these two AHR ligands activate Notch signaling in ER-expressing 
breast cancer cells (Figures 20 and 24). In the canonical Notch pathway, the binding of a Notch 
ligand induces the proteolytic cleavage of the NICD from the Notch receptor and this is mediated 
by γ-secretase and ADAM (Borggrefe & Liefke, 2012). In mammals, there are five Notch 
ligands (JAG1, JAG2, DLL1, DLL3 and DLL4) (Chillakuri, et al., 2013). Our finding that ITE 
and TCDD increase the levels of cleaved-NICD suggests that these two AHR ligands may have 
increased the expression of a Notch receptor ligand in MCF7 cells. We can rule out JAG1 as a 
potential Notch ligand that is induced by TCDD and ITE, because our data shows that these two 
AHR ligands reduce JAG1 expression (Figures 19-29). When considering the remaining four 
Notch ligands, our RNA-seq analysis identified almost a two-fold increase in the expression of 
DLL1 in response to the 6 hour 100nM TCDD treatment in MCF7 cells (Table 7 and 11). This 
suggests that TCDD and ITE may potentially increase the levels of cleaved-NICD by inducing 
the expression of DLL1, which in turn binds to and activates the Notch1 receptor in MCF7 and 
T47D cells (Figure 31). However, this observation is speculative. Proving that TCDD and ITE 
induce Notch signaling in MCF7 and T47D cells by promoting the binding of DLL1 to the Notch 
receptor will require future experiments. Our findings indicate that ITE and TCDD increase the 
levels of cleaved-NICD in MCF7 and T47D cells, yet these two ligands decrease the levels of 
cleaved-NICD in MDA-MB-231 cells (Figures 22-23, 25-28), and ITE decreases levels of 
cleaved-NICD in MDA-MB-157 cells (Figure 26). Our discovery that TCDD and ITE selectively 
increased the levels of cleaved-NICD in ER-positive breast cancer cells yet decreased its levels  
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Figure 31. Potential Mechanism(s) that Inhibit JAG1 Expression via AHR Activation in 
ER-positive Breast Cancer Cells  
TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin, ITE = 2-(1’H-indole-3’-carbonyl)-thiazole-4-
carboxylic acid methylester, AHR = Aryl Hydrocarbon Receptor, DLL1 = Delta-like Ligand 1, 
ER = Estrogen Receptor, NICD = Notch Intracellular Domain, HES1 = Hairy Enhancer of Split 
1, JAG1 = Jagged1, miRNA-21 = microRNA-21. Green Arrows = Increased Expression, Red 
Arrows = Decreased Expression.  
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in TNBC cells, suggests that the ER may contribute to the observed increases in cleaved-NICD 
in response to ligand-activated AHR. The findings of prior reports showing that the AHR and ER 
crosstalk supports our postulate that the ER may play a role in mediating ITE- and TCDD-
stimulated increases in cleaved-NICD levels in ER-positive breast cancer cells.   
 With regard to TNBC cells, we postulate that the observed decrease in cleaved-NICD 
levels in response to ITE and TCDD is secondary to the reductions in JAG1 protein. Prior reports 
have identified that JAG1 is the primary Notch ligand that triggers activation of the Notch1 
receptor (leading to increases in cleaved-NICD levels) in TNBC cell lines (Cohen, et al., 2010; 
Yamamoto, et al., 2013; Dickson, et al., 2007; Reedijk, et al., 2005). We, therefore, hypothesize 
that TCDD and ITE first downregulate JAG1, which in turn leads to decreases in the activity of 
Notch signaling and reduces the levels of cleaved-NICD in TNBC cells (MDA-MB-231 and 
MDA-MB-157). Based on the findings in these prior reports, we propose that the downregulation 
of cleaved-NICD levels in response to TCDD and ITE in TNBC cells (MDA-MB-231 and 
MDA-MB-157) is caused by the observed reductions in JAG1 protein levels.   
5.5.2. Potential Mechanisms by which TCDD and ITE Reduce JAG1 Expression in 
ER-negative and ER-positive Breast Cancer Cells 
 We propose that there are several mechanisms by which TCDD and ITE could reduce the 
expression of JAG1 in ER-positive and ER-negative breast cancer cells. Regarding ER- 
expressing breast cancer cells (MCF7 and T47D), the levels of HES1 protein were induced by 
TCDD and ITE (Figures 20 and 24). Given that HES1 is a transcriptional repressor that has been 
shown to directly suppress the transcription of JAG1 in other cellular systems (So, et al., 2015; 
Kobayashi & Kageyama, 2010), it is possible that TCDD and ITE inhibit the expression of JAG1 
by increasing the levels of HES1 (Figure 31). However, TCDD and ITE do not increase HES1 in 
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MDA-MB-231 and MDA-MB-157 cells, indicating that these two AHR ligands do not suppress 
the expression of JAG1 by increasing the HES1 in these two TNBC cell lines (Figure 26). In 
addition to HES1, prior reports have shown that miRNA-21 (microRNA-21) inhibits the 
translation of JAG1 mRNA in MCF7 cells (Selcuklu, Donoghue, Kerin, & Spillane, 2012). 
Considering that the non-toxic AHR ligand DIM has been reported to increase the expression of 
miRNA-21 in MCF7 cells (Jin, 2011), it is possible that TCDD and ITE reduces the expression 
of JAG1 in ER-positive breast cancer cells by increasing the levels of miRNA-21 (Figure 31). 
The potential for a miRNA-21-based mechanism for suppressing the expression of JAG1 in 
response to ligand-activated AHR is more likely to occur in ER-positive breast cancer cells and 
not TNBC cells, given that prior reports have shown that this particular microRNA is not 
inducible in TNBC cells (i.e., MDA-MD-231 and MDA-MB-468) (Selcuklu, Donoghue, Kerin, 
& Spillane, 2012; Jin, 2011).   
For reasons detailed in the previous paragraph, we postulate that increases in HES1 or 
miRNA-21 in response to TCDD or ITE could induce the observed downregulation of JAG1 in 
ER-positive, but not TNBC cells. We hypothesize that AHR-mediated suppression of NF-kB is 
the primary mechanism by which ITE and TCDD suppress the transcription of JAG1 in TNBC 
cells (MDA-MB-231 and MDA-MB-157) (Figure 32). NF-kB is a transcription factor that is 
more highly expressed and active in TNBC compared with ER-positive breast cancer 
(Yamamoto, et al., 2013; Yamaguchi, et al., 2009). The higher activity and expression of NF-kB 
in TNBC cells is attributed to constitutive expression of pro-inflammatory cytokines (i.e., IL-6 
and TNFα), which act through their cell surface receptors to induce signaling that increases the 
levels and activity of NF-kB (Figure 13). The NF-kB family is composed of five members p50, 
p52, RelA, RelB, and c-Rel, which promote JAG1 expression (Yamamoto, et al., 2013). 
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Figure 32. Potential Mechanism that Inhibits JAG1 Expression via AHR Activation in ER-
negative Breast Cancer Cells 
TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin, ITE = 2-(1’H-indole-3’-carbonyl)-thiazole-4-
carboxylic acid methylester, AHR = Aryl Hydrocarbon Receptor, IL-6 = Interleukin-6, RelA = 
V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A. Green Arrows = Increased 
Expression, Red Arrows = Decreased Expression. 
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The primary NF-kB subunit that has been reported to transcriptionally activate JAG1 is RelA 
(Bash, et al., 1999; Johnston, Dong, & Hughes, 2009). Furthermore, RelA was identified to 
specifically increase the transcription of JAG1 and not the other four Notch ligands (i.e., JAG2, 
DLL1, DLL3 and DLL4) (Yamamoto, et al., 2013). Prior reports have shown that the AHR 
signaling pathway extensively crosstalks with the NF-kB pathway to influence target gene 
expression (Tian, 2009; Beischlag, Luis Morales, Hollingshead, & Perdew, 2008; Kim, et al., 
2000; Salisbury & Sulentic, 2015) (Figure 13). Notably, TCDD-activated AHR signaling inhibits 
the binding of RelA to NF-kB binding sites in target genes (Tian, 2009; Salisbury & Sulentic, 
2015) (Figure 13). Based on the findings of these prior reports, we hypothesize that ITE or 
TCDD-activated AHR signaling inhibits the binding of RelA to NF-kB binding sites on the 
JAG1 promoter, and reduces the transcription and expression of JAG1 in TNBC cells (Figure 
32). Proving that ligand-activated AHR signaling suppresses RelA binding to the promoter of 
JAG1 can be addressed in future studies. 
5.5.3. Potential Mechanisms by which ITE Inhibits the Migratory and Invasive 
Activity of MDA-MB-231 Cells 
 Our findings show that ITE inhibits the migratory and cell invasive activity of MDA-
MB-231 cells (Figures 29A-29C). Prior reports have shown that JAG1 and cleaved-NICD 
increase the movement and invasive activity of MDA-MB-231 cells (Leong, et al., 2007; 
Shimizu, et al., 2011). Our data indicates that ITE reduced the levels of JAG1 (Figures 25-28) 
and cleaved-NICD (Figures 26-27) in TNBC cells. We, therefore, propose that ITE inhibits the 
migratory and invasive activity of MDA-MB-231 cells by decreasing the levels of JAG1 and 
cleaved-NICD (Figure 29). Prior reports have provided insight into the mechanisms by which 
JAG1 and cleaved-NICD promote the migratory and invasive activity of TNBC cells using the 
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MDA-MB-231 cell model (Shimizu, et al., 2011). The secreted serine protease, µPA, converts 
plasminogen to plasmin, and it has been shown to be a marker of breast cancer recurrence, high 
metastatic risk, and poor breast cancer prognosis (Shimizu, et al., 2011). Shimizu et al. 
demonstrated that siRNA-mediated knockdown of JAG1 or Notch1 caused reductions in the 
expression of µPA in three TNBC cell lines, including MDA-MB-231 cells (Shimizu, et al., 
2011). The authors conducted further work and showed that reducing the expression of JAG1 or 
µPA was sufficient to suppress the migratory and invasive activity of MDA-MB-231 cells 
(Shimizu, et al., 2011). Collectively, Shimizu et al demonstrated that JAG1-mediated Notch 
signaling induced the transcription of µPA upon the NICD binding to the promoter region of the 
µPA gene, which in turn promoted the invasive and migratory activity of MDA-MB-231 cells 
(Shimizu, et al., 2011). While our findings show that ITE reduces the levels of JAG1 and 
cleaved-NICD in TNBC cells, a future study will be required to investigate whether ligand-
activated AHR signaling also reduces the expression of µPA in MDA-MB-231 cells.  
 In addition to inducing the expression of µPA, JAG1 and cleaved-NICD have been 
reported to increase the transcription and expression of a Snail Family of Transcriptional 
Repressor (SNAI) member (Leong, et al., 2007). The SNAI2 (Slug) gene encodes a 
transcriptional repressor that upon binding to E-box motifs suppresses the transcription and 
expression of E-cadherin (Bolós, et al., 2003). The suppression of E-cadherin induces EMT and 
promotes the mesenchymal phenotype, which is more migratory and invasive compared with the 
properties of the epithelial phenotype (Bolós, et al., 2003). Thus, JAG1 and the NICD have been 
proposed to increase the migratory and invasive activity of TNBC cells by increasing the 
expression of Slug, which in turn downregulates E-cadherin and promotes EMT (Niessen, et al., 
2008). Considering the findings of these prior reports, it is possible that ITE by reducing the 
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levels of JAG1 and the NICD also reduces the expression of Slug and suppresses EMT in TNBC 
cells. Recent studies have also suggested that Notch signaling induces a specialized type of EMT 
during normal heart development and that Notch up-regulates SNAI1 (Snail) in endothelial cells 
to promote mesenchymal transformation (Timmerman, et al., 2004; Noseda, et al., 2004). 
Whether ITE downregulates Slug or Snail in TNBC cells can be addressed in future studies.  
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CHAPTER 6 
SNAIL: AN ESSENTIAL REGULATOR FOR EMT 
The SNAI family of zinc-finger transcription factors consist of Snail, Slug and SNAI3 
(Smuc), which all share an evolutionarily conserved role in mesoderm formation in vertebrates 
(Nieto, 2002). They possess a highly conserved carboxy-terminal region that contain 4-6 
acetylene-type zinc fingers, which regulate sequence-specific interactions within DNA promoters 
containing a CAGGTG E-box sequence (Wu & Zhou, 2010). Snail expression in both vertebrate 
and Drosophila suppress gene expression through the interaction with the co-repressor C-
terminal binding protein (CtBP) and also by directly promoting repressor complex formation 
(Nieto, 2002). Peinado et al. was able to demonstrate that Snail interacted with co-repressor 
complex Histone Deacetylase Complex Subunit Sin3a (SIN3A), histone deactylase 1 (HDAC1), 
and histone deactylase 2 (HDAC2) in order to inhibit E-cadherin expression (Peinado, Ballestar, 
Esteller, & Cano, 2004).  
Snail employs global effects on the genome in epithelial cells and by altering the gene 
expression profile. Therefore, it is involved in regulating EMT (Kalluri & Weinberg, 2009), cell 
survival (Emadi Baygi, Soheili, Schmitz, Sameie, & Schulz, 2010), apoptosis (Kurrey, et al., 
2009), cell polarity (Moreno-Bueno, Portillo, & Cano, 2008) and stem cell-like properties 
(Kurrey, et al., 2009). The regulatory and functional roles of Snail emerged as one of the hottest 
topics in medicine these past few years in cancer biology. This chapter will focus on the 
regulation of Snail and discuss its functions in EMT and stem cells, as well as how our lab shows 
that TCDD and ITE regulate Snail in an AHR-dependent manner. 
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6.1. Regulation of Snail 
Snail has been identified as a highly unstable protein and is regulated by both protein 
stability and cellular location. The expression of Snail is regulated by an integrated and complex 
signaling network at the transcriptional and post-transcriptional level. This network includes 
integrin-linked kinase (ILK), PI3K, MAPKs, GSK-3b, and NF-kB pathways (De Craene, van 
Roy, & Berx, 2005; Wu, Y. et al., 2009). Fibroblast growth factor (FGF) and EGF signaling 
induces Snail expression by suppressing the activity of GSK-3b (Wu & Zhou, 2010).  
Many signaling pathways that are involved in embryonic development also regulate Snail 
expression. One example is the TGFb signaling pathway, which induces Snail expression via 
Smad binding directly to the Snail promoter in hepatocytes, epithelial and mesothelial cells (Xu, 
Lamouille, & Derynck, 2009). Additionally, Notch signaling utilizes two distinct mechanisms 
that regulate Snail expression synergistically by recruiting the NICD to the Snail promoter and 
by NICD-HIF1a promoting expression of lysyl oxidase (LOX), a known stabilizer of Snail 
(Sahlgren, Gustafsson, Jin, Poellinger, & Lendahl, 2008; Peinado, et al., 2005). The Wnt 
signaling pathway also stabilizes Snail by suppressing GSK-3b activity (Yook, Li, Ota, Fearon, 
& Weiss, 2005). 
Snail expression can also be regulated by the NF-kB pathway via transcriptional and 
post-transcriptional mechanisms. GSK-3b inhibition stimulates the transcription of Snail by 
activating the NF-kB pathway (Bachelder, Yoon, Franci, de Herreros, & Mercurio, 2005). Post-
transcriptionally, TNFa is the major signaling pathway that induces Snail stabilization. TNFa-
NF-kB-stabilized Snail is mediated by the transcriptional induction of casein kinase-b (CSN2), 
which results in the inhibition of phosphorylation and ubiquitylation of Snail by GSK-3b (Wu, 
Y., et al. 2009). 
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6.2. Snail, EMT, and Stem Cells 
EMT is a profound event for large-scale cell movement during morphogenesis at the time 
of embryonic development (Wang, Shi, Chai, Ying, & Zhou, 2013). During this process, 
epithelial cells detach from neighboring cells and gain mesenchymal properties, which enables 
them to break through the basement membrane that separates different tissues within the embryo 
(Kalluri & Weinberg, 2009). One of the hallmarks of EMT is the functional loss of E-cadherin, 
which is thought to be metastatic suppressor during tumor growth and progression (Hanahan & 
Weinberg, 2011). Snail is a prominent inducer of EMT by strongly repressing E-cadherin 
expression (Barrallo-Gimeno & Nieto, 2005).  
Because a similar process occurs at the invasive front of metastatic cancer, it has been 
proposed that tumor cells exploit the developmental EMT program for their metastatic 
dissemination. Metastasis is responsible for a majority of cancer patient deaths and is divided 
into a series of steps, including detachment of tumor cells from the primary tumor, invasion, 
intravasation, anoikis-resistance, extravasation, and secondary-site colonization (Pantel & 
Brakenhoff, 2004). EMT is involved in the metastatic cascade of many solid tumors and entails 
the molecular reprogramming and phenotypic changes that characterize the conversion of 
immobile cancer epithelial cells to motile mesenchymal cells. Therefore, expression of Snail 
positively correlates with tumor grade, recurrence, metastasis, and poor prognosis in various 
cancer types (Peinado, Olmeda, & Cano, 2007; Hemavathy, Ashraf, & Ip, 2000; Moody, et al., 
2005; Chen, et al., 2010). 
From a physiological stand-point, stem cells are the basis for tissue homeostasis in the 
adult organism (Fuchs, Tumbar, & Guasch, 2004). Recent evidence has shown that Snail plays a 
role in the preservation of stem cell function. de Frutos et al was able to demonstrate that Snail 
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plays a fundamental role in controlling bone mass and bone homeostasis by acting as a repressor 
of RUNX2 and Vitamin D Receptor (VDR) transcription (de Frutos, et al., 2009). The expression 
of Snail is tightly regulated in bone development and its activity on osteoblasts regulates bone 
cell differentiation in order to ensure proper bone remodeling (Wu & Zhou, 2010). Additionally, 
Snail also regulates genes that are involved in neural stem cell self-renewal and multi-potency 
(Southall & Brand, 2009). These observations identify that Snail is an important factor to the 
preservation of stem cell function and maintenance.  
6.3. TCDD and ITE Regulate Snail in an AHR-dependent Manner 
Knowing that JAG1-dependent Notch signaling promotes expression of various target 
genes that are required to promote cancer growth at various stages of tumor progression, we 
questioned if whether the target genes downstream are also affected by ITE and TCDD 
treatments in breast cancer cells. Therefore, we measured the changes of Snail, a down-stream 
target of JAG1-Notch1 signaling that is critical for promoting EMT by suppressing the 
expression of E-cadherin (Li, Masiero, Banham, & Harris, 2014).  
When T47D and MDA-MB-231 cells were treated with 10nM TCDD, our data indicated 
that TCDD was able to significantly decrease Snail expression after 24 hours (Figure 33). In the 
case of ITE, we treated T47D, MDA-MB- 231, and MDA-MB-157 cells with 10µM ITE for 3 
days to determine if there were any changes in Snail expression and observed decreases in Snail 
in all three cell lines (Figure 33), signifying that the regulation of Snail via activation of the AHR 
is independent of the ER.  
In order to determine if regulation of Snail was AHR-dependent, MDA-MB-231 cells 
transfected with non-targeting siRNA or AHR-targeting siRNA were treated with vehicle or 10 
µM ITE for 3 days. We found a significant reduction in the levels of Snail protein in the  
140 
 
Figure 33. Activation of AHR via TCDD and ITE Inhibits Snail Expression in Breast 
Cancer Cells 
A) T47D and MDA-MB-231 cells were treated with vehicle or 10 nM TCDD for 24 h. B) T47D, 
MDA-MB-231, and MDA-MB-157 cells were treated with vehicle or 10µM ITE every 12 h for 3 
days. Total cellular protein was isolated and subjected to western blot analysis. Blots were 
probed with the indicated antibodies. Levels of Snail were normalized to GAPDH. Results 
shown are the means ± SEM of three independent experiments. Significant reductions by ITE are 
indicated by *P < 0.05 or **P<0.01. 
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control cells treated with ITE compared with cells treated with vehicle (Figure 34). Finding that 
ITE reduces the levels of Snail protein in control cells is consistent with our prediction that ITE 
is functioning as an AHR ligand in MDA-MB-231 cells. We observed that AHR knockdown 
cells were not responsive to ITE-stimulated reductions in Snail, indicating that the suppressive 
effect of ITE on Snail expression is transmitted through the AHR (Figure 34). Collectively, our 
data suggests that various AHR ligands that have been known to promote anti-cancer effects is 
potentially achieved through a common mechanism of reducing JAG1 expression. This in turn 
would expect to decrease the expression of genes that are targets of JAG1-dependent signaling, 
which are required for cancer progression. 
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Figure 34. AHR Knockdown Indicates ITE-stimulated Suppression of Snail Expression in 
MDA-MB-231 Cells is AHR-dependent 
Control cells were transfected with non-targeting siRNA and AHR knockdown cells were 
transfected with AHR-targeting siRNA. Forty-eight hours after transfection, cells were treated 
with vehicle or 10µM ITE every 12 hours for 3 days. Total cellular protein was isolated and 
subjected to western blot analysis. Blots were probed with the indicated antibodies. Levels of 
Snail and AHR were normalized to GAPDH. Data shown are the means ± SEM of three 
independent experiments. Significant reductions by ITE or AHR-targeting siRNA are indicated 
by ***P<0.001. 
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CHAPTER 7 
DISCUSSION AND FUTURE DIRECTIONS 
7.1. Discussion 
Towards the end of my research project, AHR signaling became even more fascinating 
compared to when I first began studying it over three years ago. With AHR biology being so 
diverse in its ability to bind various ligands, the endogenous roles seem to reveal themselves 
slowly and branch out into a variety of cellular functions. In the realm of toxicology, the AHR is 
one of the most commonly studied receptors, given the breadth of compounds which work 
through AHR signaling to exert their effects. Even though the AHR has been studied extensively 
in response to over 400 exogenous ligands, which include environmental pollutants/toxicants, 
various drugs, and phytochemicals, there is still much to learn about endogenous AHR cellular 
signaling. It is important to note that the AHR is an evolutionarily conserved protein, which has 
played a vital role for allowing researchers to make great strides in understanding the 
endogenous function of AHR. Moreover, researchers were also able to help characterize 
endogenous AHR ligands that are produced by the microflora present in the body, based on diet 
composition (Denison, Soshilov, He, DeGroot, & Zhao, 2011). While AHR research has shifted 
from toxicology-based to a more cancer-based emphasis (Safe, Cheng, & Jin, 2017), it is clear 
there is still much to learn regarding AHR functionality in both normal and cancer cell 
physiology.  
Our research objective was simple as well as diverse, which was to reveal a new tumor 
suppressing role for the AHR in breast cancer by hypothesizing that non-toxic AHR ligands can 
induce anti-cancer effects by regulating the expression of JAG1 and the Notch signaling 
pathway. Since that has been accomplished, we can continue to approach this objective from 
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alternate perspectives, as will be detailed later in this chapter. First, our findings show that 
TCDD and ITE reduce JAG1 in both ER-positive (MCF7 and T47D) and ER-negative (MDA-
MB-231 and MDA-MB157) breast cancer cells as a novel discovery and provides a new insight 
into the mechanism by which ligand-activated AHR signaling inhibits cancer hallmarks 
including cell invasion and migration (Figures 19-29). However, our findings also show that the 
AHR acts as a Notch signaling modulator, which is potentiated in a cell-type dependent manner. 
This is due to the AHR activating the Notch signaling pathway in ER-positive cells (Figures 20 
and 24) but inhibiting it in ER-negative cells (Figures 22, 26-27). Additionally, we were able to 
characterize cell-cell communication and cell movement as new bio-functional roles for AHR 
through RNA-seq analysis (Table 6). Therefore, future work involving the identification of 
downstream target genes that are unique to JAG1-dependent Notch signaling and that are also 
regulated by AHR activation would increase the evidence for the tumor-suppressing roles of the 
AHR. The following sections will cover the therapeutic implications for targeting the AHR in 
both ER-positive and ER-negative breast cancer cells.  
7.1.1. Therapeutic Implications for Targeting ER-positive Breast Cancer via AHR 
Activation 
It is important for us to consider the potential therapeutic implications for targeting the 
AHR through the use of non-toxic agonists for the treatment of ER-positive breast cancer. It has 
been demonstrated that the protective effects of AHR ligands on tumor growth are related to the 
ability of the receptor to antagonize ER signaling (Murray, Patterson, & Perdew, 2014). The 
functional outcomes of the antagonistic AHR-ER crosstalk are apparent in both in vitro and in 
vivo models in which TCDD was shown to completely reverse the proliferative effects of 
estrogen mediated signaling (Weng, Tsai, Kulp, & Chen, 2008; McDougal, Wormke, Calvin, & 
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Safe, 2001). In addition to the antagonistic effects on ER signaling, the AHR also regulates key 
processes required for breast cancer cell growth (McDougal, Wilson, & Safe, 1997), cell cycle 
control (Barhoover, Hall, Greenlee, & Thomas, 2010), chemokine signaling (Hsu, et al., 2007), 
and cell migration (Hall, et al., 2010).  
There are some cases that argue activation of the AHR promotes breast cancer 
progression and that inhibiting AHR activity is the best route for the treatment of ER-positive 
breast cancer. Dubrovska et al. demonstrated tamoxifen-resistant MCF7 cells maintain the CSC 
population through the C-X-C motif chemokine receptor 4 (CXCR4), which resulted in the 
activation of AHR-dependent gene transcription (Dubrovska, et al., 2012). This research 
proposed that inhibition of CXCR4 or AHR (via antagonists) specifically targets the CSC 
population and could be beneficial for the treatment of tamoxifen-resistant breast cancer. 
However, it is uncertain if AHR activation occurs in a ligand-dependent manner in this particular 
case, as the role of the AHR in facilitating cell cycle progression is primarily manifested in the 
absence of an exogenous ligand because treatment with AHR agonists inhibits cell cycle 
progression (Gomez-Duran, et al., 2009; Greenlee, Hushka, & Hushka, 2001; Elferink, Ge, & 
Levine, 2001). It is therefore important to consider the possibility that there is a genuine ligand-
independent AHR activation mechanism as it was demonstrated by Ikuta et al, who showed that 
tumor cells with high levels of the AHR undergo dynamic nucleocytoplasmic shuttling (Ikuta, et 
al., 2000). Dynamic nucleocytoplasmic shuttling could lead to AHR and ARNT 
heterodimerization in the absence of ligand and present a different physiological outcome 
compared to ligand-activated AHR signaling. This mechanism could also potentially occur in the 
CSC population of ER-positive breast cancer cells, where the AHR promotes pro-tumorigenic 
characteristics in a ligand independent manner (Oesch-Bartlomowicz, et al., 2005). However, our 
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lab measured gene expression with cancer profiling gene arrays that revealed TCDD-treated 
MCF7 breast cancer cells decreased the mRNA expression of CXCR4, signifying another 
addition to the tumor-suppressing role for ligand activated AHR signaling in MCF7 cells (Raw 
reads and processed RNA-seq data were deposited in the Gene Expression Omnibus (GEO) at 
the National Center for Biotechnology Information and are accessible via accession number 
GSE98515). Hall et al. also demonstrated that TCDD inhibited expression of CXCR4 in both 
ER-positive and ER-negative breast cancer cells (Hall, et al., 2010). Interestingly, Chiaramonte 
et al. demonstrated that Notch activation was able to promote both multiple myeloma and 
ovarian cancer growth and metastasis by promoting the expression of CXCR4, making the Notch 
signaling pathway a viable target for treatment in these particular cancers (Chiaramonte, et al., 
2015). Based on our data and current literature, it is possible that AHR activation inhibits JAG1 
expression, resulting in the decrease of CXCR4 mRNA expression as shown by our RNA-seq 
analysis. Therefore, it is safe to postulate that even though both ITE and TCDD activated the 
Notch pathway in ER-positive breast cancer by increasing cleaved-NICD and HES1 levels, the 
decreased expression of JAG1 and CXCR4 indicates that JAG1-dependent Notch signaling may 
be responsible for the regulation of CXCR4. However, further studies must be conducted to fully 
elucidate this mechanism.  
A study conducted by Al-Dhfyan et al. provides another example on how AHR activation 
mediates the expansion of the BCSC population in MCF7 cells. This extensive study provided 
the first strong evidence that activation of the AHR-CYP1A1 pathway via TCDD and 7,12-
dimethylbenz(a)anthracene (DMBA) promoted CSC development, maintenance, self-renewal, 
and chemo-resistance through inhibition of phosphatase and tensin homolog (PTEN) and 
activation of b-catenin and Akt-pathways (Al-Dhfyan, Alhoshani, & Korashy, 2017). Moreover, 
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they showed that inhibition of the AHR via a-naphthoflavone sensitized CSCs to chemotherapy 
by increasing the percentage of apoptotic CSCs in response to doxorubicin. However, even 
though this study provides mechanistic insight into the relationship between AHR activation and 
the CSC population from a toxicological stand-point, it does not establish appropriate clinical 
relevance for antagonizing AHR for the treatment of ER-positive breast cancer. This study 
utilized only highly stable carcinogenic compounds to determine functional relevance of AHR 
activation on BCSCs as a means to promote AHR antagonism as a viable form of treatment. 
Additionally, this study did not provide any evidence if this same outcome occurs with known 
non-carcinogenic AHR agonists that have been demonstrated to promote inhibitory effects on the 
CSC population and possess true clinical relevance. AHR agonists such as tranilast 
(Prud’homme, et al., 2010), IC3 (Weng, Tsai, Kulp, & Chen, 2008), and DIM (Jin, 2011) were 
shown to effectively inhibit the growth of both ER-positive and ER-negative breast cancer 
similar to that of TCDD with none of the adverse effects. Moreover, their data regarding TCDD 
treatments in MCF7 cells does not align with our data, as they showed that TCDD did not 
increase the nuclear translocation of the NICD, hence why they claim the Wnt signaling pathway 
is involved in CSC development, maintenance, and self-renewal. This can potentially be due to 
the differences in our timed treatments as they treated MFC7 cells with TCDD for 3 days, which 
may result in identifying down-stream effects of TCDD treatments rather than initial changes in 
gene expression. Finally, and most importantly, this study looked at different functional 
outcomes compared to our research as they studied AHR-regulated changes in mammosphere 
formation and chemo-resistance while we observed changes in metastatic behavior involving 
invasion and migration. Overall, what these discrepancies dictate is that the activation of the 
AHR in the context of promoting the CSC phenotype in ER-positive breast cancer may require a 
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process that balances the apparent advantage of modulating AHR activity for invasion, motility, 
and colonization with the need for growth and proliferation. Unfortunately, the role of the AHR 
in cellular physiology suffers from the toxicological origins of the receptor. In reality, the AHR 
should be viewed in the same realm as other cellular receptors (i.e. ER, AR, and PR) with a 
normal physiological role that can be disrupted by xenobiotic chemicals rather than a receptor 
that evolved primarily as a xenobiotic sensor.  
Despite the discrepancies present with AHR activation regarding the promotion of cell 
proliferation and stem-cell maintenance, our lab was able to show AHR activation prevents 
cancer promoting bio-functions, such as EMT and the metastatic process (i.e. invasion and 
migration, see Figure 29). These anti-cancer functions are easily postulated due to our discovery 
that both TCDD and ITE inhibit JAG1 expression in MCF7 cells, a vital component for the 
promotion of metastasis, drug-resistance, and tumor recurrence (Li, Masiero, Banham, & Harris, 
2014). Our hypothesis that TCDD inhibits these invasive and metastatic features in breast cancer 
cells correlates with a study conducted by Hall et al., that demonstrated breast cancer cells 
treated with exogenous AHR agonists (TCDD and DIM) significantly inhibited cell invasiveness 
and motility by Boyden chamber assay and inhibited colony formation, in ER-positive cells 
(Hall, et al., 2010). This is because they observed that AHR activation reduced the number of 
invaded cells by 70% in MCF7, SKBR3, and ZR-75-1 breast cancer cell lines. In correlation with 
this functional outcome, TCDD was able to significantly repress CXCR4 and matrix 
metallopeptidase 9 (MMP9), two prominent genes heavily associated with metastasis (Hao, et 
al., 2007). This observation not only correlates with our research, but also with a study 
conducted by Dai et al, that demonstrated knockdown of JAG1 via siRNA resulted in decreased 
expression of MMP9 in colorectal cancer cells, resulting in decreased invasion (Dai, et al., 
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2014). Additionally, knockdown of AHR via siRNA and the use of the AHR antagonist a-
naphthoflavone demonstrated that these anti-invasive outcomes were AHR-dependent (Hao, et 
al., 2007). Together these studies suggest that the inhibition of motility and invasiveness by 
exogenous AHR agonists are receptor-mediated and that endogenous AHR activity promotes an 
anti-cancer role through inhibiting the metastatic process. Our discovery that the decreased 
expression of JAG1 via TCDD and ITE in MCF7 cells could help elucidate the mechanism 
behind the anti-metastatic effects of AHR activation.  
Ultimately, the use of the non-toxic AHR agonists such as ITE in the presence of anti-
estrogenic treatments such as tamoxifen may provide a synergistic effect in the treatment of ER-
positive breast cancer, especially drug-resistant breast cancer. The therapeutic strategy 
combining AHR agonists and anti-estrogenic therapies is valid and logical, based on the study 
conducted by Darakhshan & Ghanbar, where the combination of tranilast (a potent AHR agonist 
which will be covered later in this chapter) and tamoxifen induced anti-tumorigenic effects in a 
synergistic manner in MCF7 breast cancer cells (Darakhshan & Ghanbar, 2013).  
7.1.2. Therapeutic Implications for Targeting ER-negative Breast Cancer via AHR 
Activation 
 Some early stage and most later stage mammary tumors are ER-negative and patients 
with ER-negative breast cancer do not respond well to endocrine therapy; successful adjuvant 
chemotherapy requires the use of more highly cytotoxic agents commonly used to treat other 
endocrine-independent tumors. These agents generally target some aspect of nuclear function 
(i.e. DNA-chelation) or modulate microtubule formation/breakdown and include compounds 
such as doxorubicin, cyclophosphamide, gemcitabine, taxanes, and capecitabine, a precursor of 
5-flurouracil (5-FU) (Ismail-Khan & Bui, 2010). Evidence and observations from multiple 
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studies on the use of AHR agonists for the treatment in ER-negative breast cancers possesses less 
discrepancy and controversy compared to that of ER-positive breast cancer. These observations 
may be due to the increasing evidence that the AHR plays a role in the inhibition of the 
metastatic and invasive cellular processes, which are much more prominent in the ER-negative 
breast cancer subtype (Hanieh, 2015; Hall, et al., 2010; Prud’homme, et al., 2010). These 
observations stem from various extensive studies that show that treatment with exogenous AHR 
agonists significantly inhibited cell invasiveness and motility in the Boyden chamber assay and 
inhibited colony formation in soft agar regardless of ER, PR, or HER2 status (Hall, et al., 2010; 
Meng, et al., 2000; Darakhshan & Ghanbar, 2013). This observation further signifies that the 
anti-cancer mechanism behind AHR activation is not limited to the antagonistic action on ER-
dependent signaling. Zhang et al. demonstrated that both TCDD and the relatively non-toxic 
AHR agonist 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) induced CYP1A1-dependent 
ethoxyresorofin-O-deethylase (EROD) activity and inhibited proliferation of seven ER-negative 
cell lines (BT474, HCC38, MDA-MB453, MDA-MB-435, MDA-MB-436, MDA-MB-157 and 
MDA-MB-468) (Zhang, et al., 2009). In the case for MDA-MB-231 cells, Hall et al. 
demonstrated decreased cell motility, invasiveness, and mammosphere formation in the presence 
of TCDD and DIM (Hall, et al., 2010). Moreover, Prud’homme et al. clearly demonstrated that 
tranilast is an AHR agonist with inhibitory effects on BCSCs and was especially effective against 
CSCs in TNBC specifically selected for drug resistance (Prud’homme, et al., 2010). Therefore, 
AHR activation presents a strong clinical application for the treatment for breast cancer, 
especially for the TNBC subtype. However, there are a few studies that contribute AHR 
activation to increased tumor progression and increased malignancy in ER-negative breast cancer 
and are discussed below. 
151 
One of those studies was conducted by Miret et al., which demonstrated that the 
progression of TNBC occurs through AHR activation with the carcinogenic environmental 
molecule hexachlorobenzene (HCB), and resulted in enhanced invasion and migration through 
the promotion of the Smad, Jun amino-terminal kinase (JNK), and p38 pathway (Mireta, et al., 
2016). Enhanced invasion and migration indicates that HCB modulates crosstalk between AHR 
and TGFb and consequently exacerbates a pro-migratory phenotype in MDA-MB-231 cells, 
which contributes to a high degree of malignancy. Another case for AHR activation promoting 
malignancy in MDA-MB-231 cells was demonstrated by D’Amato et al., as they showed that the 
tryptophan metabolite kynurenine increased activation of AHR while cells were in suspension, 
which in turn inhibits the cell death process anoikis during the metastatic process (D’Amato, et 
al., 2015). Moreover, inhibition or knockdown of tryptophan 2,3-dioxygenase (TDO2) decreased 
kynurenine production, increased anoikis sensitivity, while inhibiting proliferation, migration, 
and invasion. Additionally, AHR inhibition or knockdown also decreased proliferation, 
migration, and anchorage-independent growth. D’Amato et al. revealed that the TDO2-AHR 
signaling axis activated in TNBC cells promoted anoikis resistance and metastasis, and that 
pharmacological inhibition of TDO2 decreased lung colonization in a preclinical model of 
TNBC. 
These studies identify AHR as a tumor promoting factor in TNBC. However, there are 
some therapeutic strategies to consider when incorporating AHR agonists in breast cancer 
treatment regimens. Even though an endogenous AHR agonist such as kynurenine was able to 
promote the metastatic process, we are unaware as to how these treatments regulate JAG1 
expression. Moreover, kynurenine has been identified to be a weak AHR agonist (Mezrich, et al., 
2010), signifying that it has a low binding affinity to the AHR and can possibly be out-competed 
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with non-toxic AHR ligands that are known to inhibit cancer as well as have a higher binding 
affinity to the AHR, such as tranilast and ITE (Henry, Bemis, Henry, Kende, & Gasiewicz, 
2006). This study allows us to postulate that perhaps these tumor-promoting AHR ligands may 
not reduce JAG1 expression and may even increase its expression, which only adds to the 
complexity of the endogenous regulatory roles of AHR and warrants further investigation. 
However, as stated in the previous section, the role of the AHR in facilitating tumor progression 
is only manifested in either the absence of a non-toxic exogenous AHR ligand (i.e. tranilast, 
omeprazole, DIM, IC3) or through the knockdown and inhibition of the AHR (Ikuta, et al., 2000; 
Al-Dhfyan, Alhoshani, & Korashy, 2017). Considering the fact that AHR signaling plays a 
critical role in immunity, development, and hematopoiesis, targeting the AHR with antagonists 
may promote unwarranted side effects during treatment. 
Our studies reveal for the first time that TCDD and the endogenous AHR agonist ITE 
plays a tumor suppressive role in two TNBC cell lines (MDA-MB-231 and MDA-MB-157) 
(Figures 23, 25-30). We were able to determine that TCDD significantly decreased JAG1 
expression after 24 hours in MDA-MB-231 cells, and that ITE was able to not only significantly 
decrease JAG1 expression after 24 hours but was able to maintain JAG1 suppression over the 
course of 5 days (Figure 25). Additionally, MDA-MB-231 cells treated with ITE for 3 days were 
also able to inhibit the Notch signaling pathway because of the decrease in JAG1 (Figure 26). 
This decrease of JAG1 expression was further indicted by observing decreases in the NICD 
levels as well as the decrease of direct Notch target gene, HES1. Our AHR knockdown studies 
were also able to demonstrate that inhibition of the Notch signaling pathway was AHR-
dependent, as removal of the AHR prevented ITE from suppressing JAG1 expression and 
promoted the recovery of the Notch signaling pathway (Figure 27). In fact, in AHR knockdown 
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cells not treated with ITE, there was significant increase in both JAG1 and NICD levels, 
indicating that the AHR may act as a tonic JAG1 suppressor (Figure 27). MDA-MB-157 cells 
were also treated with ITE for 3 days and mirrored the outcome of MDA-MB-231 cells, as the 
decrease in JAG1 expression resulted in the inhibition of the Notch signaling pathway (Figure 
26). From the functional perspective, we were able to demonstrate that the decrease in JAG1 
expression from both ITE and JAG1-targeting siRNA inhibited both migration (scratch assay) 
and invasion (Boyden chamber) of MDA-MB-231 cells (Figure 30).  
Collectively, these results along with previously published data identify that activation of 
the AHR inhibits invasion and migration, primarily through decreasing the expression of JAG1 
and ultimately inhibiting the Notch signaling pathway in TNBC cells. Other than regulating 
migration and invasion, JAG1-dependent Notch signaling also plays an important role in drug-
resistance and CSC maintenance (Li, Masiero, Banham, & Harris, 2014). This allows us to 
hypothesize that ITE may promote inhibitory effects on BCSCs by decreasing JAG1 expression 
and restore sensitivity to treatment regimens as it was demonstrated with the AHR agonist 
tranilast. Tranilast was able to enhance treatment response and cytotoxicity in ER-negative breast 
cancer in conjunction with tamoxifen and induced apoptosis in a synergistic manner (Darakhshan 
& Ghanbar, 2013).  
7.1.3. Preliminary Data 
We expanded upon our first report showing that the decrease in JAG1 via TCDD and ITE 
were AHR-dependent by studying other AHR ligands that have been identified to be non-toxic as 
well as promote anti-cancer effects. One of the AHR ligands of interest was tranilast, an anti-
allergy medication that has gained attention for its anti-metastatic effects that were shown in both 
in vivo and in vitro studies (Rogosnitzky, Danks, & Kardash, 2012). We applied tranilast 
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(200µM) to MDA-MB-231 cells every 24 hours for 1, 3 and 5 days and discovered that tranilast 
reduced JAG1 on day 3 and day 5 significantly, compared with vehicle-treated controls (Figure 
29). Overall, we were able to show that small molecules which are structurally unrelated to each 
other may be able to promote AHR-dependent anti-cancer effects with the same mechanism, by 
decreasing JAG1 expression. From this data and our current knowledge, we can now pose a new 
question: Our laboratory has identified three AHR ligands that induce anti-cancer effects, do 
other non-toxic AHR ligands reduce JAG1 expression as a common mechanism behind their 
anti-cancer effects?  
Even though TCDD has been identified as a carcinogen, its ability to inhibit cancer 
progression in vitro as well as in breast cancer patients who’ve been exposed to this chemical 
after diagnosis has also been documented (Murray, Patterson, & Perdew, 2014). This presented a 
unique paradox, where AHR activation was identified to possess both pro-cancer and anti-cancer 
affects and developed a schism between researchers in terms of identifying the endogenous 
function of the AHR as well as the strategy for targeting AHR signaling in cancer therapies. 
Based on the findings from our research, we hypothesized that decreases in JAG1 would 
decrease the expression of JAG1-dependent downstream target genes that have previously been 
identified to promote cancer progression, such as Snail (Chen, Imanaka, Chen, & Griffin, 2010) 
(Figures 33 and 34). Interestingly, we discovered that AHR knockdown breast cancer cells via 
AHR-targeting siRNA are unable to suppress JAG1 levels in the presence of both TCDD and 
ITE (Figure 27). In fact, MDA-MB-231 cells treated with AHR-targeting siRNA showed that 
JAG1 expression was significantly increased in the untreated AHR-targeting siRNA treated 
group compared to the untreated control siRNA group (Figure 27). Our findings in this study 
complemented those found by Safe et al., leading to the discovery of a novel pathway by which 
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the AHR functions to modulate the Notch signaling pathway as a method for suppressing cell 
cycle progression and metastasis in response to various non-toxic small molecules from both 
endogenous (produced via metabolism by the micro flora in the GI tract) and exogenous (present 
due to diet, environment, and medication regimen) sources (Safe, Cheng, & Jin, 2017). This 
research regarding the diet and microbiome composition could help propose another potential 
therapy target for treating breast cancer as well as provide new insight on how small molecules 
from our environment and diet can potentially regulate developmental signaling pathways and 
the induction of corresponding changes in cellular physiology. With this information we can 
pose two questions: 1) Does AHR activation also change the expression levels of JAG1 target 
genes that are known to promote cancer progression? 2) How do AHR ligands that have been 
identified as tumor-promoting, besides TCDD, effect JAG1 expression as well as target genes 
downstream of JAG1-dependent signaling? 
As promising and novel as this discovery is, what is critical to note is that even though 
the decrease in JAG1 expression is AHR-dependent, it is not a direct AHR target gene (GEO 
accession number GSE98515). Our research led to a discovery that uncovers an extremely 
important connection between the small molecules present in our environment and cancer 
progression through the modulation of developmental signaling pathways. However, the 
mechanism behind AHR-dependent JAG1 suppression has yet to be completely understood. A 
viable mechanism can potentially be determined by identifying if any of the 189 TCDD-treated 
AHR-direct target genes (Table 7) can also act as a repressor of JAG1 or if AHR decreases 
expression of a certain gene that is known to promote JAG1 expression. Elucidating the 
complete mechanism can serve a critical importance in determining the differences between the 
endogenous functionality of the AHR in the both cancerous and non-cancerous cell lines, 
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considering that increased JAG1 protein levels in cancer cells correlate with increased 
aggressiveness and metastatic potential while normal epithelial type or non-malignant cells have 
little to no JAG1 expression (Cohen, et al., 2010). Therefore, it is important to ask the questions: 
1) What are some AHR-direct target genes that can act as a suppressor of JAG1 expression? 2) 
Does AHR inhibit expression of a gene that promotes JAG1 expression? 
We studied the regulation of JAG1 via ITE in two ER-positive cell lines (MCF7 and 
T47D) and two TBNC cell lines (MDA-MB-231 and MDA-MB-157) (Figures 19-29). 
Surprisingly, when we treated HCC1134 TNBC cells with ITE every 12 hours for 5 days, JAG1 
expression was increased significantly compared to the control group (Figure 35), which is 
completely opposite of the results in MDA-MB-231 cells. However, the levels of the AHR in 
HCC1143 cells were significantly lower compared to MDA-MB-231 cells (Figure 35). These 
results tell us that the amount of AHR present within the cell can potentially determine the 
direction JAG1 is regulated as well as may be used as a biomarker to determine the efficacy of 
treatment with AHR agonists. This further suggests that suppressing expression of JAG1 is an 
endogenous function of AHR, where low AHR levels resulted in the promotion of JAG1 
expression in the presence of ITE. Moreover, this observation may also shed insight on how 
AHR signaling can promote both pro-cancer and anti-cancer effects via activation of the AHR as 
well as how the initial amount of JAG1 and or AHR in cancer cells may potentially give rise to 
different cellular outcomes. Additionally, the increase in JAG1 levels may also occur because 
HCC1143 cells fall under a different sub-category of TNBC cells compared to MDA-MB-231 
cells, as HCC1143 are classified as basal-like, while MDA-MB-231 are classified as 
mesenchymal-like. This observation can be justified based on an extensive study conducted by 
Yamamoto et al. that demonstrated NF-kB-dependent induction of JAG1 and the Notch-  
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Figure 35. Activation of AHR via ITE Promotes JAG1 Expression in HCC1143 Breast 
Cancer Cells 
HCC1143 and MDA-MB-231 cells were treated with vehicle or 200µM Tranilast every 24 hours 
for 5 days. Total cellular protein was isolated and subjected to western blot analysis. Levels of 
JAG1 and HES1 were normalized to GAPDH. Results shown are the means ± SEM of three 
independent experiments. Significant differences in untreated HCC1143 cells compared with 
untreated MDA-MB-231 cells are indicated by #P < 0.05, ## P<0.01, or ### P<0.001. Significant 
changes in expression by ITE are indicated by *P < 0.05, **P<0.01, or ***P<0.001. 
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dependent expansion of the CSC population occurs only in the basal-like subtype of TNBC 
(Yamamoto, et al., 2013). Ultimately, this observation can lead us to ask the question: Could 
direct JAG1 inhibition via monoclonal antibodies or small molecule inhibitors be a novel 
chemotherapy tactic for the treatment of breast cancer as it may by-pass the controversy behind 
the use of AHR agonists in the treatment for breast cancer?  
In short, we have uncovered several novel roles for the AHR in breast cancer. The AHR 
is required for the anti-cancer effects of non-toxic AHR ligands in breast cancer cells (Hall, et 
al., 2010). TCDD, a prominent and well-studied AHR ligand, exposed the mechanism behind the 
anti-cancer effects of AHR (Murray, Patterson, & Perdew, 2014). These anti-cancer effects 
resulted in the discovery of non-toxic AHR ligands that are currently produced endogenously by 
the diet and certain medications (Hubbard, Murray, & Perdew, 2015). Finally, ITE (Cheng, et al., 
2015) and tranilast (Rogosnitzky, Danks, & Kardash, 2012) treatment studies revealed that JAG1 
(Li, Masiero, Banham, & Harris, 2014) is required for the proliferation, invasion and cell-
movement of TNBC cells and that various targets downstream of JAG1-dependent signaling are 
also regulated by activation of the AHR. The next section will discuss the preliminary data that 
we currently have that can help answer some of the questions that were mentioned in this 
section, as well as provide insight for future projects surrounding the relationship between JAG1 
and the AHR. 
7.2. Rationale for New Experiments 
We hypothesize that other non-toxic AHR ligands induce their anti-cancer effects by 
decreasing the expression of JAG1 and thereby reducing the expression levels of other 
oncogenes that require JAG1-dependent Notch signaling. The rationale for this hypothesis stems 
from prior reports showing that JAG1 is increased in more aggressive cancer types and is known 
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as an indicator of poor prognosis (Cohen, et al., 2010). Upon activating the Notch signaling 
pathway, JAG1 induces gene expression that promotes various functions in cancer biology 
including but not limited to metastasis, EMT, proliferation, drug-resistance, and CSC 
maintenance (Li, Masiero, Banham, & Harris, 2014). The activation of the AHR is highly 
relevant to the suppression of breast cancer, considering that overexpression of JAG1 is 
sufficient to induce growth of normal mammary cells and induce mesenchymal characteristics 
(Duryagina, et al., 2013). The JAG1 gene is not only amplified in more aggressive subtypes of 
breast cancer but also in ovarian cancer (Steg, et al., 2011), brain cancer (Purow, et al., 2005), 
and various types of leukemia (Li, Masiero, Banham, & Harris, 2014). In this regard, one study 
noted JAG1 was critical for MDA-MB-231 breast cancer growth in vitro and in vivo (Chen, et 
al., 2016). Our preliminary data demonstrate that the amount of AHR protein present within the 
cell may perhaps determine the regulatory outcome of JAG1 expression, as we showed that ITE-
treated HCC1143 TNBC cells increased JAG1 expression and that the AHR levels are much 
lower compared to the MDA-MB-231 cell line (Figure 35). Given the previous reports and 
current data, we hypothesize that regulation of JAG1-dependent signaling via activation of the 
AHR could be determined by the amount of AHR protein that is present within the cell. 
High JAG1 expression is linked to promoting metastasis in various cancer types and 
Snail expression has also been shown to be a necessity for the metastatic process. Snail is 
required for promoting the transformation of epithelial cells into mesenchymal cells, in order to 
induce cell-movement and invasion (Chen, Imanaka, Chen, & Griffin, 2010). This is because 
Snail inhibits the expression of E-cadherin by binding directly to its promoter and blocking its 
transcription, thereby suppressing the characterizations of the epithelial cell type. Our 
preliminary data demonstrate that AHR signaling decreases the expression of JAG1 and Snail via 
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TCDD and ITE (Figures 20-22, 24-26, 33) and we provide the first evidence that this could be 
mediated in an AHR-dependent manner (Figures, 23, 27-28, 34). Given the previous reports and 
our current data, we hypothesize that the decrease in JAG1 expression reduces the levels of 
downstream target genes of JAG1-dependent Notch signaling such as Snail as the mechanism for 
the anti-metastatic activity of AHR activation.  
It is well established that the Notch pathway and, in particular, JAG1-dependent Notch 
activation plays an important role in tumor biology because it affects both cancer cells and 
multiple components of the vascular and immunological microenvironment. It has also been 
shown that excess Notch activation transforms normal breast cells found in pre-invasive and 
invasive human breast cancer and correlates with early recurrence (Li, Masiero, Banham, & 
Harris, 2014). Moreover, inhibition of Notch signaling reduced BCSC activity (Simões, et al., 
2015). However, the major concern for targeting the Notch pathway by GSIs was the GI toxicity 
that resulted in severe diarrhea; as the Notch signaling pathway is necessary to maintain the 
goblet cell population to maintain consistent water absorption in the GI tract (Katoh & Katoh, 
2007). Furthermore, GSIs may target proteases other than g-secretase, which could result in 
unwarranted regulatory array of cellular functions. In order to overcome such limitations, recent 
studies have shown natural products that are non-toxic to humans, such as DIM (Hall, et al., 
2010), IC3 (Weng, Tsai, Kulp, & Chen, 2008), and other indoles and isoflavones (Sarkar, Li, 
Wang, & Kong, 2010) could potentially inhibit the metastatic and invasion process via reducing 
the expression of Notch receptors and/or Notch receptor ligands. Interestingly, many of these 
natural products act as AHR ligands. Given this known data, we hypothesize that the endogenous 
AHR ligand ITE can increase sensitivity to current cancer therapy agents such as tamoxifen. The 
following sections will detail future experiments that will be done to test our hypothesis. 
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7.3. Characterizing the Role of AHR-dependent Regulation of JAG1 in Other Breast 
Cancer Cell Lines Using ITE 
An agonist of the AHR was isolated from porcine lung tissue and identified as ITE. Three 
experiments support the conclusion that ITE is an AHR agonist: 1) ITE was shown to compete 
with radioactive TCDD for binding to the AHR in human, murine, killifish, and zebrafish (Song, 
et al., 2002), 2) Saturation-binding isotherms indicated a high affinity interaction between ITE 
and the AHR (Henry, Bemis, Henry, Kende, & Gasiewicz, 2006) and 3) ITE treatments changed 
the AHR to its DRE-binding conformation and promoted CYP1A1 expression in a 
concentration- and time-dependent manner (Henry, Bemis, Henry, Kende, & Gasiewicz, 2006; 
Song, et al., 2002). Furthermore, administration of ITE to pregnant mice led to AHR signaling in 
fetal tissues without the toxicities related to TCDD exposure, indicating in vivo bioactivity 
(Nugent, et al., 2013).  
Given our current data and knowledge, AHR signaling promotes a suppressive effect on 
JAG1 expression potentially by the given amount of AHR protein present in the cell (Figure 35). 
These experiments would establish if the AHR levels, which vary between cell lines, is 
responsible for the regulatory outcome of JAG1 expression. Two TNBC cell lines showed 
differential regulation in JAG1 expression, which can potentially be linked to the amount of 
AHR protein present in the cell (Figure 35). This is because the levels of the AHR in HCC1143 
cells were significantly lower compared to MDA-MB-231 cells (Figure 35). This data also 
mimicked the results from the AHR knockdown experiments conducted in MDA-MB-231 cells 
when treated with ITE, where loss of the AHR removed the ability for ITE to reduce JAG1 
expression (Figures 23 and 27). Therefore, it is imperative to conduct ITE treatments in various 
breast cancer cell lines, as well as non-cancerous mammary cell lines, to help identify and 
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establish the true nature of the AHR and its role in the regulation of JAG1 expression. 
Non-cancerous MCF-10A cells, ER-positive breast cancer cells (MCF7, T47D, BT474 
and SUM185), ER-negative breast cancer cells with the basal-subtype (SUM190, HCC1143, 
MDA-MB-468), ER-negative with the mesenchymal subtype (BT549, MDA-MB-231 and 
MDA-MB-157) and the HER2-overexpressing subtype (MDA-MB-453 and SKBR3) would be 
plated in 6-well plates at a density of 200,000 cells/mL and grown to full confluency before 
being treated every 12 hours for 3 days with either ITE (10µM) or control vehicle. Cells will be 
rinsed with PBS, and total cellular extract will be collected in SDS sample buffer [40% glycerol, 
8% SDS, 5% BME, 0.04% bromophenol blue in Tris-HCl pH 6.8]. Proteins will be heat 
denatured and then separated by SDS/PAGE followed by transfer to PVDF membrane. The blots 
will be incubated overnight at 4 °C while rocking in primary antibody followed by an incubation 
period of 90 minutes in secondary antibody at room temperature (37°C). Blots will then be 
rinsed five times (5 minutes per rinse) with PBST before undergoing chemiluminescence to 
identify JAG1, cleaved-NICD, HES1, and AHR protein concentrations before and after ITE 
treatment; GAPDH will used as a loading control. ChemiDoc MP Imaging System will be 
utilized to quantify band density and acquire western blot images.  
A two-tailed unpaired t-test will be used to determine significant changes in AHR, JAG1, 
HES1 and cleaved-NICD, due to the TCDD and ITE activating Notch signaling in ER-positive 
breast cancer (MCF7 and T47D), while inhibiting it in ER-negative breast cancer (MDA-MB-
231 and MDA-MB-157) and that ITE increased JAG1 and HES1 protein expression in HCC1143 
breast cancer cells. 
Cell lines that experienced significant reductions or increases in JAG1 expression will 
undergo AHR knockdown with AHR-targeting siRNA, to determine if these changes in JAG1 
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expression are AHR-dependent. In brief, cell suspensions of 200,000 cells/mL concentrations 
will be mixed with 100nM of AHR siRNA with 3µL of Lipofectamine RNAiMAX in 
DMEM/FBS (10%) for ~20 minutes. Cells will then be immediately plated on 35mm tissue 
culture plates in DMEM/FBS (10%) and cultured for 48 hours before being treated with 10µM 
ITE every 12 hours for 3 days, followed by western blot analysis of GAPDH (loading control), 
JAG1, cleaved-NICD, HES1 and AHR. For significance to be determined, a one-way ANOVA 
will be used along with a Tukey’s Post-hoc test, to compare changes in protein levels among the 
different groups. 
To determine if ITE affects cell migration and invasion, scratch and Boyden Chamber 
assays will be conducted on cell lines that regulated expression of JAG1. For the scratch assay, 
cells will be plated in 12-well tissue culture plates at a concentration of 50,000 cells/well for 24 
hours prior to treatment. The cells will be treated with vehicle or 10µM ITE in DMEM/FBS 
(1%) every 12 hours for 5 days, then a scratch will be made in each well with a pipette tip. Media 
will be aspirated to remove floating cells. Vehicle (DMSO) or 10µM ITE will be reapplied in 
DMEM/FBS (1%). The scratches will be photographed at 0 hours and at 24 hours post scratch 
using the Lycia Microscope and the exposed surface area of the plates will be measured using 
ImageJ analysis software. For the Boyden chamber assays, cells will be plated on 35 mm tissue 
culture plates in DMEM/FBS (10%) for 24 hours prior to treatment. After cells are treated with 
vehicle or 10µM ITE in DMEM/FBS (10%) every 12 hours for 5 days, they will be detached 
from tissue culture plates (using trypsin) and counted. 100,000 cells will be immediately 
transferred to cell invasion chambers in 500µL of media. Chambers filled with cells will be 
incubated in 24-well tissue culture plates containing DMEM/FBS (10%) as the chemoattractant 
and incubated for 36 hours. Following the incubation in the presence of vehicle (DMSO) or 
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10µM ITE, a cotton swab will be used to remove non-adherent cells that were not invasive. 
Invasive cells will be stained with crystal violet for 10 minutes at room temperature, then rinsed 
gently with water and then incubated in DMSO for 10 minutes with orbital shaking to extract 
crystal violet. Cell lysates will be measured at 560nm for invasive activity. For the indicated 
siRNA experiments, the cell invasion will be assayed 48 hours after transfection.  
7.4. Characterizing the Regulation of JAG1 and the Anti-cancer Effects of ITE Using an in 
vivo Model 
 To confirm the regulation of JAG1 and its corresponding anti-cancer effects in vivo, 
female NOD scid gamma mice (8 weeks of age and weighed 18-22 grams) will be injected 
unilaterally with MDA-MB-231 cells (2.5x106 cells/animal) in 200µL of 50:50 
Matrigel/Collagen I into the fourth abdominal fat pad by subcutaneous injection at the base of 
the nipple as described by Iorns et al (Iorns, et al., 2012). When the tumor volume reaches 
approximately 110mm3, the mice will be divided into homogeneous blocks based on their tumor 
volumes followed by randomly assigning each block into the vehicle control and ITE treatment 
group (N = 5/group). The vehicle (DMSO) or ITE (80 milligrams (mg)/mL in DMSO) will be 
administered by intraperitoneal injection once daily for 28 days at a volume of 1mL/kg body 
weight.  
A gross body weight and tumor volume will be determined twice weekly using a scale 
and calipers expressed in mm3, respectively. Tumor weights will be converted from tumor 
volumes by assuming a tumor density of 1 mm3 = 1 mg. A net body weight will be obtained by 
subtracting a tumor weight from a gross body weight. After the final injection, mice will be 
given an additional day to document the tumor volume, body weight, and other clinical signs 
before mice are euthanized by CO2 asphyxiation. At the time of sacrifice, a macroscopic 
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examination of metastases will be noted in lung, liver, and kidney; any visible metastatic foci 
will be counted.  
For western blot analysis, primary tumor tissue samples will be collected and 
homogenized in lysis buffer containing protease inhibitors. The protein will be collected via 
centrifugation and concentrations will be determined by a bicinchoninic acid protein assay. 40µg 
of total protein will be boiled in SDS sample buffer [40% glycerol, 8% SDS, 5% BME, 0.04% 
bromophenol blue in Tris-HCl pH 6.8] for 10 minutes and then separated by SDS/PAGE 
followed by transfer to a PVDF membrane. The blots will be incubated overnight at 4°C with 
rocking in primary antibody followed by an incubation period of 90 minutes in secondary 
antibody at room temperature (37°C). Blots will then be rinsed five times (5 minutes per rinse) 
with PBST before undergoing chemiluminescence to identify JAG1, cleaved-NICD, HES1, and 
AHR protein concentrations before and after ITE treatment; GAPDH will used as a loading 
control. ChemiDoc MP Imaging System will be utilized to quantify band density and acquire 
western blot images.      
7.5. Determining the Effects of ITE in Combination with Tamoxifen in Breast Cancer Cells 
Darakhshan & Ghanbar demonstrated that the combination between tranilast and 
tamoxifen enhanced anti-tumor effects in both ER-positive (MCF-7) and ER-negative cells 
(MDA-MB-231) as this particular combination resulted in synergistic effects on growth, 
proliferation, TGFb signaling as well as vascular endothelial growth factor (VEGF) and MMP9 
expression (Darakhshan & Ghanbar, 2013). These studies suggest that combining non-toxic 
AHR agonists such as ITE with current breast cancer chemotherapies as a novel approach to 
increase treatment efficacy for both ER-positive and ER-negative breast cancer. This 
combination could be particularly effective in patients with aggressive cancer types such as ER-
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negative breast cancer due to increased dependency of JAG1-Notch signaling (Li, Masiero, 
Banham, & Harris, 2014). Regarding ER-positive breast cancer, ~50% of breast cancer patients 
treated with tamoxifen experienced tumor reoccurrence combined with drug-resistance due to 
increased JAG1 expression in the CSC population in breast tumors (Simões, et al., 2015). 
Therefore, utilizing a non-toxic AHR agonist such as ITE may help target the CSC population in 
drug-resistant breast cancer cells due to its ability to decrease JAG1 expression.  
For cell culture and treatments, MCF-7 and MDA-MB-231 breast cancer cells would be 
grown and maintained at 37 °C with 5% CO2 in DMEM/FBS (10%). The concentrations of 
tamoxifen used will be 1, 2, 5, 10, and 20µM, concentrations of ITE will be 0.01, .1, 1, 10, 
100µM, and the combination treatment will be conducted in 2µM tamoxifen with a range of 
concentrations of ITE (0.01, 0.1, 1, 10, 100µM) every 12 hours for 3 days.  
For western blot analysis, after 3 days of treatment, cells will be rinsed with PBS and 
total cellular extract will be isolated in 250µL of SDS sample buffer [40% glycerol, 8% sodium 
SDS, 5% BME, 0.04% bromophenol blue in Tris-HCl pH 6.8]. Proteins will be heat denatured 
and then separated by SDS/PAGE followed by transfer to PVDF membrane. The blots will be 
incubated overnight at 4°C with rocking in primary antibody followed by an incubation period of 
90 minutes in secondary antibody at room temperature (37°C). Blots will then be rinsed five 
times (5 minutes per rinse) with PBST before undergoing chemiluminescence to identify JAG1, 
cleaved-NICD, HES1, and AHR protein concentrations before and after ITE treatment; GAPDH 
will be used as a loading control. ChemiDoc MP Imaging System will be utilized to quantify 
band density and acquire western blot images. A two-tailed unpaired t-test will be conducted for 
each concentration to determine significant changes in protein expression between treated and 
untreated cells. 
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For RT-qPCR, total RNA will be extracted using RNA purification columns (Qiagen). 
Reverse transcription will be performed on 300ng of RNA using cDNA synthesis kits (Applied 
Biosystems (Foster City, CA)) in accordance with the suppliers’ instructions. Real-time PCR will 
be conducted with the StepOnePlus (Applied Biosystems) using SYBR green master mix 
(Applied Biosystems) in accordance with the suppliers’ protocols. Samples will be analyzed in 
triplicate and the average will be normalized to GAPDH loading control. Relative changes in 
gene expression will be quantitated using the 2−ΔΔCT formula. A two-tailed unpaired t-test will be 
conducted for each concentration to determine significant changes in mRNA expression between 
treated and untreated cells. 
One property of BCSCs is the ability to form colonies in soft agar, so a colony forming 
assay will be conducted (Prud’homme, et al., 2010; Cheng, et al., 2015). Briefly, 20,000 cells in 
0.5% agar will be layered on preformed 0.8% agar layer using a 35mm non-tissue culture dish. 
The cells in agar will be treated with either vehicle, 2µM tamoxifen, 10µM ITE or a combination 
of both in DMEM/FBS (10%) every 12 hours for 7 days. Colonies will be counted under a 
microscope using low magnification (4x) and photographed after 7 days. 
To identify any changes in cell population, a cell proliferation assay will be conducted. 
1x104 cells/well of either MCF-7 or MDA-MB-231 will be transferred to 96-well plates and be 
incubated overnight. When treatments begin, 300µL of fresh medium with the indicated drug 
concentrations will be added to each well and incubated. Treatments will be replenished every 12 
hours for 3 days and will also be tested in triplicate as well as replicated independently three 
times. After 72 hours, 20µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) solution (5mg/mL in PBS) will be added to each well and incubated for 4 hours. The 
media with MTT will be discarded and 100µL of DMSO will be added to dissolve formazan 
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crystals at room temperature for 30 minutes. The optical density of each well will be determined 
at 570nm and the percentage of cell viability will be calculated according to the following 
equation: Cell viability (%) = [A570(sample)/A570(control)] x 100. 
To determine changes in migration, a scratch assay will be conducted in 12-well tissue 
culture plates at a concentration of 50,000 cells/well and grown to full confluency prior to 
treatment. Cells will be treated with vehicle, 2µM tamoxifen, 10µM ITE or a combination of 
both every 12 hours for 3 days before a scratch is made in each well with a pipette tip. Media 
will be aspirated to remove floating cells and vehicle treatments will be reapplied in DMEM/FBS 
(1%). The scratches will be photographed at 0 hour and at 24 hours post scratch using the Lycia 
Microscope. The exposed surface area of the plates will be measured using ImageJ analysis 
software. 
To determine changes in invasion, a Boyden chamber assay will be conducted. Cells will 
be plated on 35 mm tissue culture plates in DMEM/FBS (10%) for 24 hours prior to treatment. 
After cells are treated with vehicle, 2µM tamoxifen, 10µM ITE or a combination of both every 
12 hours for 3 days, the cells will be detached from tissue culture plates (using trypsin) and 
counted. 100,000 cells will be immediately transferred to cell invasion chambers in 500µL of 
media. Chambers filled with cells will then be incubated in 24-well tissue culture plates 
containing DMEM/FBS (10%) as the chemoattractant for 36 hours. Each experiment will include 
a negative control in which chambers filled with cells will be incubated with DMEM lacking 
FBS. Following the 36 hour incubation period in the presence of vehicle (DMSO) or 10µM ITE, 
a cotton swab will be used to remove non-adherent cells that were not invasive. Invasive cells 
will be stained with crystal violet for 10 minutes at room temperature and then rinsed gently with 
deionized water. Stained cells will be incubated in DMSO for 10 minutes with orbital shaking to 
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extract crystal violet. Cell lysates will be measured at 560nm for invasive activity. 
7.6. Characterizing JAG1 Regulation with Other Non-toxic AHR Ligands 
Given our current data and knowledge, AHR promotes a suppressive effect on JAG1 
expression in breast cancer cells when treated with ITE (Figures 24-29). Currently, there are 
known AHR agonists that have been documented to inhibit cancer growth and progression; 
however, the mechanisms behind their anti-cancer effects have yet to be determined (Weng, 
Tsai, Kulp, & Chen, 2008; Jin, 2011). A promising and productive approach for developing anti-
cancer agents has been the repositioning of pharmaceuticals that were originally developed for 
other purposes (Safe, Cheng, & Jin, 2017). Some AHR-active pharmaceuticals such as tranilast 
and omeprazole may be effective AHR-dependent anti-cancer agents for single or 
combination cancer chemotherapies for treatment of breast cancers. Other diet based AHR 
agonists such as IC3 and DIM have also been identified as potential drug candidates (Hall, et al., 
2010; Weng, Tsai, Kulp, & Chen, 2008). Therefore, it is imperative to conduct experiments in 
breast cancer cell lines that responded to ITE in order to help determine if the regulation of JAG1 
expression possesses a common mechanistic outcome among other non-toxic AHR ligand 
treatments. Table 12 depicts a summary of the known effects of non-toxic AHR in various breast 
cancer cell lines along with the changes in functional outcomes. 
7.6.1. JAG1 and Tranilast  
Tranilast is an orally active non-toxic drug that is used for the treatment of allergies and 
can be taken daily (Rogosnitzky, Danks, & Kardash, 2012). There is clear evidence for the anti-
cancer effects of tranilast in both in vivo and in vitro models, through the inhibition of both cell 
proliferation and cell cycle progression in several mammary carcinoma cell lines, including the 
human lines MDA-MB-231, MCF-7, and BT- 474 (Chakrabarti, Subramaniam, Abdalla, Jothy,  
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Table 12. Currently Known Anti-cancer Effects Contributed by Non-toxic AHR Ligands 
 
 
 
 
 
 
 
 
 
 
 
 
ITE Tranilast Omeprazole IC3 DIM
Molecular 
Structure
Tested Breast 
Cancer Cell Lines
MCF7
T47D
MDA-MB-231
MDA-MB-157
MCF7
MDA-MB-231
BCSCs
BT-474
MCF7
MDA-MB-231
MFC7
MDA-MB-231
MDA-MB-468
MCF7
T47D
MDA-MB-231
SKBR3
Targeted 
Signaling 
Pathways
TGF-β
Notch
TGF-β
MAPK
N/A Estrogen
pAkt
NF-κB
Targeted
Oncogenes
(Decreased Expression)
JAG1
Snail
Oct4
Bcl-2
Oct4
SNAIL
Cluster of 
Differentiation 135
MMP9
CXCR4
Cyclin E
Cyclin D1
Bcl-2
VEGF
MMP9
Cyclin-dependent 
Kinase 6
COX2
Survivin
SOX4
Bcl-2
Cyclin-dependent 
Kinase 6
Functional 
Outcome
Reduced migration
and invasion
Reduced
mammosphere 
formation, 
proliferation and 
invasion
Reduced migration 
and invasion
Induced cell cycle 
arrest and
decreased proliferation, 
migration, and invasion
Reduced invasion 
and migration
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& Prud’homme, 2009; Prud’homme, et al., 2010; Darakhshan & Ghanbar, 2013). Moreover, 
tranilast was then identified as an AHR agonist with inhibitory effects against CSCs from TNBC 
selected for anti-cancer drug resistance by inhibiting colony formation, mammosphere formation 
and stem cell marker expression. Knowing that JAG1 promotes the BCSC phenotype, it is 
important to determine if tranilast reduces JAG1 expression in breast cancer cells and to identify 
if the regulation is AHR–dependent. 
Non-cancerous MCF-10A cells, ER-positive breast cancer cells (MCF7, T47D, BT474 and  
SUM185), ER-negative breast cancer cells with the basal-subtype (SUM190, HCC1143, MDA-
MB-468), ER-negative with the mesenchymal-subtype (BT549, MDA-MB-231 and MDA-MB-
157) and the HER2-overexpressing subtype (MDA-MB-453 and SKBR3) will be treated, 
processed, and analyzed in the same manner described in section 7.3., but instead of ITE, breast 
cancer cells lines will be treated with either 200µM tranilast or vehicle (DMSO). 
7.6.2. JAG1 and Omeprazole  
Omeprazole is a well-known and commonly used proton pump inhibitor that has been 
identified to clearly inhibit MDA-MB-231 cell migration and invasion in in vitro models (Jin, 
Lee, Pfent, & Safe, 2014). This response was attenuated after knockdown of the AHR by siRNA 
or after co-treatment with AHR antagonists. Moreover, these in vitro assays were complemented 
by inhibition of lung metastasis of MDA-MB-231 cells in mice that had cells administered via 
tail vein injection and treated with 200µM omeprazole and resulted in decreased expression of 
pro-metastatic genes MMP9 and CXCR4 in a AHR-independent and –dependent manner, 
respectively (Jin, Lee, Pfent, & Safe, 2014). Interestingly, Notch signaling increases expression 
of CXCR4 in order to maintain the CSC phenotype in renal cell carcinoma and promotes 
migration in ovarian cancer (Chillakuri, et al., 2013). Therefore, it is imperative to conduct 
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omeprazole treatments in breast cancer cell lines, as well as in non-cancerous mammary cell 
lines to help identify if the decrease in JAG1 expression acts as the mechanism responsible for 
inducing anti-cancer effects.  
Non-cancerous MCF-10A cells, ER-positive breast cancer cells (MCF7, T47D, BT474 
and SUM185), ER-negative breast cancer cells with the basal-subtype (SUM190, HCC1143, 
MDA-MB-468), ER-negative with the mesenchymal-subtype (BT549, MDA-MB-231 and 
MDA-MB-157) and the HER2-overexpressing subtype (MDA-MB-453 and SKBR3) will be 
treated, processed, and analyzed in the same manner described in section 7.3., but instead of ITE, 
breast cancer cells lines will be treated with either 200µM omeprazole or control vehicle.  
7.6.3. JAG1, Indole-3-Carbinol (I3C) and 3,3’-Diindolylmethane (DIM) 
Phytochemicals derived from precursor glucosinolates in cruciferous vegetables (i.e. 
broccoli, cabbage, and cauliflower) such as the indoles have already been used therapeutically 
and have been shown to possess potent anti-cancer activity (Murray, Patterson, & Perdew, 2014). 
More importantly, phytochemicals have been the focus of clinical trials due to their reduced side 
effects in normal cells and pronounced anti-cancer activities (Weng, Tsai, Kulp, & Chen, 2008). 
Most of the attention has been given to IC3 and its stable condensation product DIM. IC3 was 
identified to promote anti-cancer activity by increasing expression of microRNA-34a, a tumor 
suppressive microRNA that is transcriptionally regulated by p53 (Hargraves, He, & Firestone, 
2016). Interestingly, in vitro studies have determined that miRNA-34a decreases chemotherapy 
resistance, cell proliferation and metastasis in human breast cancer cells through inhibition of the 
Notch signaling pathway (Wang, Li, Kong, Ahmad, Banerjee, & Sarkar, 2010b). This is because 
microRNA-34a targets both Notch1 and JAG1 mRNA and suppresses its translation to protein 
(Hashimi, et al., 2009). More recently, DIM was also shown to increase the expression of 
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miRNA-21 and the microRNA-212/132 cluster, which acted as a metastatic suppressor by 
targeting JAG1 and SOX4, respectively (Hanieh, 2015). Therefore, it is imperative to conduct 
IC3 and DIM treatments in breast cancer cell lines, as well as in non-cancerous mammary cell 
lines in order to identify if there is a decrease in JAG1 expression. 
Non-cancerous MCF-10A cells, ER-positive breast cancer cells (MCF7, T47D, BT474 
and SUM185), ER-negative breast cancer cells with the basal-subtype (SUM190, HCC1143, 
MDA-MB-468), ER-negative with the mesenchymal-subtype (BT549, MDA-MB-231 and 
MDA-MB-157) and the HER2-overexpressing subtype (MDA-MB-453 and SKBR3) will be 
treated, processed and analyzed in the same manner described in section 7.3., but instead of ITE, 
breast cancer cell lines will be treated with either 200µM I3C, DIM 25µM DIM, or control 
vehicle. 
7.7. Identifying Potential AHR-dependent Mechanisms that Regulate JAG1 Expression in 
Breast Cancer Cells 
Even though the decrease in JAG1 expression is AHR-dependent, it is important to note 
that JAG1 is not a direct AHR target gene. As a result, the mechanism behind AHR-dependent 
JAG1 suppression has yet to be completely understood. There are logical hypotheses that can 
explain this outcome in various ways. It is important to note that the RNA-seq data from the 
TCDD treated MCF7 breast cancer cells were analyzed 6 hours after a 100nM TCDD treatment, 
signifying that the reduction of JAG1 mRNA as a rapid and early occurrence that may occur 
without binding directly to the JAG1 promoter. Therefore, one of the mechanisms can involve 
activation of a gene that suppresses JAG1 expression, which can potentially be identified from 
any of the 41 TCDD/AHR-direct target genes that can also act as a repressor of JAG (Table 9). 
This data set can also identify a second potential mechanism, which involves AHR activation 
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increasing expression of certain microRNAs that are known to target JAG1 mRNA and lead to 
the decrease of JAG1 protein levels. Lastly, another potential AHR-dependent mechanism that 
decreases JAG1 levels can occur via crosstalk with other signaling pathways by squelching co-
factors away from the NF-kB signaling pathway proteins. Each of these proposed potential 
mechanisms will be reviewed in detail along with experimental designs in the following sections. 
7.7.1. JAG1 and HES1 
One potential mechanism that can potentially explain how the AHR decreases JAG1 
expression is by increasing the expression of a gene that suppresses JAG1 expression, which can 
potentially be one of the 189 TCDD-treated AHR direct target genes (Table 7). Several lines of 
evidence suggest that activation of the AHR reduces the expression of JAG1 by increasing HES1 
expression. Even though HES1 is a direct target gene of the Notch signaling pathway and has 
been identified as an indicator for Notch signaling activation (Borggrefe & Liefke, 2012), HES1 
also acts to suppress JAG1 expression as a negative-feedback mechanism for the Notch pathway 
(Bray, 2006). Moreover, differential gene expression analysis shows that HES1 mRNA is 
induced 1.8-fold after a 6 hour 100nM TCDD treatment and TCDD-stimulated AHR ChIP-seq 
analysis has identified AHR binding sites in the HES1 gene (Table 9). Another prior report has 
demonstrated that HES1 is a direct AHR gene target in T47D breast cancer cells (Kobayashi, et 
al., 2009). More importantly, HES1 is a transcriptional repressor that binds to HES1 sites in the 
JAG1 gene and inhibits the transcription of JAG1 in embryonic stem cells by binding directly to 
the JAG1 promotor to suppress its transcription. Stable increases in HES1 would explain how 
AHR activation via ITE induces long-term suppression (5 days) of JAG1 in MDA-MB-231 cells 
(Figure 25), while the AHR is rapidly degraded by the proteasome soon after AHR activation 
(Figure 15). Therefore, it is imperative that we conduct AHR knockdown experiments, in order 
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to study if the increased expression of HES1 plays a role in the regulation of JAG1 in the 
presence of ITE and to determine if any change in regulation is AHR-dependent.  
Non-cancerous MCF-10A cells and ER-positive (MCF7, T47D, BT474 and SUM185) 
breast cancer cells will undergo AHR knockdown transfections with HES1-targeting siRNA, in 
order to determine if these reductions in JAG1 expression are AHR-dependent. In brief, cell 
suspensions at 200,000 cells/mL will be mixed with 100nM of AHR-siRNA with 3µL of 
Lipofectamine RNAiMAX in DMEM/FBS (10%) for ~20 min. Cells will be immediately plated 
on 35mm tissue culture plates in DMEM/FBS (10%) and cultured for 48 hours before being 
treated with ITE (10µM) every 12 hours for 3 days, followed by western blot analysis of 
GAPDH (loading control), JAG1, cleaved-NICD, HES1 (positive control) and AHR. For 
significance to be determined for reduction in the levels of JAG1 and HES1 protein, a one-way 
ANOVA will be used along with a Tukey’s Post-hoc test, to compare the changes in protein 
among the four groups. 
To determine if HES1 knockdown affects cell migration and invasion in the presence of 
ITE, scratch and Boyden Chamber assays will be conducted on cell lines that inhibited 
expression of JAG1. For the scratch assay, HES1-targeting siRNA transfected breast cancer cells 
will be plated in 12-well tissue culture plates at a concentration of 50,000 cells/well for 24 hours 
prior to treatment. The cells will be treated with vehicle or 10µM ITE in DMEM/FBS (1%) 
every 12 hours for 5 days; a scratch will be made in each well with a pipette tip. Media will be 
aspirated to remove floating cells, then vehicle (DMSO) or 10µM ITE will be reapplied in 
DMEM/FBS (1%). The scratches will be photographed at 0 hours and at 24 hours post scratch 
using a Lycia Microscope and the exposed surface area of the plates will be measured using 
ImageJ analysis software. 
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 For the Boyden chamber assays, HES1-targeting siRNA transfected cells will be plated 
on 35mm tissue culture plates in DMEM/FBS (10%) for 24 hours prior to treatment. After cells 
are treated with vehicle or 10µM ITE in DMEM/FBS (10%) every 12 hours for 5 days, they will 
be detached from tissue culture plates (using trypsin) and counted. 100,000 cells will be 
immediately transferred to cell invasion chambers in 500µL of DMEM. Chambers filled with 
cells will be incubated in 24-well tissue culture plates containing DMEM/FBS (10%) as the 
chemoattractant for 36 hours. Following an incubation period of 36 hours in the presence of 
vehicle (DMSO) or 10µM ITE, a cotton swab will be used to remove non-adherent cells that 
were not invasive. Invasive cells will be stained with crystal violet for 10 minutes and then 
rinsed gently with tap water and then incubated in DMSO for 10 minutes with orbital shaking to 
extract crystal violet. Cell lysates will be measured at 560nm for invasive activity.  
7.7.2. JAG1 and microRNA-21 
MicroRNAs are attractive candidates as upstream regulators of metastatic progression 
because they can post-transcriptionally regulate entire sets of genes. There are a few examples of 
AHR ligands that regulate microRNAs and in turn promote anti-tumor effects. DIM was 
identified to induce microRNA-146a expression and inhibited cancer cell invasion by 
suppressing EGFR, NF-kB and metastasis-associated protein 2 (MTA2) (Li, et al., 2010). DIM 
also upregulated let-7b and miR-200c in gemcitabine-resistant pancreatic cancer cells, causing a 
reversal of EMT via suppression of zinc finger E-box binding homeobox 1 (ZEB1), Slug, and 
Vimentin, which in turn induced up-regulation of E-cadherin (Li, et al., 2009). TCDD and DIM 
were also able to suppress breast cancer metastasis by increasing the expression of the 
microRNA-212/132 cluster, which targeted SOX4 expression (Hanieh, 2015). Collectively, 
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identifying microRNAs that are regulated by the AHR but also target JAG1 mRNA are viable 
candidates for ITE- and TCDD-mediated JAG1 suppression. 
Therefore, another possible mechanism for the decrease in JAG1 expression is that the 
AHR may also indirectly promote the expression of miR-21, a microRNA that targets JAG1 
mRNA and prevents its translation into protein (Selcuklu, Donoghue, Kerin, & Spillane, 2012). 
Selcuklu et al. were able to demonstrate that MCF7 cells stimulated with estrogen showed 
increased expression of JAG1. In contrast to JAG1, miR-21 is downregulated by estrogen 
mediated signaling and is negatively correlated in breast cancer cells. When estrogen is applied 
to MCF7 cells, miR-21 expression is down-regulated through a regulatory site in the miRNA-21 
producing gene (MIRN21) promoter region. The ability for the AHR to potentially promote 
expression of miR-21 was already demonstrated in a study showing that the AHR ligand DIM 
increased miR-21 expression and targeted cell division cycle 25A (cdc25A) in MCF7 cells, 
resulting in decreased cell proliferation (Jin, 2011). However, increases in miR-21 expression 
have been demonstrated with other AHR ligands. Therefore, TCDD and ITE may promote the 
expression of miR-21 by inhibiting its estrogen-mediated suppression and may potentially serve 
as the mechanism behind decreased JAG1 expression in ER-positive breast cancer cells. 
Non-cancerous MCF-10A cells and ER-positive (MCF7, T47D, BT474 and SUM185) 
breast cancer cells will be cultured in DMEM/FBS (10%) at 37°C, then plated in 6-well plates at 
a density of 200,000 cells/mL and grown to full confluency. To induce JAG1 expression, cells 
will be treated with estrogen (50nM) overnight before being treated every 12 hours for 3 days 
with either ITE (10µM) or control vehicle. Cells will be rinsed with PBS, and total cellular 
extract will be isolated in SDS sample buffer [40% glycerol, 8% SDS, 5% BME, 0.04% 
bromophenol blue in Tris-HCl pH 6.8]. Proteins will be heat denatured and then separated by 
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SDS/PAGE followed by transfer to PVDF membrane. GAPDH loading control western blot will 
be used to confirm equal protein loading (~15µL/sample). The blots will be incubated overnight 
at 4°C with rocking in primary antibody followed by an incubation period of 90 minutes in 
secondary antibody at room temperature. Blots will then be rinsed five times (5 minutes per 
rinse) with PBST before undergoing chemiluminescence to identify JAG1 and AHR protein 
concentrations before and after ITE treatment. ChemiDoc MP Imaging System will be utilized to 
quantify band density and acquire western blot images. A one-tailed unpaired t-test will be 
conducted to determine significant changes in protein expression between treated and untreated 
cells. 
In order to determine if AHR regulates miR-21 expression and if miR-21 regulates JAG1 
expression, transient transfections with siRNA will be performed as described in Section 4.4. In 
brief, cell suspensions (200,000 cells/1mL) will be mixed with 100nM of either miR-21-targeting 
siRNA, AHR-targeting siRNA or control-siRNA with 3µL of Lipofectamine RNAiMAX in 
DMEM/FBS (10%) for ~20 minutes before being treated every 12 hours for 3 days with either 
ITE (10µM) or control vehicle.  
RT-qPCR will be used to measure changes in JAG1 mRNA and miR-21 expression. 
Total RNA will be extracted using RNA purification columns (Qiagen). Reverse transcription 
will be performed on 300ng of RNA using cDNA synthesis kits (Applied Biosystems (Foster 
City, CA)) in accordance with the suppliers’ instructions. StepOnePlus (Applied Biosystems) 
will be used to take PCR measurements. Amplifications will be carried out using SYBR green 
master mixes (Applied Biosystems) according to the manufactures protocols. Samples will be 
done in triplicate and the average normalized to GAPDH will be quantified using the 
2−ΔΔCT formula.    
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In order to determine if the JAG1 3’-untranslated region (UTR) is targeted by miR-21 in 
ER-positive breast cancer cells, reporter constructs and a luciferase assay will be conducted. The 
JAG1 3’-UTR region (632 bp) harboring the miR-21 binding site will be PCR amplified from 
human genomic DNA, cloned into endonuclease Spel/Hind III restriction sites in the pMIR-
REPORTS luciferase vector, designated as pMIR/JAG1 3’-UTR. A mutated sequence will be 
generated using Quikchange Lightning SDM kit, designated as pMIR/JAG1-UTRdel. Cells will 
be co-transfected with 300ng of each plasmid (pMIR/JAG1-UTR, pMIR/JAG1-UTRdel, or 
pMIR) and 1ng of phRL renilla vector (for normalization) in 24-well plates. After 24 hours of 
transfection, a dual luciferase assay will be performed according to the manufacturer’s protocol.  
7.7.3. JAG1 and NF-kB Signaling  
 Even though increases in HES1 and miR-21 are prime candidates for the suppression of 
JAG1 expression in the presence of TCDD and ITE, these mechanisms may not apply to the ER-
negative breast cancer subtype because HES1 expression was suppressed in MDA-MB-231 and 
MDA-MB-157 cells (Figures 26). Moreover, miR-21 expression was regulated in an ER-
dependent manner and was shown to be unaltered in MDA-MB-231 cells in the presence of 
estrogen according to the study conducted by Selcuklu et al. (Selcuklu, Donoghue, Kerin, & 
Spillane, 2012). It is therefore unlikely that TCDD or ITE reduces JAG1 expression in MDA-
MB-231 and MDA-MB-157 through increased expression of miR-21 and may occur through a 
different mechanism. 
It is possible that the decrease in JAG1 expression in ER-negative breast cancer cells can 
potentially occur though a crosstalk mechanism that involves AHR activation and the NF-kB 
signaling pathway (Figures 13 and 32). TNBC exhibits high levels of constitutively active NF-
kB signaling by inflammatory cytokines and induces JAG1 expression in order to promote 
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Notch-dependent expansion of the CSC population (Yamamoto, et al., 2013). Yamamoto et al. 
were able to clearly demonstrate that JAG1 expression is NF-kB-dependent in TNBC. Moreover, 
this study was also able to determine that the NF-kB signaling pathway is highly activated in 
basal-like (HCC1143) and mesenchymal-like (MDA-MB-231) subtype tumors and is 
significantly positively-correlated with JAG1 expression. Interestingly, the expression levels of 
other Notch ligands (i.e. JAG2 and DLL4) were not significantly affected by NF-kB signaling, 
indicating that JAG1 is a unique gene that is specifically regulated by NF-kB in TNBC.  
Specifically, in MDA-MB-231 cells, activation of the NF-kB signaling pathway via 
TNFa did not induce expression of JAG1 mRNA or protein, although the induction of RelB, a 
known NF-kB-inducible gene, was observed. On the contrary, JAG1 expression was 
significantly decreased upon exposure to TNFa after 24 hours and signifies that JAG1 
expression is not induced by the non-canonical NF-kB pathway via RelB in MDA-MB-231 cells 
(Figure 13). Rather, JAG1 expression is most likely regulated by the canonical NF-kB pathway 
through RelA in MDA-MB-231 cells, which was demonstrated by Bash et al. in HeLa-derived 
HtTA-1 cells (Bash, et al., 1999) (Figures 13 and 31). However, it is important to note that 
TNFa induces JAG1 expression via RelB in the basal-like (HCC1143) subtype. Therefore, JAG1 
expression is likely regulated by the non-canonical pathway in addition to the canonical pathway, 
signifying that the level of total NF-kB activation (the sum of canonical and non-canonical 
activation) may determine the level of JAG1 expression (Yamamoto, et al., 2013). The ability for 
the activation of the AHR to cross-talk with the NF-kB signaling pathway has been well-
documented and was reviewed in detail in the third chapter (Vogel, et al., 2007; Tian, 2009; 
Sheppard, et al., 1998) (Figure 13). In short, activation of the AHR promoted direct protein 
binding between the AHR and RelA, proposing that the mutual repressive effects were 
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modulated by the formation of inactive AHR-RelA dimers, which in turn reduces the 
concentration of available nuclear AHR protein and RelA needed for AHR-NF-kB-mediated 
gene expression (Tian, 2009). This cross-talk interaction can potentially reduce expression of 
JAG1 in MDA-MB-231 and MDA-MB-157 cells and therefore may promote the ability for the 
AHR to induce anti-metastatic effects in the mesenchymal subtype of TNBC.  
Non-cancerous MCF-10A cells, ER-negative breast cancer cells with the basal-subtype 
(SUM190, HCC1143, MDA-MB-468), ER-negative with the mesenchymal-subtype (BT549, 
MDA-MB-231 and MDA-MB-157) and the HER2-overexpressing subtype (MDA-MB-453 and 
SKBR3) will be cultured in DMEM/FBS (10%) at 37°C, then plated in 6-well plates at a density 
of 200,000 cells/mL and grown to full confluency before being treated every 12 hours for 3 days 
with either ITE (10µM) or control vehicle. For western blot analysis, after 3 days of treatment 
cells will be rinsed with PBS, and total cellular extract will be isolated in 250µL of SDS sample 
buffer [40% glycerol, 8% SDS, 5% BME, 0.04% bromophenol blue in Tris-HCl pH 6.8]. 
Proteins will be heat denatured and then separated by SDS/PAGE followed by transfer to PVDF 
membrane. The blots will be incubated overnight at 4 °C with rocking in primary antibody 
followed by an incubation period of 90 minutes in secondary antibody at room temperature. 
Blots will then be rinsed five times (5 minutes per rinse) with PBST before undergoing 
chemiluminescence to identify JAG1, cleaved-NICD, RelA, RelB, and AHR protein 
concentrations before and after ITE treatment; GAPDH will used as a loading control. 
ChemiDoc MP Imaging System will be utilized to quantify band density and acquire western 
blot images. A two-tailed unpaired t-test will be conducted for each cell-line in order to 
determine significant changes in protein expression between treated and untreated cells. 
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In order to determine if RelA and RelB regulates JAG1 expression, transient transfection 
with siRNA will be performed as described in Section 4.4. In brief, cell suspensions (200,000 
cells/mL) will be mixed with 100nM of either RelA-targeting siRNA, RelB-targeting siRNA, or 
control-siRNA with 3µL of Lipofectamine RNAiMAX in DMEM/FBS (10%) for ~20 minutes 
before being treated every 12 hours for 3 days with either ITE (10µM) or control vehicle.  
In order to determine if heterodimers RelA-AHR or RelB-AHR are formed in the 
presence of ITE, a co-immunoprecipitation (Co-IP) experiment will be conducted. After the 3 
day ITE treatment, cells will be washed twice with cold PBS, harvested by scraping, and 
collected by centrifugation at 1500 x g. Cells will then be lysed in lysis buffer (20 millimolar 
(mM) 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), pH 7.4, 125mM 
sodium chloride (NaCl), 1% Triton X-100, 10mM ethylenediaminetetraacetic acid (EDTA), 
2mM ethyleneglycol-bis-(b-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA), 2mM sodium 
orthovanadate (NA3VO4), 50mM sodium fluoride (NaF), 20mM zinc chloride (ZnCl2), 10mM 
sodium pyrophosphate (Na4P2O7), 1 mM phenylmethylsulfonyl fluoride (PMSF), and 5µg/mL 
leupeptin) and centrifuged for 15 minutes at 12,000 x g, and supernatant fraction will be 
collected. Anti-AHR antibodies will be added to the lysate, and the binding reactions will be 
performed at 4°C for 2 hours on a rotary shaker, then 30µL of GammaBind Plus Sepharose beads 
will be added to precipitate the antibody-antigen complex. The beads will be washed 3 times in 
lysis buffer and boiled in 2x SDS sample buffer and undergo western blot analysis with anti-
RelA and anti-RelB primary antibodies at a 1:1000 concentration and corresponding secondary 
antibody. 
To determine if ITE affects RelA-AHR and RelB-AHR heterodimers binding to the 
JAG1 promoter, a ChIP assay will be conducted. Cells (500,000 per 60mm plate) will be plated 
183 
and grown in DMEM/FBS (10%) before being treated with ITE or DMSO for 3 hours. 
Formaldehyde (1%) will be added to the medium for 10 minutes, followed by glycine (.5 molar 
(M)) for 5 minutes. Cells will then be rinsed with PBS, collected in PBS, pelleted by 
centrifugation, and lysed in 300µL of lysis buffer (1% SDS, 5mM EDTA, 50mM Tris-HCl, pH 
8) per 60mm plate plus protease inhibitors for 15 minutes on ice. Cell extracts will be sonicated 
(5 times, 10 seconds each) and diluted 1:10 in dilution buffer (16.7mM Tris-HCl, pH 8, 167mM 
NaCl, 1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100), rotated overnight at 4°C with 1µg of 
non-specific IgG, Anti-RelA, or Anti-RelB antibody. Antibody-chromatin complexes will be 
collected using 5 µL of magnetic protein A beads with rotation at 4°C for 90 minutes. Using 
magnetic separation, beads will be washed sequentially with buffer 1 (20mM Tris-HCl, pH 8, 
150 mM NaCl, 2 mM EDTA, 0.1% SDS), buffer 2 (20mM Tris-HCl, pH 8, 500 mM NaCl, 2 
mM EDTA, 0.1% SDS), buffer 3 (10mM Tris-HCl (pH 8), 0.25 lithium chloride (LiCl), 1 mM 
EDTA, 1% NP-40, 1% deoxycholate), and then 1X 10mM Tris-HCl with 0.1mM EDTA (TE) 
buffer for 5 minutes each and incubated at 65°C for 4 hours in elution buffer (1% SDS, 0.1M 
sodium bicarbonate (NaHCO3)) with proteinase K. DNA will be purified and analyzed using RT-
qPCR. Primers spanning RelA and RelB response elements in the JAG1 promoter and DREs in 
the CYP1A1 promoter will be used. 
7.8. Identifying Snail as a JAG1 Downstream Target Gene that Promotes Invasion and 
Migration 
It has been proposed that the initial steps in metastasis involve an EMT-like process, 
which is the process that converts cells from an epithelial, non-motile morphology to become 
migratory and prone to invade other tissues (Hanahan & Weinberg, 2000). EMT is accompanied 
by specific changes in gene expression, such as down-regulation of E-cadherin, by which its 
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promoter is repressed by several transcriptional repressors, including the zinc finger transcription 
factor Snail (Wang, et al., 2009). Up-regulation of Snail correlates with metastasis and poor 
prognosis, whereas silencing of Snail is critical for reducing tumor growth and invasiveness 
(Wang, et al., 2009). Knowing that JAG1-dependent Notch signaling promotes expression of 
various target genes that are required to promote cancer growth at various stages of tumor 
progression, we questioned if whether the downstream target genes are also affected by ITE and 
TCDD treatments in breast cancer cells. Furthermore, Notch can up-regulate Snail and induce 
EMT in a normoxic environment during normal development in cardiac cell differentiation 
(Timmerman, et al., 2004), although the detailed molecular mechanism for how Notch 
controls Snail expression remains to be established. Sahlgren et al. were able to further 
demonstrate that Notch signaling controls Snail expression by two distinct but synergistic 
mechanisms, involving both direct transcriptional activation of Snail and an indirect mechanism 
operating via LOX, leading to elevated Snail protein levels in cervical, colon, glioma, and 
ovarian cancer (Sahlgren, Gustafsson, Jin, Poellinger, & Lendahl, 2008). 
We found a significant reduction in the levels of Snail protein in both ER-positive and 
ER-negative breast cancer cells treated with ITE and TCDD compared with control cells treated 
with vehicle (Figures 33 and 34). Our preliminary data demonstrates that AHR decreases the 
expression of JAG1 and Snail, and we provide the first evidence that this could be mediated 
through an AHR-dependent manner (Figure 34). Given the previous reports and our current data, 
we hypothesize that the decrease in JAG1 expression reduces the levels of downstream target 
genes of JAG1-dependent Notch signaling such as Snail as the mechanism for the anti-metastatic 
activity of AHR activation. We observed that cells with AHR knockdown were not responsive to 
ITE-stimulated reductions in Snail, indicating that the suppressive effect of ITE on Snail 
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expression is transmitted through the AHR (Figure 34). However, it has not been determined if 
Snail expression is regulated in a JAG1-dependent manner in breast cancer cells. 
Non-cancerous MCF-10A cells, ER-positive breast cancer cells (MCF7, T47D, BT474 
and SUM185), ER-negative breast cancer cells with the basal-subtype (SUM190, HCC1143, 
MDA-MB-468), ER-negative with the mesenchymal-subtype (BT549, MDA-MB-231 and 
MDA-MB-157) will be treated, processed, and analyzed in the same manner described in section 
7.4.  
In order to determine if JAG1 regulates Snail expression in the presence of ITE, transient 
transfection with short interfering RNA (siRNA) will be performed as described in section 4.4. 
In brief, cell suspensions (200,000 cells/mL) will be mixed with 100nM of JAG1-siRNA or 
control-siRNA with 3µL of Lipofectamine RNAiMAX in DMEM/FBS (10%) for ~20 minutes 
before being treated every 12 hours for 3 days with either ITE (10µM) or control vehicle.  
7.9. Anticipated and Alternative Outcomes for Proposed Experiments 
Given our preliminary data showing TCDD and ITE can stimulate a marked decrease in 
JAG1 expression in ER-positive (MCF7 and T47D) and ER-negative (MDA-MB-231 and MDA-
MB-157) breast cancer cells, I expect that cell lines with high levels of AHR and JAG1 
expression will inhibit the expression of JAG1. This decrease in JAG1 expression in turn will 
reduce the migratory and invasive activity of breast cancer cells that rely on JAG1-dependent 
signaling. Moreover, I expect to see the basal-like subtypes (SUM190, HCC1143, MDA-MB-
468) to either increase JAG1 expression or have no significant change when treated with ITE 
compared to the control group. 
Given our current data and previous literature showing that the combination of non-toxic 
AHR agonists with current anti-estrogenic treatments proves to be an effective treatment for ER-
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positive breast cancer, I expect cell colony formation, proliferation, invasion, and metastasis to 
be inhibited in a synergistic manner in the ITE and tamoxifen combination treatment 
(Darakhshan & Ghanbar, 2013). Additionally, I expect the anti-proliferative effects to be more 
prominent in MCF7 cells compared to that of MDA-MB-231 cells due to ITE not affecting cell 
proliferation in ER-negative breast cancer cells (Figure 32). I also expect to see decreases in 
JAG1 expression in both cell lines and for the Notch pathway to be inhibited in only MDA-MB-
231 cells. As for the MCF7 cells, I suspect the Notch signaling pathway to be affected in the 
presence of both ITE and tamoxifen, as estrogen signaling promotes Notch-mediated tumor 
growth and proliferation (Selcuklu, Donoghue, Kerin, & Spillane, 2012). Moreover, I suspect 
that combinations that include an anti-estrogen treatment such as tamoxifen and a Notch 
inhibitor may be effective in ER-positive breast cancer (Rizzo, et al., 2008). 
Regarding other non-toxic, anti-cancer AHR ligands, I expect that tranilast will inhibit the 
expression of JAG1, which in turn will also reduce the migratory and invasive activity of breast 
cancer cells. I also believe the basal-subtype cell lines may exhibit decreases in JAG1 levels, due 
to tranilast also being identified as a TGFb inhibitor, a known promoter of JAG1 expression 
(Rogosnitzky, Danks, & Kardash, 2012). I expect that omeprazole will inhibit the expression of 
JAG1 in an AHR-dependent manner, which in turn also reduces the migratory and invasive 
activity of breast cancer cells. However, cell lines with low AHR levels such as HCC1143 may 
exhibit increases or no change in JAG1 levels, which may not affect the overall physiology of 
those particular cell lines. Given the data we produced and published literature, I also expect that 
I3C and DIM will inhibit the expression of JAG1 in an AHR-dependent manner, which in turn 
may also reduce the migratory and invasive activity of breast cancer cells. Similar to omeprazole, 
I expect basal-like ER-negative cell lines such as HCC1143 to exhibit increases or no change in 
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JAG1 levels, which may not affect the overall physiology of those particular cell lines. 
In regard to the potential AHR-dependent mechanisms that suppress JAG1 expression in 
ER-positive breast cancer, I expect that cell lines transfected with HES1-targeting siRNA will 
inhibit the ability of ITE to decrease expression of JAG1 in an AHR-dependent manner, which in 
turn would not affect the migratory and invasive activity of breast cancer cells. I also expect ITE 
to increase miR-21 expression in the presence of ITE compared to the control group in ER-
positive breast cancer cells and that knockdown of AHR prevents increased expression of miR-
21, which prevents the decrease in JAG1 expression to occur in the presence of ITE. Moreover, I 
also expect to see that miR-21 knockdown cells prevent the suppression of JAG1 mRNA in the 
presence of ITE. Finally, I predict that the JAG1 3’- UTR is targeted by miR-21 in ER-positive 
breast cancer cells. It is also possible that these two mechanisms could occur simultaneously and 
or in synchronicity, as they operate via independent pathways. However, more research needs to 
be conducted to investigate this co-operative inhibition. 
As for the regulation of JAG1 in the ER-negative basal-like breast cancer subtype, I 
expect to see ITE induce AHR-RelB heterodimer formation and promote the expression of JAG1 
by binding to the JAG1 promoter, that RelB knockdown prevents increases in JAG1 expression, 
and that RelA knockdown does not alter changes in JAG1 expression. In the mesenchymal-
subtype, I expect to see ITE induce AHR-RelA heterodimer formation and inhibit the expression 
of JAG1 by decreasing the amount of RelA binding to the JAG1 promoter, that RelA knockdown 
prevents the suppression of JAG1, and that RelB knockdown does not alter changes in JAG1 
expression. 
In regard to identifying potential downstream targets of JAG1-dependent signaling that 
promotes the metastatic process, I expect to see the decrease in Snail expression in ITE-treated 
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ER-positive breast cancer cells as well as mesenchymal-subtype ER-negative breast cancer cells 
compared to the untreated group and that it occurs in a JAG1-dependent manner. In the basal-
like subtype of ER-negative breast cancer, there may be either no change or a promotion in Snail 
expression due to the unaffected or increased expression in JAG1 upon ITE exposure.   
7.10. Conclusion 
Investigating the changes in JAG1 levels in the presence of both known anti- and pro-
cancer AHR ligands can provide important insight on how the expression of JAG1 in cancer 
cells as well as changes in cell migration and invasion are altered in a ligand-dependent manner 
(Hall, et al., 2010). These anti-cancer effects and changes in cell migration and invasion were 
confirmed by treating MDA-MB-231 breast cancer cells with both TCDD and ITE in the absence 
of AHR (siRNA) and an AHR antagonist, CH-223191 (Figures 23, 27-28). CH-223191 is 
reported to selectively antagonize the binding of halogenated AHR ligands to the AHR binding 
site and was able to prevent TCDD-stimulated reductions in JAG1 expression, but not ITE-
stimulated reductions. Not only does this finding indicate that ITE decreases JAG1 expression 
through a different binding site used by TCDD, ITE binds AHR even in the presence of CH-
223191. This data allows researchers to come to an understanding that the basis of information 
which supports both the use of AHR agonists and antagonists in the treatment of various cancers 
is initially valid and logical. Because TCDD is a known carcinogen, the use of AHR antagonists 
such as CH-223191 prevented TCDD from inducing toxicity, originally giving the AHR the role 
as a tumor promoter. However, as researchers began to see the anti-cancer effects from non-
halogenated AHR ligands produced from either the natural products present in the diet or 
medications being taken, a paradox started to take form and further increased the debate on the 
role of the AHR in cancer biology. 
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Therefore, considering all the evidence being presented in this dissertation promoting the 
use of non-toxic and clinically relevant AHR agonists for the treatment of breast cancer, I can 
safely oppose the use of AHR antagonists and inhibitors for the treatment of breast cancer. The 
opposition to utilize AHR antagonists is due to two main factors, which include: 1) research 
claiming that AHR promotes toxicity and cancer progression utilized highly stable known 
carcinogenic compounds that possess no clinical relevance or weak endogenous AHR agonists 
that could be out-competed by exogenous non-toxic AHR agonists with higher AHR-binding 
affinity and 2) inhibition of AHR through the use of antagonists or inhibitors to treat breast 
cancer can potentially cause unwarranted long-term side-effects in patients undergoing treatment 
due to the endogenous roles the AHR regulates which include, but are not limited to immunity, 
development, and hematopoiesis. Therefore, the use of AHR antagonists and inhibitors for the 
purpose of cancer treatment could result in the inability to fight infections, reduce wound healing 
efficiency, and induce anemia.  
Moreover, the case where ITE increases JAG1 expression in the basal-like ER-negative 
subtype (HCC1143) also allows us to propose that establishing a treatment strategy by targeting 
JAG1 directly through the use of monoclonal antibodies, small molecule inhibitors, or JAG1 
mRNA suppression as a method for the treatment of breast cancer. This proposal is due to a 
number of factors, including: 1) research showing that JAG1-dependent Notch signaling 
promotes various bio-functions that contribute to cancer progression and does not possess any 
discrepancy in terms of JAG1 functioning as a tumor suppressor, unlike AHR. Even though there 
are some cases where Notch signaling acts as a tumor suppressor, none of those studies were 
linked through activation with JAG1. 2) Targeting JAG1 on the extracellular membrane directly 
via monoclonal antibodies or small molecules that target JAG1 mRNA and/or its expression to 
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avoid the use of GSIs, resulting in targeting the Notch pathway that promotes cancer progression 
and not Notch pathway that is needed for normal cellular homeostasis. 3) Most importantly, this 
approach may help bypass the controversy for the utilization of AHR agonists for the treatment 
of breast cancer.  
In conclusion, I succeeded in showing that activation of AHR through the use of a non-
toxic AHR agonist (ITE) induced inhibition of JAG1 expression in both ER-positive and ER-
negative breast cancer cells, which resulted in decreased cell migration and invasion. This 
research could help propose another potential therapy target for treating breast cancer as well as 
provide new insight on how small molecules from our environment and diet can potentially 
regulate developmental signaling pathways and the induction of those corresponding changes in 
the outcomes of cellular physiology. 
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APPENDIX B: ABBREVIATIONS 
3-MC….3-methylcholanthrene 
4-HT….4-hydroxytamoxifen 
5-FU….5-flurouracil 
ABC….ATP binding cassette 
ABCG2….ATP binding cassette, sub-family G member 2 
ADAM….a-disintegrin and metalloproteinase 
ADCs….antibody-drug conjugates 
ADH1β….alcohol dehydrogenase 1β 
ADP….adenosine diphosphate 
AHH….aryl hydrocarbon hydroxylase 
AHR….aryl hydrocarbon receptor 
AHRR….aryl hydrocarbon receptor repressor 
AIs….aromatase inhibitors 
Akt…serine-threonine protein kinase 
ALDH1….aldehyde dehydrogenase1 
ALDH1A3….aldehyde dehydrogenase 1, family member A3 
ANOVA….analysis of variance 
AP-1….activator protein-1 
APC….adenomatous polyposis coli 
APEX1….apurinic/apyrimidinic endodeoxyribnuclease 1 
AR….androgen receptor 
ARNT….aryl hydrocarbon receptor nuclear translocator 
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ATP….adenosine triphosphate 
B[α]P….benzo[α]pyrene 
Bcl-2….B-cell lymphoma-2 
BCRP….breast cancer resistance protein 
BCSCs….breast cancer stem cells 
bHLH….basic helix-loop-helix 
BLIA….basal-like immune activated 
BLIS….basal-like immune suppressed 
BME….β-mercaptoethanol 
BRG1….brahma-related gene 1 
c-myc….v-myc avian myelocytomatosis viral oncogene homolog 
c-Rel….v-rel avian reticuloendotheliosis viral oncogene homolog 
C2….calcium-binding 
CAIX….carbonic anhydrase IX 
cAMP….cyclic adenosine monophosphate 
CAXII….carbonic anhydrase 12 
CBP….CREB binding protein 
CCND1….cyclin D1 
CCND3….cyclin D3 
CCNE….cyclin E 
CD133….cluster of differentiation 133 
CD24….cluster of differentiation 24 
CD34….cluster of differentiation 34 
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CD44….cluster of differentiation 44 
CD46….cluster of differentiation 46 
cdc25A….cell division cycle 25A 
CDK2….cyclin-dependent kinase 2 
CDK8….cyclin-dependent kinase 8 
CDKN1A….cyclin-dependent kinase inhibitor 1A 
ChIP….chromatin-immunoprecipitation 
ChIP-seq….chromatin immunoprecipitation-sequencing 
CK1α….casein kinase 1α 
CMF…. cyclophosphamide, methotrexate, and fluorouracil 
CMML….chronic myelomonocytic leukemia 
Co-IP….co-immunoprecipitation 
CO2….carbon dioxide 
CoRs….co-repressors 
COS2….kinesin motor protein costal-2 
COX2….cyclooxygenase 2 
CRD….cysteine-rich domain 
CREB….cAMP response element binding protein 
CSCs….cancer stem cells 
CSL…. RBP-Jk/Su(H)/lag-1 
CSN2….casein kinase-β 
CtBP….c-terminal binding protein 
CTLA4….cytotoxic T-lymphocyte-associated protein 4 
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CUL4B….cullin 4B 
CXCL10….C-X-C motif chemokine ligand 10 
CXCR4….C-X-C motif chemokine receptor 4 
CYP1A1….cytochrome P450, family 1 subfamily A member 1 
CYP1B1….cytochrome P450, family 1 subfamily B member 1 
CYP450….cytochrome P450 
DCs….dendritic cells 
DDB1….damaged DNA binding protein 1 
Dhh….desert hedgehog 
DICD….DLL intracellular domain 
DIM….3,3-diindolylmethane 
Dlg….discus large homolog 
DLL….delta-like ligand 
DLL1….delta-like ligand 1 
DLL3….delta-like ligand 3 
DLL4….delta-like ligand 4 
DM1….emtansine 
DMBA….dimethylbenz(a)anthracene 
DMEM….Dulbecco’s Modified Eagle Medium 
DMEM/FBS (1%)….DMEM containing 1% FBS 
DMEM/FBS (10%)….DMEM containing 10% FBS 
DMSO….dimethyl sulfoxide 
DNA ….deoxyribonucleic acid 
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DRE….dioxin response element 
DSL…delta-serrate-lag1 
DVL….dishevelled 
ECD….extracellular domain 
EDTA….ethylenediaminetetraacetic acid 
EGF….epidermal growth factor 
EGFR….epidermal growth factor receptor 
EGTA….ethyleneglycol-bis-(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid 
EMT….epithelial-mesenchymal transition 
ER….estrogen receptor 
ERE….estrogen response element 
EROD….ethoxyresorofin-O-deethylase 
FBS….fetal bovine serum 
FBXW7….F-box and WD repeat domain containing 7 
FDA….Food and Drug Administration 
FDR….false discovery rate 
FGF….fibroblast growth factor 
FGFR2….fibroblast growth factor receptor 2 
FICZ….6-formylindolo [3,2-b]-carbazole 
Foxp3….forkhead box P3 
FSH….follicle stimulating hormone 
G-CSF….granulocyte colony-stimulating factor 
GAPDH….glyceraldehyde-3-phosphate dehydrogenase 
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GEO….Gene Expression Omnibus 
GHR….growth hormone receptor 
GI….gastrointestinal 
Gli….glioma associated oncogene 
Gli-1….glioma associated oncogene-1 
Gli-2….glioma associated oncogene-2 
Gli-3….glioma associated oncogene-3 
Gli-A….activated Gli 
Gli-R….restricted Gli 
GM-CSF….granulocyte macrophage colony-stimulating factor 
GSCs….glioma stem cells 
GSH….glutathione 
GSIs….𝛾-secretase inhibitors 
GSK-3β….glycogen synthase kinase-3β 
GSK2….glycogen synthase kinase 2 
GSTs….glutathione-S-tranferases 
HCB….hexachlorobenzene 
HDAC1….histone deactylase 1 
HDAC2….histone deactylase 2 
HEPES….2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HER1….human epidermal growth factor receptor 1 
HER2….human epidermal growth factor receptor 2 
HER3….human epidermal growth factor receptor 3 
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HER4….human epidermal growth factor receptor 4 
HES….hairy enhancer of split 
HES1….hairy enhancer of split 1 
HES5….hairy enhancer of split 5 
HEY….HES related family bHLH transcription factor with YRPW motif 
HEY1….HES related family bHLH transcription factor with YRPW motif 1 
HGF….human growth factor 
Hh….hedgehog 
HIF-1α….hypoxia inducible factor 1α 
HNSCC….head and neck squamous cell carcinoma 
HRE….hypoxic response element 
HSCs….hematopoietic stem cells 
HSP90….heat shock protein 90 
I3C….indole-3-carbinol 
ICD….intracellular domain 
ICZ.…indolo [3,2-b] carbazole  
IDeA….Institutional Development Award 
iDRE….inhibitory dioxin response element 
IFN𝛾….interferon-g 
IGF-1R….insulin-like growth factor-1 receptor  
Ihh….indian hedgehog 
IKKα….inhibitor of NF-κB subunit α 
IL-1β….interleukin-1β 
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IL-10….interleukin-10 
IL-17….interleukin-17 
IL-2….interleukin-2 
IL-22….interleukin-22 
IL-6….interleukin-6 
IL-8….interleukin-8 
IL1R1….interleukin 1 receptor, type 1 
ILK….integrin-linked kinase 
IPA….Ingenuity Pathway Analysis 
ITE….2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid methylester 
IκB….inhibitor of NF-κB 
IκBK….inhibitor of NF-κB kinase 
JAG1….Jagged1 
JAG2….Jagged2 
JICD….JAG1 intracellular domain 
JNK…. Jun amino-terminal kinase 
Kb….kilobases 
KIF7….kinesin family member 7 
KIT….KIT proto-oncogene receptor tyrosine kinase 
LAR….luminal/androgen receptor  
LCK….lymphocyte-specific protein tyrosine kinase 
LEF1….lymphoid enhancing factor 1 
Lfng….lunatic fringe 
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LH….luteinizing hormone  
LiCl….lithium chloride 
LOX….lysyl oxidase 
LPS….lipopolysaccharide 
LRP….low-density lipoprotein receptor 
LRP5….low-density lipoprotein 5 
LRP6….low-density lipoprotein 6 
M….molarity 
mAbs….monoclonal antibodies 
MAML….mastermind-like 
MAP3K1….mitogen-activated protein kinase kinase kinase 1 
MAPK….mitogen-activated protein kinase 
MCDF….6-methyl-1,3,8-trichlorodibenzofuran 
MES….mesenchymal  
MIRN21….miRNA-21 producing gene 
miRNA-21….microRNA-21 
mg….milligrams 
mL….milliliter 
mm….millimeter 
mM….millimolar 
MMP2….matrix metallopeptidase 2 
MMP7….matrix metallopeptidase 7 
MMP9….matrix metallopeptidase 9 
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mRNA….messenger RNA 
MRP1….multidrug resistance-associated protein 1 
MT….metallothionein 
MTA2….metastasis-associated protein 2  
mTOR….mechanistic target of rapamycin 
MTT….3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
myc….MYC proto-oncogene 
NA3VO4….sodium orthovanadate 
Na4P2O7….sodium pyrophosphate 
NaCl….sodium chloride 
NAD+….nicotinamide adenine dinucleotide 
NaF….sodium flouride 
NaHCO3….sodium bicarbonate 
NCOA-1….nuclear receptor co-activator-1 
NF-κB….nuclear factor-κB 
NICD….Notch intracellular domain 
NICD1….Notch1 intracellular domain 
NICD2….Notch2 intracellular domain 
NIK….NF-κB inducing kinase 
NLS….nuclear localization sequence 
ng….nanograms 
nm….nanometer 
nM….nanomolar 
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O2….oxygen 
OCT4….octamer-binding protein 4 
OH….hydroxyl group 
OX40L….tumor necrosis factor receptor, superfamily member 4 
P-gp….P-glycoprotein 
p….phosphate group 
PAGE….polyacrylamide gel electrophoresis 
PAHs….polycyclic aromatic hydrocarbons 
PARP….poly-(ADP-ribose) polymerase 
PBS….phosphate buffer saline 
PBST….PBS with 0.05% Tween-20 
pCR….pathologic complete response 
PDGF….platelet-derived growth factor 
PDGF-b….platelet-derived growth factor-b 
PDGFR-β….platelet-derived growth factor receptor-β 
PDZ….PSD-95/Dlg/ZO-1 
PHAHs….polycyclic halogenated aromatic hydrocarbons 
PHD….prolyl hydroxylase domain 
PI3K….phosphoinositide-3-kinase 
PIK3CA….phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α 
Pin1….prolyl-cis/trans-isomerase 1 
PKA….protein kinase A 
PMSF….phenylmethylsulfonyl flouride 
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PPAR𝛾….peroxisome profilerator-activated receptor 𝛾 
PR….progesterone receptor 
PSD-95….postsynaptic density protein-95 
PTCH1….patched1 
PTEN….phosphatase and tensin homolog 
PVDF….polyvinylidene difluoride 
pVHL….von Hippel-Lindau tumor suppressor gene product 
qPCR….quantitative polymerase chain reaction 
RA….rheumatoid arthritis 
RAS….rat sarcoma viral proto-oncogene  
RBP-Jk….recombination signal binding protein for immunoglobulin κJ region 
RBX1….ring box1  
RelA….v-Rel avian reticuloendotheliosis viral oncogene homolog A 
RelB….v-Rel avian reticuloendotheliosis viral oncogene homolog B 
RET….ret proto-oncogene 
RIN….RNA integrity number 
RIP140….receptor interacting protein 140 
RNA….ribonucleic acid 
RNA-seq….RNA-sequencing 
ROS….reactive oxygen species 
RT-qPCR….real-time quantitative PCR 
RUNX2….runt related transcription factor 2 
RUNX3….runt related transcription factor 3 
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SDS….sodium dodecyl sulfate 
SEM….standard error margin 
SERDs….selective estrogen receptor down regulators 
SERMs….selective estrogen receptor modulators 
Shh….sonic hedgehog 
SIN3A….histone deactylase complex subunit Sin3a 
siRNA….short-interfering RNA 
SMO….smoothened 
SNAI….snail family of transcriptional repressor 
Snail….SNAI1 
Slug….SNAI2 
Smuc….SNAI3 
SOX2….SRY-box 2 
SOX4….SRY-box 4 
SPEN….sharp and mint 
SRY….sex-determining region Y 
Su(H)….suppressor of hairless 
SUFU….suppressor of fused 
T-ALL….T-cell acute lymphoblastic leukemia 
T-DM1….Ado-trastuzumab emtansine 
TACE….TNFα converting enzyme 
TBL3….transducin beta like 3 
TCDD….2,3,7,8-tetrachlorodibenzo-p-dioxin 
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TCF/LEF….T-cell factor/lymphoid enhancing factor 
TDO2….tryptophan 2,3-dioxygenase 
TE….10mM Tris-HCl with 0.1mM EDTA 
TGFα….tumor growth factor α 
TGFβ….tumor growth factor β 
Th17….T-helper 17 
TILs….tumor infiltrating lymphocytes 
TKIs….tyrosine kinase inhibitors 
TLRs….toll-like receptors 
TNBC….triple negative breast cancer 
TNF….tumor necrosis factor 
TNFα….tumor necrosis factor α 
TOP2α….topoisomerase 2α 
TP53….tumor protein 53 
TP63….tumor protein 63 
Treg….T-regulatory 
TRGs….TCDD-regulated genes 
Tris-HCl….tris-hydrochloride 
TSS….transcription start site 
TUBB2B….tubulin b, class IIB 
Ub….ubiquitin  
µg….microgram 
µL….microliter 
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µM….micromolar 
µPA….urokinase-type plasminogen activator 
UTRs….untranslated regions 
VDR….vitamin D receptor 
VEGF…. vascular endothelial growth factor 
VTCN1….v-set domain containing T-cell activation inhibitor 
VWF….von Willebrand Factor 
Wnt….wingless-type MMTV integration site family 
WV-INBRE….West Virginia-IDeA Networks of Biomedical Research Excellence 
XAP2….Hepatitis B virus X-associated protein 2 
ZEB1….zinc-finger E-box binding homeobox 1 
ZO-1….zona occludens 1 
ZnCl2….zinc chloride 
avb3-integrin….integrin av and integrin b3  
α….alpha 
β….beta 𝛾….gamma 
κ….kappa 
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